PRS scores
Use the filters below to narrow the main PRS catalog. Binary traits report percentile odds ratios, while quantitative traits report percentile beta values. Click any sortable column header to reorder rows; this table defaults to increasing p-value.
Filter defaults and flag guide
By default the row filters open on retained rows so the table starts with the models most likely to be useful for comparison. “Hide non-nominal rows” keeps only rows that were nominally significant in the preserved release, and “Hide flagged rows” removes reversed-effect or underpowered rows. Turn either filter off when you need the full preserved table.
Flag guide: nominal = passed the preserved release's nominal threshold; weak = did not; reversed effect = observed direction opposite the expected effect direction; retained = nominal and warning-free. When the trait list feels too long, use the free-text Search box first.
| Trait code | Trait | Cohort | Method | GWAS source | # SNPs | P value | R² / pseudo-R² | Brier | AAUC | Top 1% effect | Flags | Links |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 174.1 |
Breast cancer [female] Overall |
UKB | PRS-CS | Michailidou K et al. 2018 | 1120410 | 2.1e-364 | 0.056 | 0.0805 | 0.652 0.645-0.658 |
4.38 OR 95% CI: 3.79-5.07 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | lassosum | Michailidou K et al. 2018 | 286144 | 2.91e-325 | 0.0514 | 0.0807 | 0.643 0.637-0.65 |
4.02 OR 95% CI: 3.46-4.67 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | PRS-CS | Michailidou K et al. 2018 | 1120410 | 1.12e-308 | 0.0497 | 0.0809 | 0.64 0.634-0.647 |
3.64 OR 95% CI: 3.12-4.25 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
UKB | PRS-CS | Schumacher FR et al. 2019 | 1120596 | 1.15e-308 | 0.0928 | 0.0791 | 0.705 0.695-0.715 |
5.58 OR 95% CI: 4.58-6.78 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
UKB | lassosum | Schumacher FR et al. 2019 | 178259 | 1.2e-292 | 0.0915 | 0.0794 | 0.699 0.69-0.71 |
5.88 OR 95% CI: 4.85-7.14 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | lassosum | Michailidou K et al. 2018 | 148560 | 1.4e-274 | 0.0449 | 0.0811 | 0.631 0.624-0.638 |
3.86 OR 95% CI: 3.31-4.5 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 712 | 1.5e-271 | 0.0437 | 0.0811 | 0.628 0.62-0.635 |
3.69 OR 95% CI: 3.16-4.31 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | P&T | Michailidou K et al. 2018 | 1682 | 2.5e-270 | 0.0455 | 0.0811 | 0.63 0.623-0.637 |
3.32 OR 95% CI: 2.83-3.9 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 1307 | 7.1e-265 | 0.0443 | 0.0812 | 0.627 0.62-0.634 |
3.49 OR 95% CI: 2.98-4.08 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
UKB | Fixed threshold (5e-05) | Schumacher FR et al. 2019 | 1223 | 2.9e-263 | 0.0793 | 0.0799 | 0.688 0.678-0.698 |
5.51 OR 95% CI: 4.52-6.71 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
UKB | P&T | Schumacher FR et al. 2019 | 1023 | 6.7e-263 | 0.0802 | 0.0799 | 0.687 0.678-0.698 |
5.88 OR 95% CI: 4.84-7.13 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 464 | 2.3e-260 | 0.0434 | 0.0812 | 0.626 0.618-0.633 |
3.81 OR 95% CI: 3.27-4.44 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
UKB | Fixed threshold (5e-06) | Schumacher FR et al. 2019 | 691 | 3.1e-257 | 0.0772 | 0.0801 | 0.686 0.676-0.696 |
5.01 OR 95% CI: 4.1-6.14 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
UKB | Fixed threshold (5e-07) | Schumacher FR et al. 2019 | 492 | 5.8e-250 | 0.076 | 0.0802 | 0.683 0.674-0.693 |
4.81 OR 95% CI: 3.92-5.91 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
UKB | GWAS Hits | Schumacher FR et al. 2019 | 377 | 8.8e-246 | 0.0746 | 0.0803 | 0.681 0.671-0.692 |
4.85 OR 95% CI: 3.95-5.95 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | GWAS Hits | Michailidou K et al. 2018 | 334 | 2.5e-245 | 0.0409 | 0.0813 | 0.622 0.615-0.63 |
3.69 OR 95% CI: 3.16-4.31 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | PRS-CS | Michailidou K et al. 2018 | 1116546 | 5.8e-243 | 0.0371 | 0.0813 | 0.623 0.615-0.63 |
3.54 OR 95% CI: 3.02-4.14 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
UKB | Fixed threshold (5e-09) | Schumacher FR et al. 2019 | 293 | 2.2e-239 | 0.0711 | 0.0804 | 0.678 0.668-0.688 |
4.51 OR 95% CI: 3.66-5.56 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 264 | 1.4e-236 | 0.039 | 0.0813 | 0.62 0.612-0.627 |
3.28 OR 95% CI: 2.79-3.86 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | P&T | Michailidou K et al. 2018 | 747 | 1.1e-235 | 0.0394 | 0.0814 | 0.621 0.614-0.628 |
3.36 OR 95% CI: 2.87-3.95 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 950 | 6.4e-226 | 0.0385 | 0.0814 | 0.617 0.61-0.625 |
3.47 OR 95% CI: 2.96-4.06 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 495 | 2.2e-225 | 0.0389 | 0.0814 | 0.617 0.61-0.625 |
3.06 OR 95% CI: 2.6-3.61 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | lassosum | Michailidou K et al. 2018 | 7118 | 4.8e-220 | 0.037 | 0.0814 | 0.615 0.607-0.622 |
3.55 OR 95% CI: 3.04-4.16 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 343 | 3.1e-218 | 0.0376 | 0.0815 | 0.615 0.607-0.622 |
3.01 OR 95% CI: 2.55-3.56 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | GWAS Hits | Michailidou K et al. 2018 | 257 | 1.8e-212 | 0.0361 | 0.0815 | 0.613 0.606-0.621 |
2.71 OR 95% CI: 2.28-3.23 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | PRS-CS | Michailidou K et al. 2018 | 1116495 | 3.3e-205 | 0.0309 | 0.0816 | 0.614 0.607-0.62 |
2.98 OR 95% CI: 2.52-3.52 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 32 | 5e-201 | 0.0295 | 0.0812 | 0.618 0.611-0.626 |
2.95 OR 95% CI: 2.46-3.53 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 32 | 5e-201 | 0.0295 | 0.0812 | 0.618 0.611-0.626 |
2.95 OR 95% CI: 2.46-3.53 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 210 | 1.6e-200 | 0.0339 | 0.0816 | 0.61 0.603-0.617 |
2.7 OR 95% CI: 2.27-3.21 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 31 | 1.2e-196 | 0.0291 | 0.0812 | 0.617 0.61-0.625 |
3.03 OR 95% CI: 2.53-3.62 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 30 | 8.6e-196 | 0.0287 | 0.0813 | 0.617 0.609-0.625 |
3.11 OR 95% CI: 2.6-3.71 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | lassosum | Michailidou K et al. 2018 | 12277 | 1.3e-194 | 0.0339 | 0.0816 | 0.608 0.601-0.615 |
3 OR 95% CI: 2.54-3.54 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 24 | 2.3e-191 | 0.0299 | 0.0813 | 0.615 0.608-0.623 |
3.05 OR 95% CI: 2.55-3.64 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | P&T | GWAS Catalog (2019-05-03) | 24 | 2.3e-191 | 0.0299 | 0.0813 | 0.615 0.608-0.623 |
3.05 OR 95% CI: 2.55-3.64 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
UKB | P&T | GWAS Catalog (2019-05-03) | 118 | 6.6e-186 | 0.0588 | 0.0813 | 0.653 0.643-0.663 |
4.34 OR 95% CI: 3.51-5.37 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-05) | Chahal HS et al. 2018 | 28 | 2.1e-185 | 0.0289 | 0.0813 | 0.611 0.604-0.619 |
2.8 OR 95% CI: 2.33-3.36 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-06) | Chahal HS et al. 2018 | 28 | 2.1e-185 | 0.0289 | 0.0813 | 0.611 0.604-0.619 |
2.8 OR 95% CI: 2.33-3.36 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-07) | Chahal HS et al. 2018 | 28 | 2.1e-185 | 0.0289 | 0.0813 | 0.611 0.604-0.619 |
2.8 OR 95% CI: 2.33-3.36 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | GWAS Hits | Chahal HS et al. 2018 | 28 | 2.1e-185 | 0.0289 | 0.0813 | 0.611 0.604-0.619 |
2.8 OR 95% CI: 2.33-3.36 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | P&T | Chahal HS et al. 2018 | 28 | 2.1e-185 | 0.0289 | 0.0813 | 0.611 0.604-0.619 |
2.8 OR 95% CI: 2.33-3.36 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 117 | 5.5e-185 | 0.0585 | 0.0813 | 0.653 0.642-0.662 |
4.31 OR 95% CI: 3.48-5.33 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 124 | 6.1e-181 | 0.0572 | 0.0813 | 0.65 0.64-0.661 |
3.8 OR 95% CI: 3.05-4.75 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 124 | 6.1e-181 | 0.0572 | 0.0813 | 0.65 0.64-0.661 |
3.8 OR 95% CI: 3.05-4.75 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 123 | 7.5e-181 | 0.0571 | 0.0813 | 0.65 0.64-0.66 |
3.77 OR 95% CI: 3.02-4.7 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 86 | 1e-178 | 0.0578 | 0.0813 | 0.649 0.638-0.659 |
4.3 OR 95% CI: 3.48-5.32 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 154 | 6.6e-176 | 0.0296 | 0.0818 | 0.603 0.595-0.61 |
2.65 OR 95% CI: 2.22-3.15 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 246 | 4.1e-175 | 0.0291 | 0.0817 | 0.603 0.595-0.61 |
2.87 OR 95% CI: 2.43-3.4 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | P&T | Michailidou K et al. 2018 | 85 | 9.6e-173 | 0.0306 | 0.0818 | 0.602 0.594-0.609 |
2.78 OR 95% CI: 2.34-3.3 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | GWAS Hits | Michailidou K et al. 2018 | 110 | 3.8e-170 | 0.0299 | 0.0818 | 0.601 0.594-0.608 |
2.5 OR 95% CI: 2.09-2.99 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | P&T | Michailidou K et al. 2018 | 174 | 3.6e-169 | 0.0287 | 0.0818 | 0.6 0.593-0.608 |
2.92 OR 95% CI: 2.47-3.46 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 77 | 2e-168 | 0.0299 | 0.0818 | 0.6 0.593-0.607 |
2.58 OR 95% CI: 2.16-3.08 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 185 | 6.6e-168 | 0.0285 | 0.0818 | 0.6 0.593-0.608 |
2.74 OR 95% CI: 2.31-3.26 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-09) | Chahal HS et al. 2018 | 22 | 1.2e-165 | 0.0273 | 0.0815 | 0.604 0.597-0.612 |
2.68 OR 95% CI: 2.23-3.23 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 113 | 2.7e-162 | 0.0272 | 0.0818 | 0.597 0.59-0.604 |
2.71 OR 95% CI: 2.28-3.22 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
UKB | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 534 | 3e-162 | 0.0259 | 0.0818 | 0.6 0.593-0.608 |
2.86 OR 95% CI: 2.41-3.39 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | GWAS Hits | Michailidou K et al. 2018 | 86 | 1.1e-157 | 0.0277 | 0.0819 | 0.597 0.59-0.604 |
2.68 OR 95% CI: 2.25-3.19 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
UKB | P&T | GWAS Catalog (2019-05-03) | 79 | 5.7e-155 | 0.028 | 0.0819 | 0.598 0.59-0.605 |
2.68 OR 95% CI: 2.25-3.18 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 423 | 1.5e-150 | 0.0235 | 0.0819 | 0.596 0.589-0.603 |
2.49 OR 95% CI: 2.08-2.98 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
UKB | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 63 | 6e-150 | 0.0273 | 0.0819 | 0.593 0.586-0.6 |
2.76 OR 95% CI: 2.33-3.28 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 64 | 1.2e-146 | 0.0255 | 0.0819 | 0.595 0.588-0.602 |
2.44 OR 95% CI: 2.04-2.92 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 93 | 1.7e-144 | 0.0249 | 0.0819 | 0.594 0.586-0.601 |
2.58 OR 95% CI: 2.16-3.08 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 86 | 3.9e-139 | 0.0245 | 0.082 | 0.592 0.585-0.6 |
2.58 OR 95% CI: 2.16-3.07 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 102 | 6.3e-132 | 0.023 | 0.082 | 0.589 0.582-0.597 |
2.26 OR 95% CI: 1.88-2.72 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 105 | 2.3e-125 | 0.0212 | 0.0821 | 0.586 0.579-0.594 |
2.24 OR 95% CI: 1.86-2.7 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | PRS-CS | Michailidou K et al. 2018 | 1120410 | 6e-101 | 0.0128 | 0.0822 | 0.579 0.572-0.586 |
2.34 OR 95% CI: 1.95-2.82 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | lassosum | Michailidou K et al. 2018 | 41744 | 3e-98 | 0.013 | 0.0822 | 0.576 0.568-0.583 |
2.25 OR 95% CI: 1.86-2.71 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
UKB | P&T | Chahal HS et al. 2018 | 9 | 3.6e-97 | 0.0144 | 0.0819 | 0.571 0.563-0.579 |
1.93 OR 95% CI: 1.56-2.39 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
UKB | Fixed threshold (5e-09) | Chahal HS et al. 2018 | 5 | 7.9e-97 | 0.0137 | 0.0819 | 0.569 0.561-0.577 |
2.13 OR 95% CI: 1.73-2.61 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
UKB | Fixed threshold (5e-05) | Chahal HS et al. 2018 | 10 | 4.3e-94 | 0.014 | 0.082 | 0.57 0.562-0.578 |
1.75 OR 95% CI: 1.4-2.18 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
UKB | Fixed threshold (5e-06) | Chahal HS et al. 2018 | 10 | 4.3e-94 | 0.014 | 0.082 | 0.57 0.562-0.578 |
1.75 OR 95% CI: 1.4-2.18 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
UKB | Fixed threshold (5e-07) | Chahal HS et al. 2018 | 10 | 4.3e-94 | 0.014 | 0.082 | 0.57 0.562-0.578 |
1.75 OR 95% CI: 1.4-2.18 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
UKB | GWAS Hits | Chahal HS et al. 2018 | 10 | 4.3e-94 | 0.014 | 0.082 | 0.57 0.562-0.578 |
1.75 OR 95% CI: 1.4-2.18 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 14 | 4.1e-93 | 0.0148 | 0.082 | 0.575 0.567-0.582 |
2.19 OR 95% CI: 1.79-2.67 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
UKB | P&T | GWAS Catalog (2019-05-03) | 14 | 4.1e-93 | 0.0148 | 0.082 | 0.575 0.567-0.582 |
2.19 OR 95% CI: 1.79-2.67 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 13 | 4.2e-89 | 0.0143 | 0.082 | 0.573 0.564-0.58 |
2.13 OR 95% CI: 1.74-2.61 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 7 | 2.1e-85 | 0.0132 | 0.082 | 0.57 0.563-0.578 |
1.86 OR 95% CI: 1.5-2.3 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-05) | Huyghe JR et al. 2019 | 87 | 4.5e-83 | 0.0336 | 0.0812 | 0.617 0.605-0.63 |
4 OR 95% CI: 3.11-5.13 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | P&T | Huyghe JR et al. 2019 | 87 | 4.5e-83 | 0.0336 | 0.0812 | 0.617 0.605-0.63 |
4 OR 95% CI: 3.11-5.13 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-06) | Huyghe JR et al. 2019 | 85 | 1.7e-82 | 0.0334 | 0.0812 | 0.617 0.605-0.63 |
3.85 OR 95% CI: 2.99-4.96 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-07) | Huyghe JR et al. 2019 | 81 | 6.6e-81 | 0.033 | 0.0812 | 0.616 0.604-0.629 |
3.85 OR 95% CI: 2.99-4.96 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | GWAS Hits | Huyghe JR et al. 2019 | 74 | 3.6e-76 | 0.031 | 0.0813 | 0.612 0.6-0.625 |
3.85 OR 95% CI: 2.99-4.96 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-09) | Huyghe JR et al. 2019 | 56 | 4.8e-69 | 0.0274 | 0.0814 | 0.607 0.594-0.62 |
3.39 OR 95% CI: 2.6-4.41 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | Chahal HS et al. 2018 | 28 | 2.5e-67 | 0.0409 | 0.106 | 0.632 0.616-0.647 |
3.61 OR 95% CI: 2.53-5.15 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | Chahal HS et al. 2018 | 28 | 2.5e-67 | 0.0409 | 0.106 | 0.632 0.616-0.647 |
3.61 OR 95% CI: 2.53-5.15 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-07) | Chahal HS et al. 2018 | 28 | 2.5e-67 | 0.0409 | 0.106 | 0.632 0.616-0.647 |
3.61 OR 95% CI: 2.53-5.15 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | GWAS Hits | Chahal HS et al. 2018 | 28 | 2.5e-67 | 0.0409 | 0.106 | 0.632 0.616-0.647 |
3.61 OR 95% CI: 2.53-5.15 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | P&T | Chahal HS et al. 2018 | 27 | 3.1e-67 | 0.0415 | 0.106 | 0.632 0.616-0.647 |
3.79 OR 95% CI: 2.68-5.35 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
MGI | PRS-CS | Schumacher FR et al. 2019 | 1119311 | 6.9e-67 | 0.0898 | 0.145 | 0.668 0.651-0.687 |
3.61 OR 95% CI: 2.28-5.72 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-09) | Chahal HS et al. 2018 | 22 | 7.7e-67 | 0.0386 | 0.106 | 0.631 0.615-0.646 |
4.04 OR 95% CI: 2.88-5.66 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 17 | 1.7e-66 | 0.0117 | 0.0822 | 0.562 0.555-0.571 |
1.65 OR 95% CI: 1.32-2.07 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
MGI | lassosum | Schumacher FR et al. 2019 | 26418 | 3.3e-66 | 0.092 | 0.145 | 0.665 0.647-0.684 |
4.92 OR 95% CI: 3.21-7.55 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | PRS-CS | Michailidou K et al. 2018 | 1119140 | 1e-65 | 0.0523 | 0.133 | 0.651 0.635-0.666 |
3.22 OR 95% CI: 2.15-4.81 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
MGI | P&T | Schumacher FR et al. 2019 | 1301 | 1.6e-65 | 0.0898 | 0.145 | 0.67 0.652-0.688 |
3.3 OR 95% CI: 2.06-5.29 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
MGI | Fixed threshold (5e-05) | Schumacher FR et al. 2019 | 1223 | 9.1e-65 | 0.0891 | 0.145 | 0.668 0.651-0.685 |
3.62 OR 95% CI: 2.27-5.76 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 133 | 2.5e-64 | 0.0084 | 0.0824 | 0.561 0.553-0.568 |
1.81 OR 95% CI: 1.48-2.22 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
MGI | Fixed threshold (5e-06) | Schumacher FR et al. 2019 | 691 | 3.1e-63 | 0.085 | 0.145 | 0.666 0.649-0.683 |
4.51 OR 95% CI: 2.94-6.94 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 30 | 7.7e-63 | 0.0421 | 0.106 | 0.63 0.615-0.646 |
3.95 OR 95% CI: 2.79-5.58 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | GWAS Hits | Michailidou K et al. 2018 | 49 | 8.9e-63 | 0.0091 | 0.0824 | 0.559 0.551-0.566 |
2.03 OR 95% CI: 1.67-2.46 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | P&T | Michailidou K et al. 2018 | 49 | 8.9e-63 | 0.0091 | 0.0824 | 0.559 0.551-0.566 |
2.03 OR 95% CI: 1.67-2.46 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 24 | 1.9e-62 | 0.044 | 0.106 | 0.629 0.613-0.645 |
4 OR 95% CI: 2.82-5.68 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 31 | 3.7e-62 | 0.0426 | 0.106 | 0.629 0.614-0.646 |
3.84 OR 95% CI: 2.71-5.43 |
Binary
nominal
|
|
| 172 |
Skin cancer Cancer code, self-reported: skin cancer (UKB GWAS (PHESANT)) |
MGI | P&T | UKB GWAS (PheCode) | 292 | 3.8e-62 | 0.0274 | 0.146 | 0.591 0.581-0.602 |
2.51 OR 95% CI: 1.89-3.34 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | P&T | GWAS Catalog (2019-05-03) | 23 | 5.4e-62 | 0.044 | 0.106 | 0.628 0.612-0.644 |
4.03 OR 95% CI: 2.86-5.69 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 32 | 1.3e-61 | 0.0433 | 0.106 | 0.628 0.613-0.644 |
3.65 OR 95% CI: 2.57-5.18 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Cancer code, self-reported: basal cell carcinoma (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 32 | 1.3e-61 | 0.0433 | 0.106 | 0.628 0.613-0.644 |
3.65 OR 95% CI: 2.57-5.18 |
Binary
nominal
|
|
| 172 |
Skin cancer Cancer code, self-reported: skin cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 365 | 4.7e-61 | 0.0267 | 0.146 | 0.591 0.581-0.603 |
1.97 OR 95% CI: 1.46-2.67 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 73 | 7.7e-61 | 0.0081 | 0.0824 | 0.56 0.552-0.567 |
1.76 OR 95% CI: 1.44-2.16 |
Binary
nominal
|
|
| 172 |
Skin cancer Cancer code, self-reported: skin cancer (UKB GWAS (PHESANT)) |
MGI | lassosum | UKB GWAS (PheCode) | 3166 | 3.1e-60 | 0.0256 | 0.146 | 0.586 0.575-0.597 |
2.26 OR 95% CI: 1.69-3.03 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | PRS-CS | Michailidou K et al. 2018 | 1119140 | 4.7e-59 | 0.0445 | 0.134 | 0.643 0.627-0.658 |
3.71 OR 95% CI: 2.52-5.47 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | lassosum | Michailidou K et al. 2018 | 118388 | 1.2e-58 | 0.0505 | 0.134 | 0.641 0.625-0.656 |
2.48 OR 95% CI: 1.63-3.77 |
Binary
nominal
|
|
| 172 |
Skin cancer Cancer code, self-reported: skin cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 105 | 2.3e-58 | 0.0251 | 0.146 | 0.585 0.575-0.596 |
2.17 OR 95% CI: 1.62-2.92 |
Binary
nominal
|
|
| 172 |
Skin cancer Cancer code, self-reported: skin cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 159 | 4.1e-58 | 0.0263 | 0.146 | 0.586 0.576-0.597 |
2.06 OR 95% CI: 1.53-2.77 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 392 | 1.2e-57 | 0.0085 | 0.0825 | 0.559 0.551-0.566 |
1.75 OR 95% CI: 1.42-2.15 |
Binary
nominal
|
|
| 172 |
Skin cancer Cancer code, self-reported: skin cancer (UKB GWAS (PHESANT)) |
MGI | GWAS Hits | UKB GWAS (PheCode) | 80 | 1.6e-57 | 0.0235 | 0.146 | 0.584 0.574-0.594 |
2.3 OR 95% CI: 1.72-3.09 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 18 | 1.6e-57 | 0.011 | 0.0822 | 0.558 0.551-0.566 |
1.6 OR 95% CI: 1.27-2.01 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin |
MGI | P&T | UKB GWAS (PheCode) | 177 | 4.3e-57 | 0.0273 | 0.136 | 0.591 0.579-0.603 |
2.89 OR 95% CI: 2.14-3.92 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 31 | 1.3e-56 | 0.0078 | 0.0825 | 0.556 0.548-0.564 |
1.95 OR 95% CI: 1.6-2.37 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
MGI | Fixed threshold (5e-07) | Schumacher FR et al. 2019 | 492 | 2e-56 | 0.0878 | 0.146 | 0.653 0.636-0.673 |
4.62 OR 95% CI: 2.99-7.13 |
Binary
nominal
|
|
| 172 |
Skin cancer Malignant neoplasm of skin |
MGI | P&T | UKB GWAS (FINNGEN) | 389 | 7.4e-56 | 0.0247 | 0.146 | 0.586 0.576-0.597 |
2.23 OR 95% CI: 1.64-3.03 |
Binary
nominal
|
|
| 172 |
Skin cancer Malignant neoplasm of skin |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 433 | 9.4e-56 | 0.0244 | 0.146 | 0.586 0.576-0.597 |
2.48 OR 95% CI: 1.84-3.34 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 160 | 1.2e-55 | 0.026 | 0.136 | 0.59 0.579-0.602 |
2.87 OR 95% CI: 2.12-3.89 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
MGI | GWAS Hits | Schumacher FR et al. 2019 | 377 | 1.8e-55 | 0.0888 | 0.146 | 0.651 0.634-0.669 |
4.44 OR 95% CI: 2.87-6.87 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 29 | 2.8e-55 | 0.023 | 0.0812 | 0.622 0.607-0.637 |
3.12 OR 95% CI: 2.18-4.46 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 29 | 2.8e-55 | 0.023 | 0.0812 | 0.622 0.607-0.637 |
3.12 OR 95% CI: 2.18-4.46 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 109 | 6.9e-55 | 0.0236 | 0.136 | 0.589 0.577-0.601 |
2.75 OR 95% CI: 2.02-3.75 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer |
MGI | Fixed threshold (5e-09) | Schumacher FR et al. 2019 | 293 | 1.4e-54 | 0.0817 | 0.146 | 0.648 0.63-0.665 |
3.99 OR 95% CI: 2.57-6.21 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin |
MGI | lassosum | UKB GWAS (PheCode) | 7231 | 2.4e-54 | 0.0244 | 0.136 | 0.59 0.578-0.601 |
3.5 OR 95% CI: 2.63-4.65 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | lassosum | Michailidou K et al. 2018 | 61635 | 5.1e-54 | 0.0433 | 0.135 | 0.634 0.618-0.65 |
4.03 OR 95% CI: 2.78-5.85 |
Binary
nominal
|
|
| 172 |
Skin cancer Malignant neoplasm of skin |
MGI | lassosum | UKB GWAS (FINNGEN) | 16316 | 1.4e-53 | 0.0218 | 0.146 | 0.584 0.573-0.594 |
1.65 OR 95% CI: 1.2-2.27 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 117 | 1.9e-53 | 0.0628 | 0.147 | 0.646 0.627-0.665 |
3.57 OR 95% CI: 2.29-5.57 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin |
MGI | GWAS Hits | UKB GWAS (PheCode) | 77 | 2.2e-53 | 0.0203 | 0.136 | 0.586 0.574-0.599 |
2.65 OR 95% CI: 1.94-3.62 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | P&T | Michailidou K et al. 2018 | 3038 | 2.2e-53 | 0.041 | 0.135 | 0.635 0.618-0.651 |
2.84 OR 95% CI: 1.88-4.28 |
Binary
nominal
|
|
| 172 |
Skin cancer Cancer code, self-reported: skin cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-09) | UKB GWAS (PheCode) | 60 | 2.4e-53 | 0.0215 | 0.146 | 0.58 0.57-0.59 |
2.68 OR 95% CI: 2.02-3.55 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 124 | 3.6e-53 | 0.0667 | 0.147 | 0.646 0.627-0.664 |
3.41 OR 95% CI: 2.17-5.35 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 124 | 3.6e-53 | 0.0667 | 0.147 | 0.646 0.627-0.664 |
3.41 OR 95% CI: 2.17-5.35 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 123 | 7e-53 | 0.0667 | 0.147 | 0.646 0.627-0.663 |
3.64 OR 95% CI: 2.33-5.68 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin |
MGI | Fixed threshold (5e-09) | UKB GWAS (PheCode) | 61 | 7.2e-53 | 0.0204 | 0.137 | 0.584 0.572-0.596 |
3.09 OR 95% CI: 2.28-4.19 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
MGI | P&T | GWAS Catalog (2019-05-03) | 122 | 7.2e-53 | 0.0667 | 0.147 | 0.646 0.627-0.664 |
3.53 OR 95% CI: 2.26-5.51 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 1307 | 1.9e-52 | 0.0392 | 0.135 | 0.634 0.618-0.65 |
2.75 OR 95% CI: 1.81-4.17 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 27 | 3.3e-52 | 0.0233 | 0.0812 | 0.619 0.603-0.634 |
3.12 OR 95% CI: 2.18-4.47 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
UKB | P&T | GWAS Catalog (2019-05-03) | 27 | 3.3e-52 | 0.0233 | 0.0812 | 0.619 0.603-0.634 |
3.12 OR 95% CI: 2.18-4.47 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 367 | 1.8e-51 | 0.0268 | 0.137 | 0.587 0.576-0.599 |
3 OR 95% CI: 2.23-4.04 |
Binary
nominal
|
|
| 172 |
Skin cancer Malignant neoplasm of skin |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 208 | 3.7e-51 | 0.0233 | 0.146 | 0.583 0.572-0.593 |
2.04 OR 95% CI: 1.5-2.79 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer;Prostate cancer (early onset) |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 86 | 4.3e-51 | 0.0563 | 0.147 | 0.643 0.625-0.661 |
2.97 OR 95% CI: 1.85-4.75 |
Binary
nominal
|
|
| 172 |
Skin cancer Malignant neoplasm of skin |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 135 | 5.3e-51 | 0.0221 | 0.146 | 0.582 0.571-0.593 |
2.02 OR 95% CI: 1.48-2.76 |
Binary
nominal
|
|
| 172 |
Skin cancer Malignant neoplasm of skin |
MGI | GWAS Hits | UKB GWAS (FINNGEN) | 95 | 2.9e-50 | 0.0217 | 0.146 | 0.581 0.57-0.592 |
2.2 OR 95% CI: 1.63-2.98 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 18 | 5.1e-50 | 0.02 | 0.0813 | 0.615 0.599-0.63 |
2.57 OR 95% CI: 1.75-3.77 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin Other malignant neoplasms of skin |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 207 | 6.4e-50 | 0.0228 | 0.137 | 0.588 0.576-0.601 |
2.63 OR 95% CI: 1.93-3.59 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin Other malignant neoplasms of skin |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 139 | 7.1e-50 | 0.0216 | 0.137 | 0.586 0.574-0.599 |
2.78 OR 95% CI: 2.05-3.77 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
UKB | Fixed threshold (5e-05) | Ransohoff KJ et al. 2017 | 20 | 7.9e-50 | 0.0193 | 0.0813 | 0.62 0.604-0.635 |
2.81 OR 95% CI: 1.93-4.07 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
UKB | Fixed threshold (5e-06) | Ransohoff KJ et al. 2017 | 20 | 7.9e-50 | 0.0193 | 0.0813 | 0.62 0.604-0.635 |
2.81 OR 95% CI: 1.93-4.07 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
UKB | Fixed threshold (5e-07) | Ransohoff KJ et al. 2017 | 20 | 7.9e-50 | 0.0193 | 0.0813 | 0.62 0.604-0.635 |
2.81 OR 95% CI: 1.93-4.07 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
UKB | GWAS Hits | Ransohoff KJ et al. 2017 | 20 | 7.9e-50 | 0.0193 | 0.0813 | 0.62 0.604-0.635 |
2.81 OR 95% CI: 1.93-4.07 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
UKB | P&T | Ransohoff KJ et al. 2017 | 20 | 7.9e-50 | 0.0193 | 0.0813 | 0.62 0.604-0.635 |
2.81 OR 95% CI: 1.93-4.07 |
Binary
nominal
|
|
| 172 |
Skin cancer Malignant neoplasm of skin |
MGI | Fixed threshold (5e-09) | UKB GWAS (FINNGEN) | 78 | 1.2e-49 | 0.0204 | 0.146 | 0.58 0.569-0.591 |
2.45 OR 95% CI: 1.82-3.29 |
Binary
nominal
|
|
| 172 |
Skin cancer Malignant neoplasm of skin |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1111490 | 2e-49 | 0.0232 | 0.146 | 0.581 0.57-0.591 |
2.25 OR 95% CI: 1.67-3.03 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 712 | 3.8e-49 | 0.0388 | 0.135 | 0.629 0.612-0.645 |
3.06 OR 95% CI: 2.04-4.59 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 464 | 8e-49 | 0.0385 | 0.135 | 0.627 0.611-0.644 |
3.38 OR 95% CI: 2.28-5.02 |
Binary
nominal
|
|
| 172 |
Skin cancer Cancer code, self-reported: skin cancer (UKB GWAS (PHESANT)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 1.8e-48 | 0.0211 | 0.146 | 0.58 0.57-0.591 |
2.42 OR 95% CI: 1.81-3.24 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin Other malignant neoplasms of skin |
MGI | Fixed threshold (5e-09) | UKB GWAS (FINNGEN) | 85 | 2.2e-48 | 0.0206 | 0.137 | 0.585 0.573-0.598 |
2.82 OR 95% CI: 2.07-3.83 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin Other malignant neoplasms of skin |
MGI | GWAS Hits | UKB GWAS (FINNGEN) | 108 | 1e-47 | 0.0199 | 0.137 | 0.584 0.572-0.598 |
2.73 OR 95% CI: 2.01-3.72 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | GWAS Hits | Michailidou K et al. 2018 | 334 | 1.6e-47 | 0.0372 | 0.136 | 0.625 0.609-0.641 |
3.32 OR 95% CI: 2.24-4.93 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Malignant neoplasm of prostate |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 67 | 1.8e-47 | 0.0614 | 0.148 | 0.638 0.62-0.656 |
3.69 OR 95% CI: 2.36-5.75 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | lassosum | Michailidou K et al. 2018 | 18356 | 2.7e-47 | 0.0336 | 0.136 | 0.624 0.607-0.641 |
2.49 OR 95% CI: 1.61-3.84 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Ransohoff KJ et al. 2017 |
MGI | GWAS Hits | UKB GWAS (PheCode) | 12 | 8e-47 | 0.0207 | 0.0951 | 0.606 0.591-0.622 |
2.62 OR 95% CI: 1.77-3.88 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 264 | 1.7e-46 | 0.0358 | 0.136 | 0.624 0.608-0.64 |
2.56 OR 95% CI: 1.68-3.9 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin Other malignant neoplasms of skin |
MGI | lassosum | UKB GWAS (FINNGEN) | 16626 | 3.2e-46 | 0.0257 | 0.137 | 0.584 0.571-0.596 |
2.22 OR 95% CI: 1.61-3.06 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin ICD-10 C44 Other malignant neoplasms of skin |
MGI | Fixed threshold (5e-07) | UKB GWAS (ICD10) | 89 | 3.5e-46 | 0.0201 | 0.137 | 0.581 0.569-0.594 |
2.37 OR 95% CI: 1.72-3.28 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin ICD-10 C44 Other malignant neoplasms of skin |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 131 | 5.9e-46 | 0.0207 | 0.137 | 0.582 0.569-0.594 |
2.38 OR 95% CI: 1.73-3.26 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin Other malignant neoplasms of skin |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1111490 | 1.1e-45 | 0.0282 | 0.137 | 0.586 0.573-0.598 |
1.99 OR 95% CI: 1.43-2.78 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | PRS-CS | Michailidou K et al. 2018 | 1115484 | 1.3e-45 | 0.0295 | 0.135 | 0.622 0.605-0.638 |
3.43 OR 95% CI: 2.32-5.05 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin ICD-10 C44 Other malignant neoplasms of skin |
MGI | GWAS Hits | UKB GWAS (ICD10) | 63 | 1.5e-45 | 0.0198 | 0.137 | 0.579 0.566-0.592 |
2.21 OR 95% CI: 1.6-3.06 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin Other malignant neoplasms of skin |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 446 | 1.6e-45 | 0.0247 | 0.137 | 0.584 0.572-0.597 |
2.7 OR 95% CI: 1.99-3.66 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin Other malignant neoplasms of skin |
MGI | P&T | UKB GWAS (FINNGEN) | 446 | 1.6e-45 | 0.0247 | 0.137 | 0.584 0.572-0.597 |
2.7 OR 95% CI: 1.99-3.66 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Malignant neoplasm of prostate |
MGI | P&T | UKB GWAS (FINNGEN) | 100 | 2.3e-45 | 0.0656 | 0.148 | 0.634 0.617-0.653 |
2.96 OR 95% CI: 1.85-4.74 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 6.7e-45 | 0.0222 | 0.137 | 0.584 0.572-0.595 |
2.35 OR 95% CI: 1.71-3.22 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | P&T | Michailidou K et al. 2018 | 1142 | 8.1e-45 | 0.0356 | 0.136 | 0.621 0.605-0.638 |
2.7 OR 95% CI: 1.77-4.1 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin ICD-10 C44 Other malignant neoplasms of skin |
MGI | lassosum | UKB GWAS (ICD10) | 2111 | 1.6e-44 | 0.021 | 0.137 | 0.581 0.569-0.592 |
2.55 OR 95% CI: 1.87-3.46 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Malignant neoplasm of prostate |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 118 | 1.6e-44 | 0.064 | 0.148 | 0.633 0.615-0.651 |
3.22 OR 95% CI: 2.03-5.09 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 14 | 2.2e-44 | 0.0058 | 0.0825 | 0.547 0.54-0.555 |
1.73 OR 95% CI: 1.41-2.13 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | P&T | Michailidou K et al. 2018 | 14 | 2.2e-44 | 0.0058 | 0.0825 | 0.547 0.54-0.555 |
1.73 OR 95% CI: 1.41-2.13 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Ransohoff KJ et al. 2017 |
MGI | P&T | UKB GWAS (PheCode) | 15 | 9.1e-44 | 0.0211 | 0.0952 | 0.604 0.587-0.62 |
2.97 OR 95% CI: 2.04-4.34 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | lassosum | Michailidou K et al. 2018 | 2708 | 9.9e-44 | 0.0055 | 0.0825 | 0.547 0.54-0.555 |
1.72 OR 95% CI: 1.4-2.11 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin ICD-10 C44 Other malignant neoplasms of skin |
MGI | P&T | UKB GWAS (ICD10) | 467 | 1.3e-43 | 0.0239 | 0.137 | 0.583 0.57-0.595 |
2.17 OR 95% CI: 1.57-3.01 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer (Schumacher FR et al. 2019) |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 64 | 2.6e-43 | 0.0576 | 0.148 | 0.631 0.612-0.649 |
3.8 OR 95% CI: 2.44-5.92 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Ransohoff KJ et al. 2017 |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 19 | 3.5e-43 | 0.0188 | 0.0952 | 0.604 0.588-0.62 |
2.68 OR 95% CI: 1.81-3.98 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Malignant neoplasm of prostate |
MGI | GWAS Hits | UKB GWAS (FINNGEN) | 49 | 3.5e-43 | 0.0562 | 0.148 | 0.63 0.613-0.648 |
2.86 OR 95% CI: 1.79-4.57 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin ICD-10 C44 Other malignant neoplasms of skin |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 321 | 3.7e-43 | 0.0232 | 0.137 | 0.581 0.569-0.593 |
2.05 OR 95% CI: 1.46-2.86 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 C43 Malignant melanoma of skin |
MGI | GWAS Hits | UKB GWAS (ICD10) | 9 | 5.2e-43 | 0.0174 | 0.0952 | 0.598 0.582-0.613 |
2.88 OR 95% CI: 1.96-4.21 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 C43 Malignant melanoma of skin |
MGI | P&T | UKB GWAS (ICD10) | 9 | 5.2e-43 | 0.0174 | 0.0952 | 0.598 0.582-0.613 |
2.88 OR 95% CI: 1.96-4.21 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer (Schumacher FR et al. 2019) |
MGI | GWAS Hits | UKB GWAS (PheCode) | 42 | 5.8e-43 | 0.0548 | 0.148 | 0.63 0.612-0.648 |
3.14 OR 95% CI: 1.99-4.96 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 950 | 6.5e-43 | 0.0348 | 0.136 | 0.618 0.602-0.635 |
2.91 OR 95% CI: 1.93-4.4 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin ICD-10 C44 Other malignant neoplasms of skin |
MGI | Fixed threshold (5e-09) | UKB GWAS (ICD10) | 51 | 1.5e-42 | 0.0177 | 0.137 | 0.574 0.562-0.587 |
2.07 OR 95% CI: 1.48-2.89 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
UKB | Fixed threshold (5e-09) | Ransohoff KJ et al. 2017 | 15 | 7.1e-42 | 0.0165 | 0.0815 | 0.61 0.593-0.624 |
2.25 OR 95% CI: 1.5-3.38 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer (Schumacher FR et al. 2019) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 110 | 3e-41 | 0.0592 | 0.149 | 0.628 0.61-0.647 |
3.55 OR 95% CI: 2.26-5.58 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer (Schumacher FR et al. 2019) |
MGI | Fixed threshold (5e-09) | UKB GWAS (PheCode) | 32 | 1e-40 | 0.052 | 0.149 | 0.627 0.609-0.644 |
2.51 OR 95% CI: 1.54-4.07 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 246 | 1.2e-40 | 0.0251 | 0.136 | 0.613 0.597-0.631 |
2.8 OR 95% CI: 1.85-4.25 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 154 | 1.4e-40 | 0.0217 | 0.136 | 0.614 0.598-0.63 |
2.28 OR 95% CI: 1.46-3.54 |
Binary
nominal
|
|
| 185 |
Cancer of prostate ICD-10 C61 Malignant neoplasm of prostate |
MGI | GWAS Hits | UKB GWAS (ICD10) | 31 | 2.6e-40 | 0.0545 | 0.149 | 0.622 0.603-0.641 |
2.93 OR 95% CI: 1.83-4.7 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | GWAS Hits | Michailidou K et al. 2018 | 257 | 2.8e-40 | 0.0285 | 0.136 | 0.614 0.599-0.63 |
2.35 OR 95% CI: 1.51-3.66 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer (Schumacher FR et al. 2019) |
MGI | P&T | UKB GWAS (PheCode) | 80 | 5.9e-40 | 0.0596 | 0.149 | 0.627 0.608-0.645 |
3.18 OR 95% CI: 2.01-5.02 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 12 | 1.3e-39 | 0.0167 | 0.0816 | 0.6 0.584-0.615 |
2.65 OR 95% CI: 1.81-3.88 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 495 | 2e-39 | 0.032 | 0.136 | 0.613 0.596-0.629 |
2.29 OR 95% CI: 1.47-3.56 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Malignant neoplasm of prostate |
MGI | Fixed threshold (5e-09) | UKB GWAS (FINNGEN) | 43 | 2.1e-39 | 0.0562 | 0.149 | 0.624 0.605-0.642 |
3.06 OR 95% CI: 1.93-4.85 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 29 | 2.4e-39 | 0.0286 | 0.0954 | 0.608 0.592-0.623 |
2.93 OR 95% CI: 2-4.3 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 29 | 2.4e-39 | 0.0286 | 0.0954 | 0.608 0.592-0.623 |
2.93 OR 95% CI: 2-4.3 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
MGI | P&T | GWAS Catalog (2019-05-03) | 29 | 2.4e-39 | 0.0286 | 0.0954 | 0.608 0.592-0.623 |
2.93 OR 95% CI: 2-4.3 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 210 | 2.6e-39 | 0.0267 | 0.136 | 0.612 0.596-0.628 |
2.82 OR 95% CI: 1.86-4.27 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 343 | 3.9e-39 | 0.0302 | 0.136 | 0.612 0.596-0.628 |
2.47 OR 95% CI: 1.6-3.81 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | PRS-CS | Michailidou K et al. 2018 | 1115436 | 4.2e-39 | 0.0285 | 0.136 | 0.613 0.595-0.63 |
3.75 OR 95% CI: 2.55-5.51 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 C43 Malignant melanoma of skin |
MGI | Fixed threshold (5e-07) | UKB GWAS (ICD10) | 14 | 5.2e-39 | 0.0144 | 0.0954 | 0.594 0.579-0.609 |
2.58 OR 95% CI: 1.73-3.84 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Malignant melanoma of skin |
MGI | Fixed threshold (5e-09) | UKB GWAS (FINNGEN) | 11 | 1.1e-38 | 0.015 | 0.0954 | 0.591 0.575-0.607 |
2.91 OR 95% CI: 1.99-4.26 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | PRS-CS | Michailidou K et al. 2018 | 1116435 | 2.1e-38 | 0.0031 | 0.0826 | 0.549 0.542-0.556 |
1.82 OR 95% CI: 1.48-2.22 |
Binary
nominal
|
|
| 185 |
Cancer of prostate ICD-10 C61 Malignant neoplasm of prostate |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 80 | 2.6e-38 | 0.0566 | 0.149 | 0.621 0.603-0.64 |
2.65 OR 95% CI: 1.63-4.3 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | lassosum | Michailidou K et al. 2018 | 98026 | 2.7e-38 | 0.0305 | 0.136 | 0.61 0.594-0.626 |
2.29 OR 95% CI: 1.47-3.59 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 27 | 4.8e-38 | 0.0283 | 0.0954 | 0.606 0.589-0.621 |
2.59 OR 95% CI: 1.74-3.86 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Malignant melanoma of skin |
MGI | P&T | UKB GWAS (FINNGEN) | 21 | 4.9e-38 | 0.0167 | 0.0954 | 0.593 0.576-0.609 |
2.97 OR 95% CI: 2.02-4.36 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Malignant melanoma of skin |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 22 | 5.2e-38 | 0.0164 | 0.0954 | 0.592 0.577-0.608 |
2.83 OR 95% CI: 1.92-4.18 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Malignant neoplasm of prostate |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 290 | 7.7e-38 | 0.0605 | 0.149 | 0.626 0.607-0.644 |
2.41 OR 95% CI: 1.45-4.01 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | P&T | Michailidou K et al. 2018 | 363 | 8e-38 | 0.0258 | 0.136 | 0.609 0.592-0.626 |
3.44 OR 95% CI: 2.31-5.13 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Ransohoff KJ et al. 2017 |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 34 | 2.1e-37 | 0.0181 | 0.0955 | 0.596 0.58-0.613 |
2.21 OR 95% CI: 1.45-3.37 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | GWAS Hits | Michailidou K et al. 2018 | 110 | 2.8e-37 | 0.0214 | 0.137 | 0.607 0.591-0.623 |
2.51 OR 95% CI: 1.63-3.86 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Ransohoff KJ et al. 2017 |
MGI | Fixed threshold (5e-09) | UKB GWAS (PheCode) | 9 | 3.3e-37 | 0.0146 | 0.0955 | 0.588 0.573-0.605 |
2.82 OR 95% CI: 1.92-4.14 |
Binary
nominal
|
|
| 185 |
Cancer of prostate ICD-10 C61 Malignant neoplasm of prostate |
MGI | Fixed threshold (5e-07) | UKB GWAS (ICD10) | 47 | 5e-37 | 0.0627 | 0.149 | 0.619 0.601-0.637 |
3.1 OR 95% CI: 1.96-4.92 |
Binary
nominal
|
|
| 185 |
Cancer of prostate ICD-10 C61 Malignant neoplasm of prostate |
MGI | P&T | UKB GWAS (ICD10) | 47 | 5e-37 | 0.0627 | 0.149 | 0.619 0.601-0.637 |
3.1 OR 95% CI: 1.96-4.92 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 62 | 5.2e-37 | 0.0208 | 0.136 | 0.607 0.589-0.623 |
3.06 OR 95% CI: 2.04-4.6 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 62 | 5.2e-37 | 0.0208 | 0.136 | 0.607 0.589-0.623 |
3.06 OR 95% CI: 2.04-4.6 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 62 | 5.2e-37 | 0.0208 | 0.136 | 0.607 0.589-0.623 |
3.06 OR 95% CI: 2.04-4.6 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 62 | 5.2e-37 | 0.0208 | 0.136 | 0.607 0.589-0.623 |
3.06 OR 95% CI: 2.04-4.6 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 62 | 5.2e-37 | 0.0208 | 0.136 | 0.607 0.589-0.623 |
3.06 OR 95% CI: 2.04-4.6 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers |
MGI | P&T | GWAS Catalog (2019-05-03) | 62 | 5.2e-37 | 0.0208 | 0.136 | 0.607 0.589-0.623 |
3.06 OR 95% CI: 2.04-4.6 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | GWAS Hits | Michailidou K et al. 2018 | 10 | 1.8e-36 | 0.0049 | 0.0826 | 0.542 0.534-0.55 |
1.49 OR 95% CI: 1.2-1.86 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Malignant neoplasm of prostate |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1111493 | 2e-36 | 0.0414 | 0.149 | 0.622 0.604-0.639 |
2.66 OR 95% CI: 1.63-4.34 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer [female], Overall (Michailidou K et al. 2018) |
MGI | lassosum | UKB GWAS (PheCode) | 6977 | 2.4e-36 | 0.0261 | 0.137 | 0.609 0.592-0.624 |
1.94 OR 95% CI: 1.21-3.11 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 12 | 3.5e-36 | 0.0252 | 0.0954 | 0.598 0.582-0.614 |
2.92 OR 95% CI: 2-4.26 |
Binary
nominal
|
|
| 172.2 |
Other non-epithelial cancer of skin ICD-10 C44 Other malignant neoplasms of skin |
MGI | PRS-CS | UKB GWAS (ICD10) | 1111490 | 6.6e-36 | 0.0182 | 0.137 | 0.575 0.562-0.587 |
1.79 OR 95% CI: 1.28-2.51 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
MGI | Fixed threshold (5e-09) | Ransohoff KJ et al. 2017 | 15 | 1.2e-35 | 0.0269 | 0.0954 | 0.603 0.587-0.619 |
3.18 OR 95% CI: 2.2-4.61 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Melanoma;Cutaneous malignant melanoma |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 18 | 1.3e-35 | 0.0272 | 0.0955 | 0.6 0.584-0.616 |
2.39 OR 95% CI: 1.58-3.61 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Self-reported malignant melanoma |
MGI | P&T | UKB GWAS (PHESANT) | 7 | 4.2e-35 | 0.0148 | 0.0956 | 0.578 0.562-0.594 |
2.65 OR 95% CI: 1.79-3.93 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer (Schumacher FR et al. 2019) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 243 | 7.5e-35 | 0.0526 | 0.15 | 0.616 0.598-0.634 |
2.9 OR 95% CI: 1.79-4.7 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 534 | 8.9e-35 | 0.0251 | 0.137 | 0.608 0.591-0.625 |
2.44 OR 95% CI: 1.56-3.81 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Malignant melanoma of skin |
MGI | GWAS Hits | UKB GWAS (FINNGEN) | 16 | 9.4e-35 | 0.0135 | 0.0955 | 0.585 0.569-0.6 |
3.26 OR 95% CI: 2.26-4.7 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
MGI | Fixed threshold (5e-05) | Ransohoff KJ et al. 2017 | 20 | 1.2e-34 | 0.0295 | 0.0955 | 0.601 0.585-0.617 |
2.54 OR 95% CI: 1.7-3.8 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
MGI | Fixed threshold (5e-06) | Ransohoff KJ et al. 2017 | 20 | 1.2e-34 | 0.0295 | 0.0955 | 0.601 0.585-0.617 |
2.54 OR 95% CI: 1.7-3.8 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
MGI | Fixed threshold (5e-07) | Ransohoff KJ et al. 2017 | 20 | 1.2e-34 | 0.0295 | 0.0955 | 0.601 0.585-0.617 |
2.54 OR 95% CI: 1.7-3.8 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
MGI | GWAS Hits | Ransohoff KJ et al. 2017 | 20 | 1.2e-34 | 0.0295 | 0.0955 | 0.601 0.585-0.617 |
2.54 OR 95% CI: 1.7-3.8 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx |
MGI | P&T | Ransohoff KJ et al. 2017 | 20 | 1.2e-34 | 0.0295 | 0.0955 | 0.601 0.585-0.617 |
2.54 OR 95% CI: 1.7-3.8 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Overall |
MGI | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 77 | 1.4e-34 | 0.0211 | 0.137 | 0.603 0.587-0.62 |
2.33 OR 95% CI: 1.51-3.6 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported basal cell carcinoma |
MGI | lassosum | UKB GWAS (PHESANT) | 183 | 2.7e-34 | 0.0202 | 0.108 | 0.587 0.57-0.604 |
2.93 OR 95% CI: 2.03-4.25 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer [female], Overall (Michailidou K et al. 2018) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 109 | 3.3e-34 | 0.017 | 0.137 | 0.605 0.588-0.622 |
2.21 OR 95% CI: 1.41-3.45 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Malignant melanoma of skin |
MGI | lassosum | UKB GWAS (FINNGEN) | 505 | 6.5e-34 | 0.0176 | 0.0957 | 0.578 0.562-0.595 |
2.34 OR 95% CI: 1.55-3.53 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Self-reported malignant melanoma |
MGI | lassosum | UKB GWAS (PHESANT) | 185 | 9.8e-34 | 0.0175 | 0.0957 | 0.571 0.555-0.587 |
2 OR 95% CI: 1.29-3.09 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Ransohoff KJ et al. 2017 |
MGI | lassosum | UKB GWAS (PheCode) | 296 | 1.1e-33 | 0.0185 | 0.0957 | 0.582 0.566-0.599 |
1.99 OR 95% CI: 1.29-3.07 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Self-reported malignant melanoma |
MGI | Fixed threshold (5e-07) | UKB GWAS (PHESANT) | 14 | 2.1e-33 | 0.0142 | 0.0956 | 0.58 0.565-0.597 |
2.48 OR 95% CI: 1.66-3.7 |
Binary
nominal
|
|
| 185 |
Cancer of prostate ICD-10 C61 Malignant neoplasm of prostate |
MGI | Fixed threshold (5e-09) | UKB GWAS (ICD10) | 21 | 2.1e-33 | 0.0466 | 0.15 | 0.61 0.591-0.628 |
2.64 OR 95% CI: 1.63-4.27 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer (Schumacher FR et al. 2019) |
MGI | lassosum | UKB GWAS (PheCode) | 1334 | 2.5e-33 | 0.0503 | 0.15 | 0.616 0.598-0.635 |
2.55 OR 95% CI: 1.55-4.2 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer [female], Overall (Michailidou K et al. 2018) |
MGI | P&T | UKB GWAS (PheCode) | 84 | 2.8e-33 | 0.0183 | 0.137 | 0.605 0.588-0.621 |
2.09 OR 95% CI: 1.31-3.32 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 185 | 3.2e-33 | 0.0228 | 0.137 | 0.601 0.584-0.617 |
2.94 OR 95% CI: 1.95-4.44 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Malignant neoplasm of prostate |
MGI | lassosum | UKB GWAS (FINNGEN) | 1809 | 3.2e-33 | 0.0528 | 0.15 | 0.616 0.597-0.636 |
4.03 OR 95% CI: 2.59-6.28 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Self-reported malignant melanoma |
MGI | Fixed threshold (5e-09) | UKB GWAS (PHESANT) | 9 | 4.3e-33 | 0.0133 | 0.0957 | 0.578 0.563-0.595 |
2.21 OR 95% CI: 1.45-3.35 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported basal cell carcinoma |
MGI | P&T | UKB GWAS (PHESANT) | 72 | 1.7e-32 | 0.0256 | 0.108 | 0.591 0.575-0.607 |
2.5 OR 95% CI: 1.68-3.71 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Malignant neoplasm of breast |
MGI | lassosum | UKB GWAS (FINNGEN) | 2267 | 3.4e-32 | 0.0241 | 0.137 | 0.6 0.584-0.616 |
2.37 OR 95% CI: 1.54-3.65 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 13 | 3.7e-32 | 0.0286 | 0.0974 | 0.599 0.579-0.618 |
3.51 OR 95% CI: 2.29-5.39 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Prostate cancer (Schumacher FR et al. 2019) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119236 | 3.8e-32 | 0.035 | 0.15 | 0.614 0.595-0.633 |
2.32 OR 95% CI: 1.42-3.78 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 C43 Malignant melanoma of skin |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 37 | 5.3e-32 | 0.0123 | 0.0957 | 0.587 0.571-0.604 |
1.84 OR 95% CI: 1.17-2.9 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Self-reported malignant melanoma |
MGI | GWAS Hits | UKB GWAS (PHESANT) | 10 | 5.4e-32 | 0.0133 | 0.0957 | 0.576 0.561-0.593 |
2.25 OR 95% CI: 1.48-3.42 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 113 | 6.1e-32 | 0.02 | 0.137 | 0.599 0.583-0.615 |
2.49 OR 95% CI: 1.61-3.85 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Malignant melanoma of skin |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 42 | 7.9e-32 | 0.0156 | 0.0957 | 0.584 0.568-0.6 |
2.49 OR 95% CI: 1.66-3.71 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Self-reported prostate cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 56 | 2e-31 | 0.0398 | 0.15 | 0.609 0.591-0.628 |
3.37 OR 95% CI: 2.14-5.3 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported basal cell carcinoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 55 | 2.2e-31 | 0.0242 | 0.108 | 0.587 0.571-0.603 |
3.05 OR 95% CI: 2.1-4.42 |
Binary
nominal
|
|
| 185 |
Cancer of prostate ICD-10 C61 Malignant neoplasm of prostate |
MGI | PRS-CS | UKB GWAS (ICD10) | 1111493 | 2.3e-31 | 0.0256 | 0.15 | 0.612 0.593-0.63 |
2.09 OR 95% CI: 1.24-3.52 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported basal cell carcinoma |
MGI | Fixed threshold (5e-07) | UKB GWAS (PHESANT) | 30 | 2.4e-31 | 0.0236 | 0.108 | 0.584 0.569-0.599 |
2.16 OR 95% CI: 1.42-3.28 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 8 | 5e-31 | 0.0043 | 0.0826 | 0.536 0.528-0.544 |
1.77 OR 95% CI: 1.44-2.17 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 14 | 6.4e-31 | 0.0291 | 0.0975 | 0.597 0.578-0.616 |
3.57 OR 95% CI: 2.33-5.47 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 C43 Malignant melanoma of skin |
MGI | Fixed threshold (5e-09) | UKB GWAS (ICD10) | 6 | 6.6e-31 | 0.0125 | 0.0958 | 0.575 0.559-0.592 |
2.26 OR 95% CI: 1.49-3.43 |
Binary
nominal
|
|
| 185 |
Cancer of prostate ICD-10 C61 Malignant neoplasm of prostate |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 256 | 6.9e-31 | 0.0476 | 0.15 | 0.61 0.591-0.629 |
2.22 OR 95% CI: 1.36-3.63 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Self-reported prostate cancer |
MGI | P&T | UKB GWAS (PHESANT) | 78 | 9e-31 | 0.041 | 0.15 | 0.608 0.59-0.628 |
3.17 OR 95% CI: 1.98-5.06 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer [female], Overall (Michailidou K et al. 2018) |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 64 | 1e-30 | 0.016 | 0.137 | 0.6 0.584-0.617 |
2.47 OR 95% CI: 1.59-3.83 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | GWAS Hits | Michailidou K et al. 2018 | 86 | 1.2e-30 | 0.0197 | 0.137 | 0.597 0.58-0.614 |
2.28 OR 95% CI: 1.46-3.56 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | P&T | Michailidou K et al. 2018 | 310 | 1.2e-30 | 0.024 | 0.137 | 0.597 0.58-0.612 |
2.98 OR 95% CI: 1.98-4.47 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-05) | Chahal HS et al. 2018 | 10 | 4e-30 | 0.0295 | 0.0976 | 0.589 0.57-0.61 |
4.54 OR 95% CI: 3.07-6.71 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | Chahal HS et al. 2018 | 10 | 4e-30 | 0.0295 | 0.0976 | 0.589 0.57-0.61 |
4.54 OR 95% CI: 3.07-6.71 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-07) | Chahal HS et al. 2018 | 10 | 4e-30 | 0.0295 | 0.0976 | 0.589 0.57-0.61 |
4.54 OR 95% CI: 3.07-6.71 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
MGI | GWAS Hits | Chahal HS et al. 2018 | 10 | 4e-30 | 0.0295 | 0.0976 | 0.589 0.57-0.61 |
4.54 OR 95% CI: 3.07-6.71 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Self-reported malignant melanoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 29 | 6.7e-30 | 0.0132 | 0.0958 | 0.579 0.564-0.596 |
1.81 OR 95% CI: 1.16-2.84 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 27 | 1.3e-29 | 0.0135 | 0.0822 | 0.565 0.551-0.577 |
2.1 OR 95% CI: 1.53-2.89 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | P&T | GWAS Catalog (2019-05-03) | 27 | 1.3e-29 | 0.0135 | 0.0822 | 0.565 0.551-0.577 |
2.1 OR 95% CI: 1.53-2.89 |
Binary
nominal
|
|
| 185 |
Cancer of prostate ICD-10 C61 Malignant neoplasm of prostate |
MGI | lassosum | UKB GWAS (ICD10) | 905 | 1.6e-29 | 0.0489 | 0.151 | 0.607 0.589-0.627 |
2.46 OR 95% CI: 1.5-4.01 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 26 | 3.1e-29 | 0.0134 | 0.0822 | 0.564 0.551-0.577 |
2.1 OR 95% CI: 1.53-2.89 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer [female], Overall (Michailidou K et al. 2018) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 289 | 3.2e-29 | 0.018 | 0.137 | 0.597 0.581-0.613 |
1.93 OR 95% CI: 1.21-3.09 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 C43 Malignant melanoma of skin |
MGI | lassosum | UKB GWAS (ICD10) | 436 | 5.6e-29 | 0.0133 | 0.0959 | 0.565 0.549-0.583 |
1.93 OR 95% CI: 1.24-3 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Self-reported prostate cancer |
MGI | Fixed threshold (5e-07) | UKB GWAS (PHESANT) | 32 | 7.3e-29 | 0.0374 | 0.151 | 0.607 0.59-0.626 |
2.83 OR 95% CI: 1.76-4.53 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Malignant neoplasm of breast |
MGI | P&T | UKB GWAS (FINNGEN) | 120 | 1.1e-28 | 0.0144 | 0.137 | 0.595 0.578-0.611 |
2.31 OR 95% CI: 1.47-3.61 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 7 | 2.3e-28 | 0.0297 | 0.0977 | 0.593 0.573-0.613 |
3.74 OR 95% CI: 2.46-5.68 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
MGI | P&T | GWAS Catalog (2019-05-03) | 7 | 2.3e-28 | 0.0297 | 0.0977 | 0.593 0.573-0.613 |
3.74 OR 95% CI: 2.46-5.68 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 63 | 2.4e-28 | 0.0169 | 0.137 | 0.593 0.576-0.61 |
2.13 OR 95% CI: 1.36-3.34 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 C50 Malignant neoplasm of breast |
MGI | lassosum | UKB GWAS (ICD10) | 4047 | 3e-28 | 0.0173 | 0.137 | 0.595 0.579-0.61 |
2.05 OR 95% CI: 1.3-3.24 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer [female], Overall (Michailidou K et al. 2018) |
MGI | GWAS Hits | UKB GWAS (PheCode) | 41 | 3.6e-28 | 0.0127 | 0.137 | 0.595 0.577-0.612 |
1.8 OR 95% CI: 1.12-2.91 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Ransohoff KJ et al. 2017 |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 138 | 3.9e-28 | 0.0116 | 0.0959 | 0.586 0.571-0.602 |
2.14 OR 95% CI: 1.4-3.26 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Malignant neoplasm of breast |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 88 | 5.6e-28 | 0.014 | 0.137 | 0.594 0.577-0.611 |
2.03 OR 95% CI: 1.28-3.23 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 35 | 8.5e-28 | 0.0033 | 0.0826 | 0.537 0.53-0.545 |
1.39 OR 95% CI: 1.11-1.74 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
MGI | P&T | Chahal HS et al. 2018 | 6 | 1.2e-27 | 0.0315 | 0.0978 | 0.583 0.564-0.603 |
3.75 OR 95% CI: 2.49-5.64 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Squamous cell carcinoma;Cutaneous squamous cell carcinoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-09) | Chahal HS et al. 2018 | 5 | 2.4e-27 | 0.0313 | 0.0979 | 0.583 0.563-0.603 |
3.65 OR 95% CI: 2.41-5.53 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER positive |
MGI | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 423 | 5.7e-27 | 0.0216 | 0.137 | 0.592 0.576-0.61 |
2.41 OR 95% CI: 1.56-3.71 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported basal cell carcinoma |
MGI | Fixed threshold (5e-09) | UKB GWAS (PHESANT) | 14 | 6.4e-27 | 0.0174 | 0.108 | 0.577 0.562-0.592 |
2.9 OR 95% CI: 1.99-4.24 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer [female], Overall (Michailidou K et al. 2018) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119237 | 2.1e-26 | 0.0189 | 0.137 | 0.59 0.573-0.607 |
1.79 OR 95% CI: 1.12-2.86 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 22 | 8.7e-26 | 0.0118 | 0.0822 | 0.561 0.548-0.573 |
1.65 OR 95% CI: 1.17-2.34 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 18 | 1.9e-25 | 0.0116 | 0.0822 | 0.561 0.548-0.573 |
1.79 OR 95% CI: 1.28-2.51 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Malignant melanoma of skin |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 153 | 2.2e-25 | 0.0103 | 0.0959 | 0.577 0.562-0.593 |
2.4 OR 95% CI: 1.59-3.63 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported basal cell carcinoma |
MGI | GWAS Hits | UKB GWAS (PHESANT) | 19 | 3e-25 | 0.0185 | 0.108 | 0.571 0.555-0.587 |
2.54 OR 95% CI: 1.72-3.74 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 12 | 9.7e-25 | 0.0112 | 0.0822 | 0.56 0.547-0.572 |
1.79 OR 95% CI: 1.28-2.51 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Malignant neoplasm of breast |
MGI | GWAS Hits | UKB GWAS (FINNGEN) | 32 | 2e-24 | 0.0104 | 0.138 | 0.585 0.569-0.603 |
1.97 OR 95% CI: 1.24-3.14 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Self-reported prostate cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 1401 | 3.5e-24 | 0.0398 | 0.151 | 0.595 0.577-0.614 |
1.53 OR 95% CI: 0.88-2.66 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Self-reported prostate cancer |
MGI | Fixed threshold (5e-09) | UKB GWAS (PHESANT) | 14 | 3.7e-24 | 0.035 | 0.151 | 0.591 0.573-0.61 |
1.67 OR 95% CI: 0.971-2.87 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported basal cell carcinoma |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 192 | 4e-24 | 0.0159 | 0.108 | 0.579 0.563-0.595 |
1.91 OR 95% CI: 1.25-2.92 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 C50 Malignant neoplasm of breast |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 66 | 4.2e-24 | 0.0109 | 0.138 | 0.585 0.568-0.601 |
2.57 OR 95% CI: 1.68-3.95 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Malignant neoplasm of breast |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 233 | 5.4e-24 | 0.0119 | 0.138 | 0.586 0.57-0.603 |
1.82 OR 95% CI: 1.13-2.93 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Malignant neoplasm of breast |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 45 | 1.3e-23 | 0.01 | 0.138 | 0.585 0.568-0.602 |
2.22 OR 95% CI: 1.43-3.46 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 C50 Malignant neoplasm of breast |
MGI | P&T | UKB GWAS (ICD10) | 42 | 1.5e-23 | 0.0127 | 0.138 | 0.584 0.568-0.601 |
1.43 OR 95% CI: 0.853-2.41 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Self-reported prostate cancer |
MGI | GWAS Hits | UKB GWAS (PHESANT) | 21 | 3.3e-23 | 0.033 | 0.151 | 0.596 0.579-0.615 |
2.39 OR 95% CI: 1.41-4.03 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Breast cancer [female], Overall (Michailidou K et al. 2018) |
MGI | Fixed threshold (5e-09) | UKB GWAS (PheCode) | 24 | 4e-23 | 0.0091 | 0.138 | 0.583 0.566-0.601 |
2.37 OR 95% CI: 1.53-3.67 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 C50 Malignant neoplasm of breast |
MGI | Fixed threshold (5e-07) | UKB GWAS (ICD10) | 29 | 4.2e-23 | 0.0103 | 0.138 | 0.582 0.565-0.599 |
1.85 OR 95% CI: 1.16-2.96 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Self-reported breast cancer |
MGI | Fixed threshold (5e-07) | UKB GWAS (PHESANT) | 33 | 1.2e-22 | 0.0096 | 0.138 | 0.581 0.564-0.598 |
2.17 OR 95% CI: 1.38-3.42 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Self-reported prostate cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 203 | 1.3e-22 | 0.0295 | 0.152 | 0.591 0.573-0.611 |
1.82 OR 95% CI: 1.07-3.11 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Self-reported breast cancer |
MGI | GWAS Hits | UKB GWAS (PHESANT) | 22 | 2.3e-22 | 0.0081 | 0.138 | 0.579 0.561-0.597 |
2.32 OR 95% CI: 1.49-3.61 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 17 | 4.7e-22 | 0.0203 | 0.0982 | 0.584 0.565-0.601 |
2.24 OR 95% CI: 1.35-3.71 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 44 | 5.4e-22 | 0.0948 | 0.0794 | 0.691 0.659-0.721 |
2.5 OR 95% CI: 1.03-6.06 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 43 | 7e-22 | 0.0943 | 0.0794 | 0.689 0.657-0.72 |
2.5 OR 95% CI: 1.03-6.06 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Self-reported breast cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 30041 | 7.8e-22 | 0.0208 | 0.138 | 0.586 0.57-0.603 |
1.59 OR 95% CI: 0.962-2.62 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Self-reported breast cancer |
MGI | Fixed threshold (5e-09) | UKB GWAS (PHESANT) | 18 | 1.1e-21 | 0.0081 | 0.138 | 0.58 0.563-0.597 |
1.86 OR 95% CI: 1.15-2.99 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Self-reported breast cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 62 | 2.9e-21 | 0.0126 | 0.138 | 0.58 0.562-0.597 |
1.72 OR 95% CI: 1.06-2.79 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 C50 Malignant neoplasm of breast |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 197 | 3e-21 | 0.0097 | 0.138 | 0.584 0.567-0.601 |
1.77 OR 95% CI: 1.08-2.9 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 40 | 3.1e-21 | 0.0949 | 0.0795 | 0.684 0.652-0.714 |
2.51 OR 95% CI: 1.04-6.07 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Self-reported breast cancer |
MGI | P&T | UKB GWAS (PHESANT) | 68 | 3.2e-21 | 0.013 | 0.138 | 0.58 0.563-0.597 |
1.54 OR 95% CI: 0.924-2.56 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Malignant neoplasm of breast |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1111495 | 3.7e-21 | 0.0176 | 0.138 | 0.581 0.564-0.597 |
2.17 OR 95% CI: 1.38-3.41 |
Binary
nominal
|
|
| 185 |
Cancer of prostate Self-reported prostate cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1111494 | 4.8e-21 | 0.021 | 0.152 | 0.591 0.573-0.609 |
2.85 OR 95% CI: 1.76-4.62 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 C50 Malignant neoplasm of breast |
MGI | GWAS Hits | UKB GWAS (ICD10) | 20 | 6.4e-21 | 0.0083 | 0.138 | 0.576 0.559-0.593 |
1.91 OR 95% CI: 1.2-3.03 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Cutaneous squamous cell carcinoma |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 18 | 8.6e-21 | 0.0178 | 0.0983 | 0.581 0.56-0.599 |
2.33 OR 95% CI: 1.44-3.77 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Malignant neoplasm of breast |
MGI | Fixed threshold (5e-09) | UKB GWAS (FINNGEN) | 21 | 3.3e-20 | 0.0076 | 0.138 | 0.575 0.558-0.592 |
2.38 OR 95% CI: 1.54-3.69 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 32 | 4.6e-20 | 0.0998 | 0.0795 | 0.675 0.64-0.707 |
4.11 OR 95% CI: 1.97-8.6 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 C50 Malignant neoplasm of breast |
MGI | PRS-CS | UKB GWAS (ICD10) | 1111495 | 7.1e-20 | 0.0137 | 0.138 | 0.578 0.56-0.596 |
2.03 OR 95% CI: 1.29-3.2 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
UKB | P&T | GWAS Catalog (2019-05-03) | 27 | 1.7e-19 | 0.1021 | 0.0796 | 0.672 0.637-0.703 |
2.52 OR 95% CI: 1.04-6.08 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 11 | 2.3e-19 | 0.0387 | 0.0811 | 0.63 0.601-0.658 |
3.26 OR 95% CI: 1.69-6.26 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 11 | 2.3e-19 | 0.0387 | 0.0811 | 0.63 0.601-0.658 |
3.26 OR 95% CI: 1.69-6.26 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 11 | 2.3e-19 | 0.0387 | 0.0811 | 0.63 0.601-0.658 |
3.26 OR 95% CI: 1.69-6.26 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported basal cell carcinoma |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1111490 | 4.2e-19 | 0.0146 | 0.109 | 0.575 0.559-0.591 |
1.42 OR 95% CI: 0.871-2.33 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | PRS-CS | Michailidou K et al. 2018 | 1119140 | 5e-19 | 0.0139 | 0.138 | 0.578 0.56-0.594 |
1.8 OR 95% CI: 1.13-2.88 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | P&T | Michailidou K et al. 2018 | 217 | 1e-18 | 0.0104 | 0.138 | 0.576 0.559-0.593 |
1.84 OR 95% CI: 1.14-2.97 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Self-reported breast cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1111495 | 1.3e-18 | 0.0139 | 0.138 | 0.576 0.56-0.592 |
1.6 OR 95% CI: 0.981-2.62 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 15 | 1.4e-18 | 0.0152 | 0.0821 | 0.571 0.555-0.588 |
2.91 OR 95% CI: 1.99-4.24 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 15 | 1.4e-18 | 0.0152 | 0.0821 | 0.571 0.555-0.588 |
2.91 OR 95% CI: 1.99-4.24 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
UKB | P&T | GWAS Catalog (2019-05-03) | 15 | 1.4e-18 | 0.0152 | 0.0821 | 0.571 0.555-0.588 |
2.91 OR 95% CI: 1.99-4.24 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] Self-reported breast cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 210 | 1.8e-18 | 0.0117 | 0.138 | 0.576 0.559-0.593 |
1.53 OR 95% CI: 0.92-2.55 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 392 | 1.8e-18 | 0.0093 | 0.138 | 0.575 0.557-0.592 |
2.15 OR 95% CI: 1.37-3.39 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 10 | 2e-18 | 0.0374 | 0.0811 | 0.626 0.597-0.655 |
3.53 OR 95% CI: 1.87-6.66 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 23 | 3.2e-18 | 0.091 | 0.0798 | 0.667 0.632-0.699 |
2.52 OR 95% CI: 1.04-6.09 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Self-reported malignant melanoma |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 129 | 6e-18 | 0.0079 | 0.0962 | 0.565 0.549-0.582 |
1.61 OR 95% CI: 1.01-2.59 |
Binary
nominal
|
|
| 172.3 |
Carcinoma in situ of skin Diagnoses - main ICD10: D04 Carcinoma in situ of skin (UKB GWAS (ICD10)) |
MGI | lassosum | UKB GWAS (PheCode) | 7 | 9.2e-18 | 0.0411 | 0.0923 | 0.569 0.541-0.595 |
3.77 OR 95% CI: 2.24-6.34 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 14 | 1.1e-17 | 0.0146 | 0.0821 | 0.569 0.553-0.586 |
3.07 OR 95% CI: 2.12-4.46 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 9 | 1.4e-17 | 0.0387 | 0.0812 | 0.62 0.591-0.649 |
4.04 OR 95% CI: 2.21-7.39 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 12 | 1.7e-17 | 0.0132 | 0.0821 | 0.569 0.552-0.586 |
2.74 OR 95% CI: 1.86-4.03 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 C50 Malignant neoplasm of breast |
MGI | Fixed threshold (5e-09) | UKB GWAS (ICD10) | 14 | 1.9e-17 | 0.0071 | 0.138 | 0.568 0.551-0.585 |
1.98 OR 95% CI: 1.25-3.13 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | lassosum | Michailidou K et al. 2018 | 18866 | 2.4e-17 | 0.0136 | 0.138 | 0.571 0.555-0.588 |
1.87 OR 95% CI: 1.16-3.01 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | P&T | GWAS Catalog (2019-05-03) | 8 | 2.9e-17 | 0.0417 | 0.0812 | 0.618 0.587-0.647 |
5.14 OR 95% CI: 2.94-8.99 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 C43 Malignant melanoma of skin |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 164 | 5.1e-17 | 0.0075 | 0.0963 | 0.566 0.55-0.583 |
1.66 OR 95% CI: 1.04-2.66 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 13 | 5.1e-17 | 0.0146 | 0.0821 | 0.567 0.551-0.584 |
2.66 OR 95% CI: 1.79-3.93 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 133 | 1.6e-16 | 0.0084 | 0.138 | 0.569 0.552-0.587 |
2.05 OR 95% CI: 1.3-3.23 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Malignant melanoma of skin |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1111490 | 4.6e-16 | 0.0083 | 0.0964 | 0.568 0.552-0.584 |
2.09 OR 95% CI: 1.35-3.22 |
Binary
nominal
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 25 | 2.9e-15 | 0.0275 | 0.0811 | 0.628 0.595-0.659 |
3.29 OR 95% CI: 1.55-6.99 |
Binary
nominal
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 28 | 5.6e-15 | 0.0258 | 0.0811 | 0.625 0.592-0.656 |
3.65 OR 95% CI: 1.77-7.56 |
Binary
nominal
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 28 | 5.6e-15 | 0.0258 | 0.0811 | 0.625 0.592-0.656 |
3.65 OR 95% CI: 1.77-7.56 |
Binary
nominal
|
|
| 172 |
Skin cancer Self-reported skin cancer |
MGI | P&T | UKB GWAS (PHESANT) | 6 | 9.9e-15 | 0.0049 | 0.148 | 0.513 0.503-0.523 |
1.56 OR 95% CI: 1.12-2.16 |
Binary
nominal
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
UKB | P&T | GWAS Catalog (2019-05-03) | 19 | 1.3e-14 | 0.0315 | 0.0812 | 0.622 0.59-0.653 |
2.93 OR 95% CI: 1.34-6.41 |
Binary
nominal
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 23 | 1.4e-14 | 0.0276 | 0.0812 | 0.623 0.592-0.656 |
3.64 OR 95% CI: 1.76-7.53 |
Binary
nominal
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 20 | 3.8e-14 | 0.0309 | 0.0812 | 0.619 0.586-0.65 |
3.64 OR 95% CI: 1.76-7.52 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | GWAS Hits | Michailidou K et al. 2018 | 49 | 1e-13 | 0.01 | 0.139 | 0.564 0.547-0.58 |
1.72 OR 95% CI: 1.05-2.81 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 44 | 1.3e-13 | 0.0527 | 0.0793 | 0.703 0.659-0.745 |
4.6 OR 95% CI: 1.75-12.1 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
UKB | P&T | GWAS Catalog (2019-05-03) | 44 | 1.3e-13 | 0.0527 | 0.0793 | 0.703 0.659-0.745 |
4.6 OR 95% CI: 1.75-12.1 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 14 | 2.1e-13 | 0.0071 | 0.139 | 0.556 0.538-0.571 |
1.69 OR 95% CI: 1.03-2.76 |
Binary
nominal
|
|
| 172 |
Skin cancer Self-reported skin cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 6 | 2.2e-13 | 0.0049 | 0.148 | 0.471 0.461-0.48 |
1.57 OR 95% CI: 1.13-2.17 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 31 | 2.8e-13 | 0.0081 | 0.139 | 0.561 0.544-0.578 |
1.62 OR 95% CI: 0.984-2.68 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 42 | 3.9e-13 | 0.0516 | 0.0795 | 0.699 0.656-0.742 |
5.34 OR 95% CI: 2.12-13.4 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 40 | 4.1e-13 | 0.0511 | 0.0795 | 0.698 0.656-0.74 |
4.6 OR 95% CI: 1.75-12.1 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 46 | 5e-13 | 0.0505 | 0.0794 | 0.697 0.652-0.74 |
4.6 OR 95% CI: 1.75-12.1 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 15 | 2.3e-12 | 0.0465 | 0.0812 | 0.618 0.582-0.652 |
3.76 OR 95% CI: 1.82-7.79 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 12 | 2.5e-12 | 0.0033 | 0.0916 | 0.574 0.552-0.596 |
1.95 OR 95% CI: 1.11-3.42 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 C43 Malignant melanoma of skin |
MGI | PRS-CS | UKB GWAS (ICD10) | 1109519 | 3e-12 | 0.0037 | 0.0965 | 0.556 0.541-0.571 |
1.88 OR 95% CI: 1.2-2.95 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
UKB | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 158 | 3.1e-12 | 0.002 | 0.0827 | 0.526 0.518-0.533 |
1.21 OR 95% CI: 0.952-1.54 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | Fixed threshold (5e-07) | Michailidou K et al. 2018 | 73 | 6.2e-12 | 0.0084 | 0.139 | 0.557 0.54-0.574 |
1.62 OR 95% CI: 0.98-2.67 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 14 | 7.1e-12 | 0.0443 | 0.0813 | 0.616 0.581-0.649 |
3.03 OR 95% CI: 1.38-6.65 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 13 | 8.1e-12 | 0.0036 | 0.0917 | 0.572 0.55-0.594 |
1.47 OR 95% CI: 0.779-2.77 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
MGI | P&T | GWAS Catalog (2019-05-03) | 13 | 8.1e-12 | 0.0036 | 0.0917 | 0.572 0.55-0.594 |
1.47 OR 95% CI: 0.779-2.77 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
UKB | P&T | GWAS Catalog (2019-05-03) | 5 | 1.1e-11 | 0.0529 | 0.0813 | 0.606 0.568-0.642 |
4.15 OR 95% CI: 2.04-8.41 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 31 | 1.2e-11 | 0.045 | 0.08 | 0.681 0.634-0.723 |
5.36 OR 95% CI: 2.13-13.5 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | GWAS Hits | Michailidou K et al. 2018 | 10 | 1.6e-11 | 0.0072 | 0.139 | 0.55 0.533-0.566 |
1.88 OR 95% CI: 1.17-3.03 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | lassosum | Michailidou K et al. 2018 | 270 | 1.6e-11 | 0.0061 | 0.139 | 0.546 0.529-0.562 |
2.11 OR 95% CI: 1.34-3.33 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 14 | 1.6e-11 | 0.0031 | 0.0917 | 0.571 0.55-0.594 |
1.32 OR 95% CI: 0.684-2.56 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 15 | 1.9e-11 | 0.0034 | 0.0917 | 0.572 0.55-0.594 |
2.12 OR 95% CI: 1.22-3.66 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 15 | 1.9e-11 | 0.0034 | 0.0917 | 0.572 0.55-0.594 |
2.12 OR 95% CI: 1.22-3.66 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Ransohoff KJ et al. 2017 |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 2e-11 | 0.0069 | 0.0965 | 0.555 0.54-0.573 |
1.64 OR 95% CI: 1.01-2.66 |
Binary
nominal
|
|
| 172.3 |
Carcinoma in situ of skin Diagnoses - main ICD10: D04 Carcinoma in situ of skin (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 5 | 3.9e-11 | 0.0262 | 0.093 | 0.557 0.531-0.582 |
2.45 OR 95% CI: 1.34-4.45 |
Binary
nominal
|
|
| 172.3 |
Carcinoma in situ of skin Diagnoses - main ICD10: D04 Carcinoma in situ of skin (UKB GWAS (ICD10)) |
MGI | P&T | UKB GWAS (PheCode) | 5 | 3.9e-11 | 0.0262 | 0.093 | 0.557 0.531-0.582 |
2.45 OR 95% CI: 1.34-4.45 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | P&T | Michailidou K et al. 2018 | 9 | 6.5e-11 | 0.0074 | 0.139 | 0.548 0.53-0.564 |
1.88 OR 95% CI: 1.18-2.99 |
Binary
nominal
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 18 | 6.9e-11 | 0.0082 | 0.082 | 0.576 0.553-0.6 |
2.12 OR 95% CI: 1.17-3.84 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | lassosum | UKB GWAS (PheCode) | 954 | 1.3e-10 | 0.0136 | 0.0819 | 0.578 0.548-0.607 |
3.21 OR 95% CI: 1.67-6.15 |
Binary
nominal
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 11 | 1.5e-10 | 0.008 | 0.082 | 0.577 0.552-0.601 |
1.32 OR 95% CI: 0.64-2.72 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
UKB | P&T | GWAS Catalog (2019-05-03) | 19 | 1.7e-10 | 0.0076 | 0.0824 | 0.552 0.534-0.569 |
1.94 OR 95% CI: 1.22-3.1 |
Binary
nominal
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
UKB | P&T | GWAS Catalog (2019-05-03) | 10 | 2e-10 | 0.0082 | 0.082 | 0.547 0.527-0.566 |
2.05 OR 95% CI: 1.24-3.4 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 12 | 2.2e-10 | 0.05 | 0.0815 | 0.605 0.569-0.639 |
3.38 OR 95% CI: 1.59-7.2 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 12 | 2.2e-10 | 0.05 | 0.0815 | 0.605 0.569-0.639 |
3.38 OR 95% CI: 1.59-7.2 |
Binary
nominal
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
UKB | P&T | GWAS Catalog (2019-05-03) | 20 | 2.3e-10 | 0.0084 | 0.082 | 0.572 0.549-0.596 |
2.6 OR 95% CI: 1.5-4.51 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 11 | 2.4e-10 | 0.0481 | 0.0815 | 0.605 0.57-0.639 |
3.02 OR 95% CI: 1.37-6.64 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 9 | 2.6e-10 | 0.0517 | 0.0802 | 0.634 0.586-0.679 |
5.04 OR 95% CI: 2.15-11.8 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 18 | 2.8e-10 | 0.0074 | 0.0824 | 0.551 0.533-0.568 |
1.94 OR 95% CI: 1.22-3.1 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 11 | 3.1e-10 | 0.0532 | 0.0803 | 0.639 0.592-0.682 |
4.41 OR 95% CI: 1.81-10.7 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 11 | 3.1e-10 | 0.0532 | 0.0803 | 0.639 0.592-0.682 |
4.41 OR 95% CI: 1.81-10.7 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 11 | 3.1e-10 | 0.0532 | 0.0803 | 0.639 0.592-0.682 |
4.41 OR 95% CI: 1.81-10.7 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 10 | 5.1e-10 | 0.053 | 0.0803 | 0.636 0.589-0.682 |
4.4 OR 95% CI: 1.81-10.7 |
Binary
nominal
|
|
| 172 |
Skin cancer Self-reported skin cancer |
MGI | Fixed threshold (5e-07) | UKB GWAS (PHESANT) | 5 | 7.4e-10 | 0.0028 | 0.148 | 0.5 0.489-0.511 |
1.56 OR 95% CI: 1.12-2.16 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | Fixed threshold (5e-09) | Michailidou K et al. 2018 | 8 | 8.4e-10 | 0.0055 | 0.139 | 0.543 0.525-0.56 |
1.74 OR 95% CI: 1.08-2.81 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
UKB | P&T | GWAS Catalog (2019-05-03) | 5 | 1.3e-9 | 0.0581 | 0.0804 | 0.628 0.582-0.675 |
4.41 OR 95% CI: 1.81-10.7 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx Self-reported malignant melanoma |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1111490 | 1.8e-9 | 0.0051 | 0.0966 | 0.547 0.531-0.563 |
1.94 OR 95% CI: 1.25-3.02 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | Fixed threshold (5e-06) | Michailidou K et al. 2018 | 35 | 1.8e-9 | 0.004 | 0.139 | 0.546 0.528-0.561 |
1.99 OR 95% CI: 1.25-3.18 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 43 | 4.7e-9 | 0.0545 | 0.0775 | 0.698 0.623-0.766 |
15.2 OR 95% CI: 5.32-43.4 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 44 | 6.1e-9 | 0.0558 | 0.0776 | 0.696 0.621-0.764 |
12.9 OR 95% CI: 4.45-37.6 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
MGI | P&T | GWAS Catalog (2019-05-03) | 44 | 6.1e-9 | 0.0558 | 0.0776 | 0.696 0.621-0.764 |
12.9 OR 95% CI: 4.45-37.6 |
Binary
nominal
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 18 | 6.4e-9 | 0.0066 | 0.082 | 0.55 0.53-0.571 |
2.28 OR 95% CI: 1.4-3.7 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 40 | 7.6e-9 | 0.0554 | 0.0778 | 0.698 0.624-0.768 |
12.5 OR 95% CI: 4.36-36.1 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 21 | 9.2e-9 | 0.0054 | 0.0824 | 0.543 0.526-0.562 |
0.852 OR 95% CI: 0.437-1.66 |
Binary
nominal
|
|
| 153.2 |
Colon cancer Cancer code, self-reported: colon cancer/sigmoid cancer (UKB GWAS (PHESANT)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 9.8e-9 | 0.0023 | 0.0827 | 0.569 0.539-0.599 |
3.85 OR 95% CI: 2.19-6.77 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 32 | 1.3e-8 | 0.0458 | 0.0779 | 0.696 0.628-0.765 |
11.3 OR 95% CI: 3.76-33.9 |
Binary
nominal
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 12 | 1.9e-8 | 0.0056 | 0.0821 | 0.541 0.521-0.561 |
2.05 OR 95% CI: 1.24-3.4 |
Binary
nominal
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 28 | 2e-8 | 0.0064 | 0.0822 | 0.562 0.539-0.585 |
1.32 OR 95% CI: 0.641-2.73 |
Binary
nominal
|
|
| 157 |
Pancreatic cancer |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 17 | 2.4e-8 | 0.0132 | 0.082 | 0.589 0.559-0.622 |
2.58 OR 95% CI: 1.19-5.57 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | P&T | UKB GWAS (PheCode) | 5 | 2.7e-8 | 0.0157 | 0.0822 | 0.569 0.538-0.598 |
1.65 OR 95% CI: 0.708-3.83 |
Binary
nominal
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 11 | 2.9e-8 | 0.0059 | 0.0821 | 0.54 0.52-0.56 |
1.6 OR 95% CI: 0.914-2.8 |
Binary
nominal
|
|
| 10001 |
Any Cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 47 | 3.4e-8 | 0.0023 | 0.182 | 0.529 0.518-0.54 |
1.22 OR 95% CI: 0.864-1.73 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 23 | 5.1e-8 | 0.0371 | 0.0784 | 0.688 0.618-0.758 |
11.1 OR 95% CI: 3.68-33.4 |
Binary
nominal
|
|
| 172.3 |
Carcinoma in situ of skin Diagnoses - main ICD10: D04 Carcinoma in situ of skin (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 14 | 6.2e-8 | 0.0124 | 0.0934 | 0.556 0.531-0.583 |
2.47 OR 95% CI: 1.35-4.5 |
Binary
nominal
|
|
| 172 |
Skin cancer Self-reported skin cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 15 | 1.2e-7 | 0.0023 | 0.148 | 0.509 0.499-0.52 |
1.52 OR 95% CI: 1.08-2.14 |
Binary
nominal
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 34 | 1.2e-7 | 0.0039 | 0.0822 | 0.559 0.535-0.581 |
1.64 OR 95% CI: 0.846-3.17 |
Binary
nominal
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 34 | 1.2e-7 | 0.0039 | 0.0822 | 0.559 0.535-0.581 |
1.64 OR 95% CI: 0.846-3.17 |
Binary
nominal
|
|
| 10001 |
Any Cancer |
MGI | lassosum | UKB GWAS (PheCode) | 179 | 1.5e-7 | 0.0037 | 0.182 | 0.523 0.512-0.535 |
1.61 OR 95% CI: 1.14-2.27 |
Binary
nominal
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 5 | 1.7e-7 | 0.0011 | 0.0822 | 0.49 0.476-0.505 |
1.97 OR 95% CI: 1.25-3.12 |
Binary
nominal
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma |
UKB | P&T | GWAS Catalog (2019-05-03) | 5 | 1.7e-7 | 0.0011 | 0.0822 | 0.49 0.476-0.505 |
1.97 OR 95% CI: 1.25-3.12 |
Binary
nominal
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 7 | 1.8e-7 | 0.0011 | 0.0822 | 0.493 0.479-0.508 |
2.13 OR 95% CI: 1.38-3.28 |
Binary
nominal
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 7 | 1.8e-7 | 0.0011 | 0.0822 | 0.493 0.479-0.508 |
2.13 OR 95% CI: 1.38-3.28 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
UKB | PRS-CS | Phelan CM et al. 2017 | 1115189 | 2.3e-7 | 0.0119 | 0.0823 | 0.568 0.542-0.595 |
1.76 OR 95% CI: 0.838-3.7 |
Binary
nominal
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 16 | 2.5e-7 | 0.0058 | 0.0821 | 0.539 0.519-0.559 |
1.6 OR 95% CI: 0.913-2.8 |
Binary
nominal
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 16 | 2.5e-7 | 0.0058 | 0.0821 | 0.539 0.519-0.559 |
1.6 OR 95% CI: 0.913-2.8 |
Binary
nominal
|
|
| 157 |
Pancreatic cancer |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 10 | 3.3e-7 | 0.0145 | 0.0822 | 0.579 0.548-0.611 |
1.64 OR 95% CI: 0.655-4.12 |
Binary
nominal
|
|
| 157 |
Pancreatic cancer |
UKB | P&T | GWAS Catalog (2019-05-03) | 10 | 3.3e-7 | 0.0145 | 0.0822 | 0.579 0.548-0.611 |
1.64 OR 95% CI: 0.655-4.12 |
Binary
nominal
|
|
| 157 |
Pancreatic cancer |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 21 | 4.9e-7 | 0.009 | 0.0822 | 0.588 0.556-0.621 |
2.57 OR 95% CI: 1.19-5.55 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 8 | 5.1e-7 | 0.0011 | 0.0919 | 0.548 0.526-0.569 |
1.68 OR 95% CI: 0.929-3.04 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
UKB | Fixed threshold (5e-07) | Phelan CM et al. 2017 | 23 | 7e-7 | 0.0038 | 0.0823 | 0.567 0.539-0.595 |
1.97 OR 95% CI: 0.971-4 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-09) | Huyghe JR et al. 2019 | 56 | 9.3e-7 | 0.0127 | 0.0827 | 0.559 0.532-0.584 |
1.89 OR 95% CI: 0.995-3.58 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
UKB | GWAS Hits | Phelan CM et al. 2017 | 16 | 1.1e-6 | 0.0056 | 0.0824 | 0.567 0.539-0.595 |
1.76 OR 95% CI: 0.839-3.69 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported rodent ulcer |
MGI | lassosum | UKB GWAS (PHESANT) | 2231 | 1.2e-6 | 0.0028 | 0.109 | 0.521 0.506-0.536 |
2.44 OR 95% CI: 1.65-3.62 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Malignant neoplasm of thyroid gland |
MGI | lassosum | UKB GWAS (FINNGEN) | 656 | 1.7e-6 | 0.011 | 0.0823 | 0.565 0.535-0.595 |
1.91 OR 95% CI: 0.861-4.22 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
UKB | Fixed threshold (5e-09) | Phelan CM et al. 2017 | 13 | 2e-6 | 0.006 | 0.0824 | 0.561 0.533-0.589 |
1.34 OR 95% CI: 0.585-3.08 |
Binary
nominal
|
|
| 153.2 |
Colon cancer Cancer code, self-reported: colon cancer/sigmoid cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 20 | 2.4e-6 | 0.0013 | 0.083 | 0.559 0.532-0.586 |
1.6 OR 95% CI: 0.733-3.51 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Malignant neoplasm of thyroid gland |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 11 | 3.4e-6 | 0.0171 | 0.0824 | 0.56 0.53-0.59 |
2.42 OR 95% CI: 1.17-4.98 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Malignant neoplasm of thyroid gland |
MGI | P&T | UKB GWAS (FINNGEN) | 11 | 3.4e-6 | 0.0171 | 0.0824 | 0.56 0.53-0.59 |
2.42 OR 95% CI: 1.17-4.98 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 58 | 3.8e-6 | 0.0017 | 0.0825 | 0.531 0.514-0.549 |
1.58 OR 95% CI: 0.948-2.63 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
UKB | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 54 | 3.8e-6 | 0.0026 | 0.0824 | 0.566 0.538-0.594 |
1.34 OR 95% CI: 0.583-3.07 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | PRS-CS | Michailidou K et al. 2018 | 1115376 | 4.2e-6 | 0.0022 | 0.139 | 0.539 0.52-0.556 |
1.51 OR 95% CI: 0.907-2.51 |
Binary
nominal
|
|
| 153.2 |
Colon cancer Cancer code, self-reported: colon cancer/sigmoid cancer (UKB GWAS (PHESANT)) |
MGI | lassosum | UKB GWAS (PheCode) | 150 | 4.9e-6 | 0.0023 | 0.083 | 0.567 0.54-0.594 |
1.17 OR 95% CI: 0.477-2.87 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-07) | Huyghe JR et al. 2019 | 81 | 5.4e-6 | 0.0157 | 0.0828 | 0.553 0.525-0.577 |
3.04 OR 95% CI: 1.79-5.17 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | P&T | Huyghe JR et al. 2019 | 81 | 5.4e-6 | 0.0157 | 0.0828 | 0.553 0.525-0.577 |
3.04 OR 95% CI: 1.79-5.17 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | Huyghe JR et al. 2019 | 87 | 6.9e-6 | 0.0155 | 0.0828 | 0.552 0.525-0.576 |
2.39 OR 95% CI: 1.33-4.27 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | Huyghe JR et al. 2019 | 85 | 7e-6 | 0.0152 | 0.0828 | 0.551 0.525-0.576 |
2.72 OR 95% CI: 1.56-4.73 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
UKB | GWAS Hits | Phelan CM et al. 2017 | 21 | 8.4e-6 | 0.005 | 0.0824 | 0.552 0.523-0.581 |
1.76 OR 95% CI: 0.839-3.69 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
UKB | P&T | Phelan CM et al. 2017 | 12 | 8.6e-6 | 0.0065 | 0.0824 | 0.558 0.53-0.586 |
1.55 OR 95% CI: 0.71-3.38 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
UKB | Fixed threshold (5e-09) | Phelan CM et al. 2017 | 19 | 1.5e-5 | 0.0044 | 0.0824 | 0.549 0.52-0.579 |
1.55 OR 95% CI: 0.709-3.38 |
Binary
nominal
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 22 | 2e-5 | 0.0268 | 0.0818 | 0.577 0.537-0.617 |
2.2 OR 95% CI: 0.855-5.66 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | GWAS Hits | Huyghe JR et al. 2019 | 74 | 2.1e-5 | 0.0152 | 0.0828 | 0.55 0.522-0.574 |
2.2 OR 95% CI: 1.21-4 |
Binary
nominal
|
|
| 10001 |
Any Cancer |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 18 | 2.5e-5 | 0.0024 | 0.182 | 0.519 0.507-0.53 |
1.25 OR 95% CI: 0.87-1.78 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
UKB | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 58 | 2.6e-5 | 0.0032 | 0.0825 | 0.556 0.529-0.584 |
1.55 OR 95% CI: 0.709-3.38 |
Binary
nominal
|
|
| 10001 |
Any Cancer |
MGI | P&T | UKB GWAS (PheCode) | 15 | 2.7e-5 | 0.003 | 0.182 | 0.517 0.506-0.527 |
1.42 OR 95% CI: 1-2.02 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Self-reported testicular cancer |
MGI | Fixed threshold (5e-07) | UKB GWAS (PHESANT) | 13 | 2.7e-5 | 0.0194 | 0.0835 | 0.663 0.594-0.729 |
1.9 OR 95% CI: 0.288-12.5 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Self-reported testicular cancer |
MGI | GWAS Hits | UKB GWAS (PHESANT) | 9 | 3.1e-5 | 0.0241 | 0.0838 | 0.658 0.594-0.719 |
2.64 OR 95% CI: 0.535-13 |
Binary
nominal
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
UKB | P&T | GWAS Catalog (2019-05-03) | 21 | 3.4e-5 | 0.0277 | 0.0818 | 0.576 0.536-0.616 |
2.2 OR 95% CI: 0.854-5.66 |
Binary
nominal
|
|
| 153.2 |
Colon cancer Cancer code, self-reported: colon cancer/sigmoid cancer (UKB GWAS (PHESANT)) |
MGI | P&T | UKB GWAS (PheCode) | 12 | 4.4e-5 | 0.0031 | 0.0831 | 0.55 0.522-0.577 |
1.6 OR 95% CI: 0.733-3.51 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
UKB | Fixed threshold (5e-07) | Phelan CM et al. 2017 | 31 | 4.5e-5 | 0.004 | 0.0825 | 0.547 0.518-0.575 |
1.76 OR 95% CI: 0.838-3.69 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
UKB | lassosum | Phelan CM et al. 2017 | 110710 | 4.9e-5 | 0.0151 | 0.0825 | 0.556 0.529-0.583 |
1.76 OR 95% CI: 0.839-3.69 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Ovarian clear cell cancer |
UKB | lassosum | Phelan CM et al. 2017 | 1098236 | 5e-5 | 0.0098 | 0.0824 | 0.546 0.52-0.574 |
1.76 OR 95% CI: 0.839-3.69 |
Binary
nominal
|
|
| 10001 |
Any Cancer |
MGI | GWAS Hits | UKB GWAS (PheCode) | 14 | 5.1e-5 | 0.0027 | 0.182 | 0.515 0.503-0.526 |
1.48 OR 95% CI: 1.04-2.1 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 5.5e-5 | 0.006 | 0.0829 | 0.548 0.523-0.572 |
1.71 OR 95% CI: 0.882-3.33 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Self-reported testicular cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 27 | 6e-5 | 0.0182 | 0.0836 | 0.643 0.574-0.713 |
3.44 OR 95% CI: 0.735-16.1 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Malignant neoplasm of thyroid gland |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 5 | 6.1e-5 | 0.0097 | 0.0825 | 0.549 0.518-0.58 |
1.39 OR 95% CI: 0.562-3.44 |
Binary
nominal
|
|
| 10001 |
Any Cancer |
MGI | PRS-CS | UKB GWAS (PheCode) | 1118667 | 6.3e-5 | 0.0009 | 0.182 | 0.521 0.51-0.532 |
1.27 OR 95% CI: 0.887-1.81 |
Binary
nominal
|
|
| 10001 |
Any Cancer |
MGI | Fixed threshold (5e-09) | UKB GWAS (PheCode) | 10 | 6.7e-5 | 0.0028 | 0.182 | 0.513 0.501-0.525 |
1.19 OR 95% CI: 0.825-1.72 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Self-reported testicular cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 771 | 6.7e-5 | 0.0505 | 0.084 | 0.656 0.593-0.717 |
2.72 OR 95% CI: 0.568-13.1 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | P&T | UKB GWAS (FINNGEN) | 31 | 6.9e-5 | 0.0376 | 0.0844 | 0.637 0.568-0.703 |
4.35 OR 95% CI: 1.08-17.5 |
Binary
nominal
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 28 | 8.8e-5 | 0.0218 | 0.0819 | 0.573 0.532-0.611 |
1.78 OR 95% CI: 0.639-4.98 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
UKB | PRS-CS | Phelan CM et al. 2017 | 1115189 | 8.9e-5 | 0.0158 | 0.0825 | 0.552 0.526-0.58 |
1.55 OR 95% CI: 0.708-3.38 |
Binary
nominal
|
|
| 157 |
Pancreatic cancer |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 32 | 9.7e-5 | 0.006 | 0.0824 | 0.56 0.528-0.595 |
1.96 OR 95% CI: 0.832-4.63 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | lassosum | UKB GWAS (FINNGEN) | 250 | 1.1e-4 | 0.0531 | 0.0839 | 0.636 0.565-0.698 |
6.35 OR 95% CI: 1.81-22.3 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 21 | 1.1e-4 | 0.0008 | 0.0921 | 0.537 0.515-0.558 |
1.08 OR 95% CI: 0.526-2.23 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 22 | 1.2e-4 | 0.0306 | 0.0845 | 0.636 0.571-0.7 |
2.24 OR 95% CI: 0.344-14.6 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Self-reported testicular cancer |
MGI | Fixed threshold (5e-09) | UKB GWAS (PHESANT) | 7 | 1.2e-4 | 0.0262 | 0.0841 | 0.65 0.587-0.713 |
4.93 OR 95% CI: 1.29-18.8 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
MGI | P&T | GWAS Catalog (2019-05-03) | 22 | 1.2e-4 | 0.0136 | 0.084 | 0.625 0.557-0.693 |
6.05 OR 95% CI: 1.73-21.2 |
Binary
nominal
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 15 | 1.2e-4 | 0.0222 | 0.0819 | 0.571 0.532-0.61 |
2.61 OR 95% CI: 1.08-6.33 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 D05 Carcinoma in situ of breast |
MGI | P&T | UKB GWAS (ICD10) | 25 | 1.4e-4 | 0.0021 | 0.139 | 0.52 0.504-0.538 |
1.39 OR 95% CI: 0.817-2.36 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 D05 Carcinoma in situ of breast |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 19 | 1.6e-4 | 0.0013 | 0.139 | 0.519 0.502-0.536 |
1.46 OR 95% CI: 0.87-2.46 |
Binary
nominal
|
|
| 10001 |
Any Cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 171 | 1.8e-4 | 0.0013 | 0.182 | 0.524 0.512-0.535 |
1.15 OR 95% CI: 0.802-1.65 |
Binary
nominal
|
|
| 172 |
Skin cancer Self-reported skin cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 132 | 1.8e-4 | 0.0019 | 0.148 | 0.515 0.504-0.526 |
1.31 OR 95% CI: 0.925-1.86 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-09) | UKB GWAS (FINNGEN) | 5 | 1.8e-4 | 0.0316 | 0.0839 | 0.651 0.585-0.715 |
4.29 OR 95% CI: 1.1-16.8 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Self-reported testicular cancer |
MGI | P&T | UKB GWAS (PHESANT) | 5 | 1.9e-4 | 0.0309 | 0.0841 | 0.649 0.586-0.714 |
3.49 OR 95% CI: 0.816-14.9 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | GWAS Hits | UKB GWAS (FINNGEN) | 6 | 2e-4 | 0.0288 | 0.0841 | 0.648 0.581-0.712 |
3.85 OR 95% CI: 0.942-15.7 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
UKB | P&T | Phelan CM et al. 2017 | 12 | 2.3e-4 | 0.0063 | 0.0826 | 0.547 0.52-0.574 |
0.511 OR 95% CI: 0.142-1.84 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
UKB | lassosum | Phelan CM et al. 2017 | 41269 | 2.8e-4 | 0.0119 | 0.0825 | 0.552 0.523-0.58 |
1.97 OR 95% CI: 0.97-3.99 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 11 | 3.3e-4 | 0.0073 | 0.0825 | 0.54 0.509-0.568 |
1.89 OR 95% CI: 0.854-4.19 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 210 | 3.8e-4 | 0.0015 | 0.0825 | 0.52 0.504-0.537 |
1.3 OR 95% CI: 0.75-2.27 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ER negative |
MGI | Fixed threshold (5e-05) | Michailidou K et al. 2018 | 158 | 4e-4 | 0.0022 | 0.14 | 0.53 0.512-0.547 |
1.53 OR 95% CI: 0.917-2.54 |
Binary
nominal
|
|
| 157 |
Pancreatic cancer |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 30 | 4.3e-4 | 0.0052 | 0.0825 | 0.554 0.522-0.588 |
2.56 OR 95% CI: 1.19-5.53 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
UKB | GWAS Hits | Phelan CM et al. 2017 | 10 | 4.4e-4 | 0.0036 | 0.0825 | 0.556 0.53-0.584 |
1.76 OR 95% CI: 0.839-3.69 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer (GWAS Catalog (2019-05-03)) |
MGI | lassosum | UKB GWAS (PheCode) | 24359 | 5.9e-4 | 0.0037 | 0.0921 | 0.538 0.517-0.557 |
0.983 OR 95% CI: 0.459-2.11 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 210 | 6.8e-4 | 0.0001 | 0.0826 | 0.545 0.515-0.574 |
1.05 OR 95% CI: 0.391-2.8 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 31 | 7.2e-4 | 0.0108 | 0.0844 | 0.606 0.533-0.679 |
4.83 OR 95% CI: 1.23-18.9 |
Binary
nominal
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 12 | 7.7e-4 | 0.0007 | 0.0825 | 0.517 0.492-0.54 |
2.17 OR 95% CI: 1.13-4.14 |
Binary
nominal
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
UKB | P&T | GWAS Catalog (2019-05-03) | 12 | 7.7e-4 | 0.0007 | 0.0825 | 0.517 0.492-0.54 |
2.17 OR 95% CI: 1.13-4.14 |
Binary
nominal
|
|
| 153.2 |
Colon cancer ICD-10 C18 Malignant neoplasm of colon |
MGI | PRS-CS | UKB GWAS (ICD10) | 1111490 | 8.9e-4 | 0.003 | 0.0832 | 0.547 0.518-0.576 |
1.65 OR 95% CI: 0.753-3.61 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary High-grade serous ovarian cancer |
UKB | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 116 | 9.4e-4 | 0.0008 | 0.0826 | 0.543 0.516-0.57 |
0.923 OR 95% CI: 0.347-2.45 |
Binary
nominal
|
|
| 153.2 |
Colon cancer ICD-10 C18 Malignant neoplasm of colon |
MGI | lassosum | UKB GWAS (ICD10) | 5740814 | 0.0011 | 0.0025 | 0.0831 | 0.545 0.518-0.574 |
1.4 OR 95% CI: 0.607-3.22 |
Binary
nominal
|
|
| 172.3 |
Carcinoma in situ of skin Diagnoses - main ICD10: D04 Carcinoma in situ of skin (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 99 | 0.0011 | 0.0062 | 0.0938 | 0.535 0.511-0.559 |
1.9 OR 95% CI: 1.01-3.58 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
UKB | Fixed threshold (5e-09) | Phelan CM et al. 2017 | 5 | 0.0012 | 0.0022 | 0.0826 | 0.544 0.516-0.572 |
1.18 OR 95% CI: 0.547-2.54 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported rodent ulcer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1073162 | 0.0016 | 0.0003 | 0.109 | 0.525 0.509-0.54 |
1.65 OR 95% CI: 1.04-2.61 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
UKB | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 207 | 0.0016 | 0.0031 | 0.0826 | 0.539 0.512-0.565 |
1.97 OR 95% CI: 0.971-3.99 |
Binary
nominal
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 8 | 0.0017 | 0 | 0.0825 | 0.513 0.49-0.537 |
2.36 OR 95% CI: 1.26-4.41 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 289 | 0.0019 | 0.0018 | 0.0826 | 0.516 0.499-0.534 |
1.58 OR 95% CI: 0.949-2.63 |
Binary
nominal
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 20 | 0.0019 | 0.0076 | 0.0821 | 0.62 0.559-0.688 |
2.64 OR 95% CI: 0.572-12.2 |
Binary
nominal
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 20 | 0.0019 | 0.0076 | 0.0821 | 0.62 0.559-0.688 |
2.64 OR 95% CI: 0.572-12.2 |
Binary
nominal
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
MGI | P&T | GWAS Catalog (2019-05-03) | 20 | 0.0019 | 0.0076 | 0.0821 | 0.62 0.559-0.688 |
2.64 OR 95% CI: 0.572-12.2 |
Binary
nominal
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 45 | 0.002 | 0.0111 | 0.0821 | 0.554 0.515-0.595 |
3 OR 95% CI: 1.3-6.93 |
Binary
nominal
|
|
| 201 |
Hodgkin's disease Self-reported hodgkins lymphoma / hodgkins disease |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 15 | 0.0021 | 0.0134 | 0.0823 | 0.616 0.555-0.68 |
1.7 OR 95% CI: 0.27-10.7 |
Binary
nominal
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 10 | 0.0021 | 0.0001 | 0.0819 | 0.611 0.541-0.682 |
2.86 OR 95% CI: 0.629-13 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 113 | 0.0024 | 0.0162 | 0.0846 | 0.606 0.526-0.682 |
0 OR 95% CI: 0-0 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 8 | 0.0026 | 0.0229 | 0.0849 | 0.618 0.553-0.684 |
2.66 OR 95% CI: 0.549-12.9 |
Binary
nominal
|
|
| 204.1 |
Lymphoid leukemia Lymphoid leukaemia |
MGI | P&T | UKB GWAS (FINNGEN) | 6 | 0.0026 | 0.0155 | 0.0819 | 0.578 0.517-0.642 |
3.69 OR 95% CI: 1.01-13.4 |
Binary
nominal
|
|
| 149.4 |
Cancer of larynx ICD-10 C32 Malignant neoplasm of larynx |
MGI | lassosum | UKB GWAS (ICD10) | 25920 | 0.0027 | 0.0068 | 0.0822 | 0.57 0.522-0.618 |
2.14 OR 95% CI: 0.649-7.06 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
UKB | GWAS Hits | Phelan CM et al. 2017 | 6 | 0.0027 | 0.0035 | 0.0826 | 0.544 0.517-0.573 |
0.922 OR 95% CI: 0.347-2.45 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 40 | 0.003 | 0.0091 | 0.085 | 0.598 0.526-0.672 |
0 OR 95% CI: 0-0 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Self-reported testicular cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 135 | 0.0031 | 0.0024 | 0.0846 | 0.608 0.539-0.676 |
3.42 OR 95% CI: 0.74-15.8 |
Binary
nominal
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 19 | 0.0031 | 0.0038 | 0.0821 | 0.618 0.552-0.687 |
2.69 OR 95% CI: 0.587-12.3 |
Binary
nominal
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 13 | 0.0032 | 0.0005 | 0.0825 | 0.511 0.486-0.535 |
2.17 OR 95% CI: 1.13-4.14 |
Binary
nominal
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 13 | 0.0032 | 0.0005 | 0.0825 | 0.511 0.486-0.535 |
2.17 OR 95% CI: 1.13-4.14 |
Binary
nominal
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 13 | 0.0032 | 0.0005 | 0.0825 | 0.511 0.486-0.535 |
2.17 OR 95% CI: 1.13-4.14 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 46 | 0.0033 | 0.0115 | 0.0851 | 0.599 0.529-0.67 |
0 OR 95% CI: 0-0 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 141 | 0.0034 | 0.0034 | 0.083 | 0.53 0.506-0.554 |
1.04 OR 95% CI: 0.459-2.36 |
Binary
nominal
|
|
| 150 |
Cancer of esophagus ICD-10 C15 Malignant neoplasm of oesophagus |
MGI | PRS-CS | UKB GWAS (ICD10) | 1081646 | 0.0036 | 0.0034 | 0.0825 | 0.564 0.525-0.604 |
2.84 OR 95% CI: 1.07-7.54 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Ovarian clear cell cancer |
UKB | PRS-CS | Phelan CM et al. 2017 | 1115187 | 0.0039 | 0.0035 | 0.0826 | 0.534 0.508-0.562 |
1.55 OR 95% CI: 0.71-3.38 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 44 | 0.0041 | 0.0105 | 0.085 | 0.594 0.526-0.666 |
0 OR 95% CI: 0-0 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Self-reported thyroid cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 8 | 0.0041 | 0.0074 | 0.0826 | 0.529 0.496-0.559 |
2.44 OR 95% CI: 1.18-5.02 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Self-reported thyroid cancer |
MGI | P&T | UKB GWAS (PHESANT) | 8 | 0.0041 | 0.0074 | 0.0826 | 0.529 0.496-0.559 |
2.44 OR 95% CI: 1.18-5.02 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 14 | 0.0042 | 0.0004 | 0.0826 | 0.535 0.508-0.562 |
1.13 OR 95% CI: 0.463-2.77 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 289 | 0.0043 | 0 | 0.0826 | 0.534 0.504-0.561 |
1.28 OR 95% CI: 0.518-3.14 |
Binary
nominal
|
|
| 184 |
Cancer of other female genital organs malignant neoplasm of female genital organs |
MGI | P&T | UKB GWAS (FINNGEN) | 8 | 0.0043 | 0.0013 | 0.0836 | 0.51 0.483-0.537 |
1.63 OR 95% CI: 0.743-3.57 |
Binary
nominal
|
|
| 153.2 |
Colon cancer Cancer code, self-reported: colon cancer/sigmoid cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 127 | 0.0044 | 0 | 0.0832 | 0.536 0.509-0.565 |
0.729 OR 95% CI: 0.243-2.19 |
Binary
nominal
|
|
| 150 |
Cancer of esophagus ICD-10 C15 Malignant neoplasm of oesophagus |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 109 | 0.0047 | 0.0019 | 0.0825 | 0.555 0.514-0.596 |
2.3 OR 95% CI: 0.798-6.63 |
Binary
nominal
|
|
| 184 |
Cancer of other female genital organs malignant neoplasm of female genital organs |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 11 | 0.0049 | 0.0001 | 0.0836 | 0.517 0.488-0.544 |
2.09 OR 95% CI: 1.03-4.27 |
Binary
nominal
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma (GWAS Catalog (2019-05-03)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.005 | 0.0004 | 0.0825 | 0.564 0.522-0.605 |
1.28 OR 95% CI: 0.332-4.95 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
UKB | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 28 | 0.0054 | 0.0026 | 0.0826 | 0.54 0.513-0.567 |
1.97 OR 95% CI: 0.971-4 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 6 | 0.0054 | 0.0174 | 0.0822 | 0.577 0.511-0.645 |
2 OR 95% CI: 0.308-13 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia (GWAS Catalog (2019-05-03)) |
MGI | P&T | UKB GWAS (PheCode) | 6 | 0.0054 | 0.0174 | 0.0822 | 0.577 0.511-0.645 |
2 OR 95% CI: 0.308-13 |
Binary
nominal
|
|
| 174.1 |
Breast cancer [female] ICD-10 D05 Carcinoma in situ of breast |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 120 | 0.0055 | 0.0007 | 0.14 | 0.517 0.499-0.534 |
1.16 OR 95% CI: 0.667-2.02 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
UKB | Fixed threshold (5e-07) | Phelan CM et al. 2017 | 13 | 0.0056 | 0.0055 | 0.0826 | 0.542 0.516-0.569 |
2.82 OR 95% CI: 1.53-5.22 |
Binary
nominal
|
|
| 187.2 |
Malignant neoplasm of testis Testicular germ cell tumor;Testicular germ cell cancer |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 42 | 0.0057 | 0.0096 | 0.0851 | 0.59 0.521-0.665 |
0 OR 95% CI: 0-0 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 10 | 0.0062 | 0.0041 | 0.083 | 0.53 0.504-0.554 |
1.53 OR 95% CI: 0.764-3.05 |
Binary
nominal
|
|
| 153.2 |
Colon cancer Malignant neoplasm of colon |
MGI | lassosum | UKB GWAS (FINNGEN) | 5715093 | 0.0064 | 0.0026 | 0.0832 | 0.536 0.51-0.567 |
0.757 OR 95% CI: 0.252-2.28 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer and mesothelioma |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1110438 | 0.0064 | 0 | 0.0826 | 0.539 0.508-0.568 |
2.18 OR 95% CI: 1.06-4.46 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer and mesothelioma |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1110438 | 0.0064 | 0 | 0.0826 | 0.539 0.508-0.568 |
2.18 OR 95% CI: 1.06-4.46 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported rodent ulcer |
MGI | P&T | UKB GWAS (PHESANT) | 8 | 0.0064 | 0.0015 | 0.109 | 0.504 0.489-0.52 |
1.42 OR 95% CI: 0.882-2.3 |
Binary
nominal
|
|
| 153.2 |
Colon cancer Malignant neoplasm of colon |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1111399 | 0.0065 | 0.0037 | 0.0832 | 0.536 0.509-0.565 |
1.82 OR 95% CI: 0.867-3.84 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Self-reported thyroid cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 69 | 0.0068 | 0.002 | 0.0827 | 0.534 0.505-0.565 |
1.13 OR 95% CI: 0.42-3.04 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 58 | 0.0074 | 0.0001 | 0.0826 | 0.525 0.497-0.553 |
1.75 OR 95% CI: 0.797-3.86 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder ICD-10 C67 Malignant neoplasm of bladder |
MGI | lassosum | UKB GWAS (ICD10) | 1130 | 0.0074 | 0.0028 | 0.0922 | 0.528 0.508-0.549 |
1.69 OR 95% CI: 0.934-3.06 |
Binary
nominal
|
|
| 172.22 |
Squamous cell carcinoma Self-reported squamous cell carcinoma |
MGI | lassosum | UKB GWAS (PHESANT) | 4279140 | 0.0076 | 0.0005 | 0.0996 | 0.523 0.503-0.543 |
1.56 OR 95% CI: 0.892-2.74 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 86 | 0.0076 | 0.0025 | 0.0827 | 0.529 0.498-0.558 |
1.92 OR 95% CI: 0.865-4.24 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
UKB | Fixed threshold (5e-07) | Phelan CM et al. 2017 | 7 | 0.0084 | 0.0048 | 0.0826 | 0.535 0.509-0.563 |
1.29 OR 95% CI: 0.562-2.94 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain ICD-10 C71 Malignant neoplasm of brain |
MGI | lassosum | UKB GWAS (ICD10) | 522 | 0.0092 | 0.0016 | 0.0824 | 0.546 0.504-0.587 |
1.42 OR 95% CI: 0.453-4.47 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain ICD-10 C71 Malignant neoplasm of brain |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 15 | 0.0097 | 0.0013 | 0.0824 | 0.541 0.5-0.582 |
3.56 OR 95% CI: 1.59-7.96 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
UKB | P&T | Phelan CM et al. 2017 | 15 | 0.0099 | 0.0066 | 0.0826 | 0.539 0.513-0.568 |
2.18 OR 95% CI: 1.11-4.3 |
Binary
nominal
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 16 | 0.0099 | 0.0019 | 0.0824 | 0.601 0.535-0.671 |
1.62 OR 95% CI: 0.258-10.1 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
UKB | lassosum | Phelan CM et al. 2017 | 1441 | 0.01 | 0.0039 | 0.0826 | 0.538 0.512-0.565 |
1.13 OR 95% CI: 0.463-2.77 |
Binary
nominal
|
|
| 145 |
Cancer of mouth |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.012 | 0.0002 | 0.0829 | 0.528 0.502-0.552 |
1.63 OR 95% CI: 0.812-3.26 |
Binary
nominal
|
|
| 150 |
Cancer of esophagus ICD-10 C15 Malignant neoplasm of oesophagus |
MGI | lassosum | UKB GWAS (ICD10) | 2001 | 0.012 | 0.0042 | 0.0826 | 0.551 0.51-0.588 |
1.81 OR 95% CI: 0.56-5.82 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | lassosum | UKB GWAS (PheCode) | 370 | 0.012 | 0.0038 | 0.083 | 0.53 0.503-0.555 |
2.76 OR 95% CI: 1.59-4.81 |
Binary
nominal
|
|
| 145 |
Cancer of mouth Malignant neoplasm of lip, oral cavity and pharynx |
MGI | P&T | UKB GWAS (FINNGEN) | 45 | 0.014 | 0.0016 | 0.0829 | 0.519 0.498-0.542 |
1.26 OR 95% CI: 0.585-2.73 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma (GWAS Catalog (2019-05-03)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.014 | 0.0002 | 0.0827 | 0.533 0.505-0.562 |
1.27 OR 95% CI: 0.514-3.12 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 25 | 0.014 | 0.0007 | 0.0827 | 0.532 0.504-0.561 |
1.34 OR 95% CI: 0.584-3.07 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 25 | 0.014 | 0.0007 | 0.0827 | 0.532 0.504-0.561 |
1.34 OR 95% CI: 0.584-3.07 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Malignant neoplasm of bronchus and lung |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1109069 | 0.015 | 0 | 0.0827 | 0.533 0.505-0.562 |
1.96 OR 95% CI: 0.926-4.14 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Self-reported bladder cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1095241 | 0.015 | 0.0008 | 0.0922 | 0.531 0.509-0.551 |
0.671 OR 95% CI: 0.279-1.61 |
Binary
nominal
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 17 | 0.015 | 0.0002 | 0.0825 | 0.53 0.495-0.563 |
1.22 OR 95% CI: 0.393-3.78 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
UKB | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 219 | 0.016 | 0.0039 | 0.0826 | 0.532 0.506-0.559 |
2.39 OR 95% CI: 1.24-4.61 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
UKB | lassosum | Phelan CM et al. 2017 | 486841 | 0.016 | 0.0051 | 0.0826 | 0.516 0.489-0.544 |
2.4 OR 95% CI: 1.24-4.62 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 14 | 0.016 | 0.0034 | 0.0824 | 0.534 0.495-0.574 |
1.41 OR 95% CI: 0.45-4.44 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Malignant neoplasm of thyroid gland |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 96 | 0.016 | 0.0042 | 0.0827 | 0.532 0.503-0.561 |
1.65 OR 95% CI: 0.708-3.83 |
Binary
nominal
|
|
| 145 |
Cancer of mouth Malignant neoplasm of lip, oral cavity and pharynx |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 21 | 0.017 | 0.0002 | 0.0829 | 0.506 0.482-0.531 |
1.79 OR 95% CI: 0.918-3.49 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 21 | 0.017 | 0.001 | 0.0827 | 0.532 0.506-0.559 |
0.923 OR 95% CI: 0.347-2.45 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
UKB | P&T | GWAS Catalog (2019-05-03) | 21 | 0.017 | 0.001 | 0.0827 | 0.532 0.506-0.559 |
0.923 OR 95% CI: 0.347-2.45 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 23 | 0.018 | 0.0008 | 0.0827 | 0.531 0.502-0.559 |
1.55 OR 95% CI: 0.709-3.38 |
Binary
nominal
|
|
| 189 |
Cancer of urinary organs (incl. kidney and bladder) Malignant neoplasm of urinary organs |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 12 | 0.019 | 0.0001 | 0.0974 | 0.489 0.473-0.505 |
1.41 OR 95% CI: 0.845-2.37 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 130 | 0.019 | 0.0019 | 0.0922 | 0.519 0.499-0.541 |
1.59 OR 95% CI: 0.876-2.87 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 109 | 0.02 | 0 | 0.0827 | 0.533 0.505-0.563 |
2.21 OR 95% CI: 1.08-4.52 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder ICD-10 C67 Malignant neoplasm of bladder |
MGI | Fixed threshold (5e-07) | UKB GWAS (ICD10) | 7 | 0.02 | 0 | 0.0922 | 0.512 0.492-0.53 |
0.578 OR 95% CI: 0.221-1.51 |
Binary
nominal
|
|
| 172.21 |
Basal cell carcinoma Self-reported rodent ulcer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 12 | 0.022 | 0.0012 | 0.109 | 0.504 0.488-0.52 |
1.14 OR 95% CI: 0.67-1.95 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Endometrioid ovarian cancer |
UKB | PRS-CS | Phelan CM et al. 2017 | 1115189 | 0.022 | 0.0004 | 0.0827 | 0.526 0.498-0.554 |
1.97 OR 95% CI: 0.973-4 |
Binary
nominal
|
|
| 202.21 |
Nodular lymphoma Follicular lymphoma |
MGI | lassosum | UKB GWAS (FINNGEN) | 2209179 | 0.022 | 0.0014 | 0.0825 | 0.538 0.504-0.573 |
1.48 OR 95% CI: 0.538-4.05 |
Binary
nominal
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia (GWAS Catalog (2019-05-03)) |
MGI | lassosum | UKB GWAS (PheCode) | 76 | 0.022 | 0.0043 | 0.0823 | 0.573 0.503-0.644 |
4.84 OR 95% CI: 1.23-19 |
Binary
nominal
|
|
| 187 |
Cancer of other male genital organs malignant neoplasm of male genital organs |
MGI | P&T | UKB GWAS (FINNGEN) | 97 | 0.023 | 0.0032 | 0.083 | 0.558 0.506-0.606 |
1.04 OR 95% CI: 0.183-5.95 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma (GWAS Catalog (2019-05-03)) |
MGI | P&T | UKB GWAS (PheCode) | 75 | 0.024 | 0.0003 | 0.0827 | 0.525 0.496-0.554 |
2.21 OR 95% CI: 1.08-4.51 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Self-reported bladder cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 17 | 0.024 | 0 | 0.0922 | 0.505 0.484-0.525 |
1.41 OR 95% CI: 0.75-2.66 |
Binary
nominal
|
|
| 149.4 |
Cancer of larynx Diagnoses - main ICD10: C32 Malignant neoplasm of larynx (UKB GWAS (ICD10)) |
MGI | P&T | UKB GWAS (PheCode) | 53 | 0.025 | 0.0018 | 0.0824 | 0.543 0.494-0.59 |
1.52 OR 95% CI: 0.384-5.98 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
MGI | P&T | GWAS Catalog (2019-05-03) | 14 | 0.025 | 0.0027 | 0.0827 | 0.529 0.503-0.558 |
1.75 OR 95% CI: 0.796-3.85 |
Binary
nominal
|
|
| 150 |
Cancer of esophagus Malignant neoplasm of oesophagus |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1070434 | 0.026 | 0.0039 | 0.0826 | 0.553 0.514-0.596 |
1.27 OR 95% CI: 0.329-4.9 |
Binary
nominal
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 D03 Melanoma in situ |
MGI | P&T | UKB GWAS (ICD10) | 147 | 0.027 | 0.0006 | 0.0969 | 0.516 0.5-0.533 |
1.07 OR 95% CI: 0.603-1.9 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer (GWAS Catalog (2019-05-03)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.027 | 0.0016 | 0.0922 | 0.525 0.503-0.547 |
0.675 OR 95% CI: 0.28-1.62 |
Binary
nominal
|
|
| 190 |
Cancer of eye Self-reported eye and/or adnexal cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 834009 | 0.027 | 0.0035 | 0.0831 | 0.586 0.508-0.658 |
4.74 OR 95% CI: 1.2-18.7 |
Binary
nominal
|
|
| 193 |
Thyroid cancer ICD-10 C73 Malignant neoplasm of thyroid gland |
MGI | P&T | UKB GWAS (ICD10) | 8 | 0.027 | 0.01 | 0.0827 | 0.52 0.488-0.55 |
2.15 OR 95% CI: 1.01-4.59 |
Binary
nominal
|
|
| 204.1 |
Lymphoid leukemia |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 5 | 0.028 | 0.0152 | 0.0823 | 0.557 0.506-0.614 |
0 OR 95% CI: 0-0 |
Binary
nominal
|
|
| 204.4 |
Multiple myeloma and malignant plasma cell neoplasms |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 11 | 0.028 | 0.0007 | 0.0822 | 0.559 0.498-0.617 |
2.61 OR 95% CI: 0.598-11.4 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
MGI | Fixed threshold (5e-09) | Phelan CM et al. 2017 | 19 | 0.029 | 0.0005 | 0.0827 | 0.552 0.506-0.595 |
1.36 OR 95% CI: 0.349-5.29 |
Binary
nominal
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 11 | 0.03 | 0.0025 | 0.0831 | 0.532 0.501-0.565 |
1.33 OR 95% CI: 0.49-3.63 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
MGI | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 54 | 0.03 | 0.0004 | 0.0827 | 0.554 0.509-0.595 |
0.806 OR 95% CI: 0.146-4.44 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous ovarian cancer |
UKB | lassosum | Phelan CM et al. 2017 | 1635861 | 0.03 | 0.004 | 0.0826 | 0.498 0.471-0.527 |
2.83 OR 95% CI: 1.53-5.23 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 12 | 0.03 | 0.0034 | 0.0825 | 0.54 0.503-0.579 |
1.02 OR 95% CI: 0.271-3.86 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 12 | 0.03 | 0.0034 | 0.0825 | 0.54 0.503-0.579 |
1.02 OR 95% CI: 0.271-3.86 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
MGI | GWAS Hits | Phelan CM et al. 2017 | 21 | 0.031 | 0.0002 | 0.0827 | 0.554 0.509-0.597 |
0.784 OR 95% CI: 0.142-4.32 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
UKB | PRS-CS | Phelan CM et al. 2017 | 1115189 | 0.032 | 0.0014 | 0.0827 | 0.522 0.491-0.548 |
3.92 OR 95% CI: 2.27-6.79 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Bladder cancer;Urinary bladder cancer (GWAS Catalog (2019-05-03)) |
MGI | P&T | UKB GWAS (PheCode) | 106 | 0.032 | 0.0025 | 0.0922 | 0.519 0.498-0.541 |
0.788 OR 95% CI: 0.35-1.78 |
Binary
nominal
|
|
| 201 |
Hodgkin's disease Self-reported hodgkins lymphoma / hodgkins disease |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1047511 | 0.032 | 0.0125 | 0.0826 | 0.574 0.501-0.642 |
1.67 OR 95% CI: 0.264-10.5 |
Binary
nominal
|
|
| 149.4 |
Cancer of larynx Malignant neoplasm of larynx |
MGI | lassosum | UKB GWAS (FINNGEN) | 87893 | 0.033 | 0.002 | 0.0824 | 0.55 0.504-0.593 |
1.51 OR 95% CI: 0.382-5.94 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 12 | 0.033 | 0.0033 | 0.083 | 0.521 0.496-0.544 |
1.39 OR 95% CI: 0.67-2.87 |
Binary
nominal
|
|
| 165 |
Cancer within the respiratory system |
MGI | lassosum | UKB GWAS (PheCode) | 879334 | 0.033 | 0.0019 | 0.0826 | 0.53 0.502-0.557 |
2.22 OR 95% CI: 1.12-4.37 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma (GWAS Catalog (2019-05-03)) |
MGI | lassosum | UKB GWAS (PheCode) | 46920 | 0.033 | 0.0011 | 0.0827 | 0.528 0.503-0.556 |
1.03 OR 95% CI: 0.387-2.77 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
MGI | Fixed threshold (5e-07) | Phelan CM et al. 2017 | 31 | 0.033 | 0.0005 | 0.0827 | 0.548 0.506-0.592 |
0.801 OR 95% CI: 0.145-4.43 |
Binary
nominal
|
|
| 187 |
Cancer of other male genital organs malignant neoplasm of male genital organs |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 64 | 0.033 | 0.0011 | 0.083 | 0.555 0.503-0.604 |
1.03 OR 95% CI: 0.181-5.88 |
Binary
nominal
|
|
| 189.2 |
Cancer of bladder Malignant neoplasm of bladder |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1097063 | 0.033 | 0.0001 | 0.0922 | 0.521 0.499-0.541 |
1.53 OR 95% CI: 0.832-2.83 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 11 | 0.035 | 0.0034 | 0.0825 | 0.538 0.501-0.577 |
0.602 OR 95% CI: 0.113-3.22 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma |
MGI | P&T | GWAS Catalog (2019-05-03) | 11 | 0.035 | 0.0034 | 0.0825 | 0.538 0.501-0.577 |
0.602 OR 95% CI: 0.113-3.22 |
Binary
nominal
|
|
| 193 |
Thyroid cancer Cancer code, self-reported: thyroid cancer (UKB GWAS (PHESANT)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.035 | 0.0002 | 0.0827 | 0.535 0.504-0.567 |
1.39 OR 95% CI: 0.562-3.45 |
Binary
nominal
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
MGI | PRS-CS | Phelan CM et al. 2017 | 1114056 | 0.036 | 0.0019 | 0.0827 | 0.552 0.513-0.598 |
0 OR 95% CI: 0-0 |
Binary
nominal
|
|
| 202.21 |
Nodular lymphoma Follicular lymphoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 26 | 0.036 | 0.0002 | 0.0825 | 0.506 0.474-0.54 |
1.82 OR 95% CI: 0.72-4.61 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 21 | 0.037 | 0.0008 | 0.0827 | 0.52 0.492-0.547 |
2.19 OR 95% CI: 1.07-4.49 |
Binary
nominal
|
|
| 172 |
Skin cancer Self-reported skin cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1103220 | 0.037 | 0.001 | 0.148 | 0.51 0.499-0.521 |
1.7 OR 95% CI: 1.22-2.38 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | P&T | UKB GWAS (PheCode) | 41 | 0.039 | 0.0063 | 0.083 | 0.517 0.493-0.541 |
1.88 OR 95% CI: 0.99-3.55 |
Binary
nominal
|
|
| 145.2 |
Cancer of tongue Malignant neoplasm of other and unspecified parts of tongue |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 931954 | 0.04 | 0.0032 | 0.0827 | 0.538 0.501-0.575 |
1.69 OR 95% CI: 0.61-4.71 |
Binary
nominal
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C19 Malignant neoplasm of rectosigmoid junction |
MGI | PRS-CS | UKB GWAS (ICD10) | 1078799 | 0.04 | 0.0002 | 0.0829 | 0.533 0.5-0.567 |
1.34 OR 95% CI: 0.491-3.65 |
Binary
nominal
|
|
| 180.3 |
Cervical intraepithelial neoplasia [CIN] [Cervical dysplasia] Self-reported cin/pre-cancer cells cervix |
MGI | Fixed threshold (5e-07) | UKB GWAS (PHESANT) | 5 | 0.04 | 0.0006 | 0.0885 | 0.514 0.486-0.543 |
0.777 OR 95% CI: 0.257-2.35 |
Binary
nominal
|
|
| 201 |
Hodgkin's disease Diagnoses - main ICD10: C81 Hodgkin's disease (UKB GWAS (ICD10)) |
MGI | lassosum | UKB GWAS (PheCode) | 1119335 | 0.04 | 0.0116 | 0.0828 | 0.569 0.501-0.634 |
1.64 OR 95% CI: 0.261-10.3 |
Binary
nominal
|
|
| 202.21 |
Nodular lymphoma Follicular lymphoma |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1048780 | 0.041 | 0 | 0.0825 | 0.532 0.497-0.568 |
2.49 OR 95% CI: 1.1-5.65 |
Binary
nominal
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 30 | 0.043 | 0.0056 | 0.083 | 0.518 0.493-0.543 |
1.55 OR 95% CI: 0.778-3.11 |
Binary
nominal
|
|
| 191.11 |
Cancer of brain Glioblastoma (GWAS Catalog (2019-05-03)) |
MGI | P&T | UKB GWAS (PheCode) | 11 | 0.043 | 0.0057 | 0.0825 | 0.53 0.492-0.57 |
2.28 OR 95% CI: 0.88-5.88 |
Binary
nominal
|
|
| 204.4 |
Multiple myeloma ICD-10 C90 Multiple myeloma and malignant plasma cell neoplasms |
MGI | P&T | UKB GWAS (ICD10) | 27 | 0.044 | 0.0013 | 0.0823 | 0.547 0.479-0.613 |
2.6 OR 95% CI: 0.593-11.4 |
Binary
nominal
|
|
| 187 |
Cancer of other male genital organs malignant neoplasm of male genital organs |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 101 | 0.046 | 0.003 | 0.0831 | 0.551 0.5-0.599 |
1.04 OR 95% CI: 0.181-5.92 |
Binary
nominal
|
|
| 187 |
Cancer of other male genital organs malignant neoplasm of male genital organs |
MGI | GWAS Hits | UKB GWAS (FINNGEN) | 45 | 0.047 | 0.0003 | 0.0831 | 0.551 0.5-0.6 |
1.01 OR 95% CI: 0.177-5.76 |
Binary
nominal
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of rectum |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1104018 | 0.048 | 0.0005 | 0.0829 | 0.531 0.495-0.563 |
1.02 OR 95% CI: 0.334-3.14 |
Binary
nominal
|
|
| 172.3 |
Carcinoma in situ of skin Diagnoses - main ICD10: D04 Carcinoma in situ of skin (UKB GWAS (ICD10)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.048 | 0.0026 | 0.0939 | 0.524 0.499-0.549 |
1.48 OR 95% CI: 0.703-3.1 |
Binary
nominal
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 18 | 0.049 | 0.0022 | 0.0827 | 0.526 0.498-0.554 |
0.584 OR 95% CI: 0.161-2.12 |
Binary
nominal
|
|
| 157 |
Pancreatic cancer |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 17 | 0.051 | 0.0107 | 0.0827 | 0.534 0.492-0.577 |
1.99 OR 95% CI: 0.704-5.62 |
Binary
weak
|
|
| 157 |
Pancreatic cancer |
MGI | P&T | GWAS Catalog (2019-05-03) | 18 | 0.051 | 0.0134 | 0.0827 | 0.537 0.493-0.579 |
1.54 OR 95% CI: 0.487-4.9 |
Binary
weak
|
|
| 170 |
Cancer of bone and connective tissue |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.053 | 0.0003 | 0.083 | 0.522 0.502-0.543 |
0.824 OR 95% CI: 0.367-1.85 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
MGI | Fixed threshold (5e-09) | Phelan CM et al. 2017 | 13 | 0.053 | 0.0006 | 0.0828 | 0.545 0.5-0.592 |
1.31 OR 95% CI: 0.337-5.12 |
Binary
weak
|
|
| 155 |
Cancer of liver and intrahepatic bile duct |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 78 | 0.054 | 0.0008 | 0.0825 | 0.533 0.492-0.573 |
0.69 OR 95% CI: 0.127-3.74 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Malignant neoplasm of kidney, except renal pelvis |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1096344 | 0.054 | 0 | 0.0826 | 0.525 0.502-0.549 |
1.56 OR 95% CI: 0.751-3.26 |
Binary
weak
|
|
| 193 |
Thyroid cancer ICD-10 C73 Malignant neoplasm of thyroid gland |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 76 | 0.054 | 0.0067 | 0.0827 | 0.527 0.494-0.558 |
1.13 OR 95% CI: 0.42-3.04 |
Binary
weak
|
|
| 149 |
Cancer of larynx, pharynx, nasal cavities |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.055 | 0.0002 | 0.0827 | 0.525 0.5-0.55 |
1.5 OR 95% CI: 0.722-3.11 |
Binary
weak
|
|
| 157 |
Pancreatic cancer |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 32 | 0.055 | 0.0053 | 0.0827 | 0.532 0.491-0.573 |
2.46 OR 95% CI: 0.942-6.41 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 116 | 0.055 | 0.0007 | 0.0826 | 0.52 0.488-0.55 |
1.14 OR 95% CI: 0.371-3.53 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 6 | 0.056 | 0.0001 | 0.0827 | 0.511 0.489-0.537 |
0.996 OR 95% CI: 0.441-2.25 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma Follicular lymphoma |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 10 | 0.056 | 0.0003 | 0.0825 | 0.493 0.462-0.526 |
1.48 OR 95% CI: 0.54-4.06 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.057 | 0.002 | 0.0826 | 0.527 0.499-0.553 |
0.718 OR 95% CI: 0.24-2.15 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung ICD-10 C34 Malignant neoplasm of bronchus and lung |
MGI | PRS-CS | UKB GWAS (ICD10) | 1108949 | 0.057 | 0 | 0.0827 | 0.525 0.494-0.552 |
1.73 OR 95% CI: 0.786-3.81 |
Binary
weak
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 18 | 0.058 | 0.0045 | 0.083 | 0.52 0.495-0.544 |
1.06 OR 95% CI: 0.467-2.4 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 18 | 0.061 | 0.0027 | 0.0832 | 0.531 0.497-0.564 |
1.94 OR 95% CI: 0.823-4.57 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
MGI | lassosum | Phelan CM et al. 2017 | 5328 | 0.061 | 0.0091 | 0.0827 | 0.544 0.497-0.589 |
2.32 OR 95% CI: 0.796-6.76 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin lymphoma |
MGI | lassosum | UKB GWAS (FINNGEN) | 4599 | 0.061 | 0.016 | 0.0827 | 0.563 0.494-0.633 |
1.6 OR 95% CI: 0.249-10.2 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Glioblastoma |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 15 | 0.062 | 0.0028 | 0.0825 | 0.532 0.494-0.57 |
1.01 OR 95% CI: 0.268-3.8 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Glioblastoma |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 14 | 0.062 | 0.0034 | 0.0825 | 0.532 0.494-0.57 |
0.599 OR 95% CI: 0.112-3.2 |
Binary
weak
|
|
| 204.22 |
Myeloid leukemia, chronic |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 9 | 0.062 | 0.006 | 0.0818 | 0.552 0.443-0.671 |
4.32 OR 95% CI: 0.481-38.8 |
Binary
weak
|
|
| 189 |
Cancer of urinary organs (incl. kidney and bladder) Malignant neoplasm of urinary organs |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1109848 | 0.063 | 0.0001 | 0.0975 | 0.513 0.498-0.53 |
1.14 OR 95% CI: 0.653-1.99 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
MGI | Fixed threshold (5e-07) | Phelan CM et al. 2017 | 23 | 0.064 | 0.0007 | 0.0828 | 0.545 0.504-0.589 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum Self-reported small intestine/small bowel cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 1487304 | 0.066 | 0.0054 | 0.0824 | 0.574 0.515-0.64 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 86 | 0.067 | 0 | 0.0827 | 0.513 0.487-0.539 |
1.73 OR 95% CI: 0.858-3.47 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Self-reported oesophageal cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 934591 | 0.068 | 0.0008 | 0.0827 | 0.535 0.493-0.579 |
1.79 OR 95% CI: 0.556-5.77 |
Binary
weak
|
|
| 204 |
Leukemia |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.068 | 0.0012 | 0.0825 | 0.532 0.494-0.567 |
2.02 OR 95% CI: 0.793-5.15 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Malignant neoplasm of cervix uteri |
MGI | lassosum | UKB GWAS (FINNGEN) | 243546 | 0.069 | 0.002 | 0.0825 | 0.538 0.498-0.578 |
1.05 OR 95% CI: 0.278-4 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 20 | 0.069 | 0.054 | 0.0819 | 0.533 0.476-0.59 |
2.67 OR 95% CI: 0.783-9.08 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 20 | 0.069 | 0.054 | 0.0819 | 0.533 0.476-0.59 |
2.67 OR 95% CI: 0.783-9.08 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
UKB | P&T | GWAS Catalog (2019-05-03) | 20 | 0.069 | 0.054 | 0.0819 | 0.533 0.476-0.59 |
2.67 OR 95% CI: 0.783-9.08 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Lymphomas |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 30 | 0.071 | 0.0003 | 0.0827 | 0.509 0.489-0.533 |
0.836 OR 95% CI: 0.347-2.01 |
Binary
weak
|
|
| 174.1 |
Breast cancer [female] ICD-10 D05 Carcinoma in situ of breast |
MGI | PRS-CS | UKB GWAS (ICD10) | 1107790 | 0.073 | 0.0016 | 0.14 | 0.519 0.503-0.536 |
1.16 OR 95% CI: 0.667-2.02 |
Binary
weak
|
|
| 153.2 |
Colon cancer Self-reported colon cancer/sigmoid cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1104674 | 0.074 | 0.0016 | 0.0833 | 0.517 0.489-0.544 |
2.7 OR 95% CI: 1.43-5.11 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Diagnoses - main ICD10: C21 Malignant neoplasm of anus and anal canal (UKB GWAS (ICD10)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.074 | 0.0006 | 0.0829 | 0.536 0.501-0.569 |
0.737 OR 95% CI: 0.2-2.72 |
Binary
weak
|
|
| 180 |
Cervical cancer and dysplasia |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119236 | 0.074 | 0.0003 | 0.0908 | 0.525 0.501-0.55 |
0.767 OR 95% CI: 0.289-2.03 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Ovarian clear cell cancer |
MGI | lassosum | Phelan CM et al. 2017 | 3387 | 0.074 | 0.0068 | 0.0828 | 0.539 0.495-0.586 |
3.04 OR 95% CI: 1.13-8.13 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma ICD-10 C82 Follicular [nodular] non-Hodgkin's lymphoma |
MGI | lassosum | UKB GWAS (ICD10) | 137530 | 0.074 | 0.0003 | 0.0826 | 0.506 0.473-0.539 |
1.82 OR 95% CI: 0.722-4.61 |
Binary
weak
|
|
| 153 |
Colorectal cancer Self-reported large bowel cancer/colorectal cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1072047 | 0.075 | 0.0009 | 0.083 | 0.523 0.499-0.547 |
0.717 OR 95% CI: 0.273-1.88 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Diagnoses - main ICD10: C81 Hodgkin's disease (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 96 | 0.075 | 0.0025 | 0.0828 | 0.562 0.489-0.632 |
1.81 OR 95% CI: 0.285-11.4 |
Binary
weak
|
|
| 153 |
Colorectal cancer Self-reported large bowel cancer/colorectal cancer |
MGI | P&T | UKB GWAS (PHESANT) | 173 | 0.077 | 0.0009 | 0.083 | 0.516 0.493-0.538 |
1.05 OR 95% CI: 0.464-2.38 |
Binary
weak
|
|
| 172.3 |
Carcinoma in situ of skin ICD-10 D04 Carcinoma in situ of skin |
MGI | PRS-CS | UKB GWAS (ICD10) | 1065239 | 0.077 | 0.0001 | 0.0939 | 0.521 0.495-0.546 |
1.24 OR 95% CI: 0.57-2.72 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Diagnoses - main ICD10: C21 Malignant neoplasm of anus and anal canal (UKB GWAS (ICD10)) |
MGI | lassosum | UKB GWAS (PheCode) | 68 | 0.078 | 0.0014 | 0.0829 | 0.525 0.492-0.556 |
2.25 OR 95% CI: 1-5.06 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
MGI | GWAS Hits | Phelan CM et al. 2017 | 16 | 0.079 | 0.0004 | 0.0828 | 0.542 0.495-0.587 |
0.787 OR 95% CI: 0.143-4.35 |
Binary
weak
|
|
| 155.1 |
Malignant neoplasm of liver, primary |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 79 | 0.08 | 0.0013 | 0.0824 | 0.53 0.48-0.578 |
1.62 OR 95% CI: 0.407-6.47 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C19 Malignant neoplasm of rectosigmoid junction |
MGI | lassosum | UKB GWAS (ICD10) | 2154790 | 0.081 | 0.0007 | 0.0829 | 0.53 0.498-0.563 |
0.441 OR 95% CI: 0.0841-2.31 |
Binary
weak
|
|
| 172.2 |
Other non-epithelial cancer of skin Self-reported non-melanoma skin cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1075656 | 0.081 | 0.0019 | 0.139 | 0.509 0.497-0.522 |
1.32 OR 95% CI: 0.898-1.93 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
MGI | P&T | GWAS Catalog (2019-05-03) | 31 | 0.081 | 0.0049 | 0.0832 | 0.521 0.49-0.551 |
1.04 OR 95% CI: 0.34-3.19 |
Binary
weak
|
|
| 189.2 |
Cancer of bladder ICD-10 C67 Malignant neoplasm of bladder |
MGI | PRS-CS | UKB GWAS (ICD10) | 1109663 | 0.081 | 0.0018 | 0.0922 | 0.517 0.495-0.539 |
1.52 OR 95% CI: 0.806-2.87 |
Binary
weak
|
|
| 159 |
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum Malignant neoplasm of digestive organs |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 6 | 0.082 | 0.0006 | 0.0826 | 0.503 0.472-0.532 |
1.38 OR 95% CI: 0.556-3.41 |
Binary
weak
|
|
| 180.3 |
Cervical intraepithelial neoplasia [CIN] [Cervical dysplasia] Self-reported cin/pre-cancer cells cervix |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 132 | 0.084 | 0.0002 | 0.0885 | 0.519 0.49-0.548 |
1.25 OR 95% CI: 0.504-3.09 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Malignant neoplasm of brain |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 6 | 0.084 | 0.0003 | 0.0825 | 0.534 0.497-0.572 |
1.01 OR 95% CI: 0.268-3.82 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma ICD-10 C82 Follicular [nodular] non-Hodgkin's lymphoma |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 91 | 0.085 | 0.0002 | 0.0826 | 0.518 0.486-0.553 |
1.47 OR 95% CI: 0.537-4.04 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary High-grade serous ovarian cancer |
UKB | P&T | Phelan CM et al. 2017 | 88 | 0.086 | 0.0019 | 0.0827 | 0.523 0.494-0.551 |
0.924 OR 95% CI: 0.348-2.46 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Malignant neoplasm of eye, brain and central nervous system |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 105 | 0.086 | 0.0001 | 0.0826 | 0.526 0.488-0.561 |
1.22 OR 95% CI: 0.394-3.79 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum Malignant neoplasm of small intestine |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 7 | 0.087 | 0.0002 | 0.0824 | 0.549 0.478-0.616 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 22 | 0.088 | 0.0047 | 0.083 | 0.515 0.49-0.538 |
2.04 OR 95% CI: 1.1-3.79 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx Malignant neoplasm of larynx |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 65 | 0.092 | 0.0004 | 0.0825 | 0.521 0.476-0.565 |
4.7 OR 95% CI: 1.91-11.5 |
Binary
weak
|
|
| 174.1 |
Breast cancer [female] ICD-10 D05 Carcinoma in situ of breast |
MGI | lassosum | UKB GWAS (ICD10) | 29211 | 0.093 | 0.0034 | 0.14 | 0.515 0.498-0.532 |
1.36 OR 95% CI: 0.802-2.32 |
Binary
weak
|
|
| 193 |
Thyroid cancer ICD-10 C73 Malignant neoplasm of thyroid gland |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 15 | 0.093 | 0.008 | 0.0827 | 0.514 0.483-0.546 |
2.42 OR 95% CI: 1.17-4.98 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Diagnoses - main ICD10: C81 Hodgkin's disease (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 7 | 0.093 | 0.0018 | 0.0828 | 0.508 0.434-0.589 |
6.71 OR 95% CI: 2.12-21.2 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Malignant neoplasm of oesophagus |
MGI | P&T | UKB GWAS (FINNGEN) | 143 | 0.094 | 0.0019 | 0.0827 | 0.538 0.492-0.577 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous ovarian cancer |
UKB | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 15 | 0.094 | 0.0001 | 0.0827 | 0.521 0.493-0.547 |
0.717 OR 95% CI: 0.239-2.15 |
Binary
weak
|
|
| 191.11 |
Cancer of brain ICD-10 C71 Malignant neoplasm of brain |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 89 | 0.094 | 0.0005 | 0.0825 | 0.522 0.481-0.559 |
2.62 OR 95% CI: 1.08-6.39 |
Binary
weak
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 27 | 0.095 | 0.0048 | 0.083 | 0.516 0.492-0.538 |
1.89 OR 95% CI: 0.998-3.59 |
Binary
weak
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | P&T | GWAS Catalog (2019-05-03) | 27 | 0.095 | 0.0048 | 0.083 | 0.516 0.492-0.538 |
1.89 OR 95% CI: 0.998-3.59 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
MGI | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 207 | 0.095 | 0.0027 | 0.0828 | 0.552 0.506-0.59 |
0.797 OR 95% CI: 0.145-4.4 |
Binary
weak
|
|
| 204 |
Leukemia |
MGI | lassosum | UKB GWAS (PheCode) | 35027 | 0.095 | 0.0027 | 0.0825 | 0.523 0.49-0.558 |
2.3 OR 95% CI: 0.959-5.51 |
Binary
weak
|
|
| 153 |
Colorectal cancer Cancer code, self-reported: large bowel cancer/colorectal cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 26 | 0.096 | 0.0047 | 0.083 | 0.515 0.491-0.538 |
2.05 OR 95% CI: 1.11-3.81 |
Binary
weak
|
|
| 204 |
Leukemia |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 129 | 0.096 | 0.0007 | 0.0825 | 0.528 0.492-0.566 |
1.23 OR 95% CI: 0.397-3.82 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue ICD-10 C02 Malignant neoplasm of other and unspecified parts of tongue |
MGI | lassosum | UKB GWAS (ICD10) | 2318649 | 0.097 | 0.0015 | 0.0828 | 0.535 0.496-0.571 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of rectosigmoid junction |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1040423 | 0.097 | 0.0004 | 0.0829 | 0.533 0.503-0.565 |
0.441 OR 95% CI: 0.0841-2.31 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor (GWAS Catalog (2019-05-03)) |
MGI | P&T | UKB GWAS (PheCode) | 11 | 0.097 | 0.0013 | 0.0827 | 0.495 0.47-0.518 |
1.95 OR 95% CI: 0.998-3.82 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma Follicular lymphoma |
MGI | Fixed threshold (5e-09) | UKB GWAS (FINNGEN) | 5 | 0.097 | 0.0001 | 0.0826 | 0.474 0.442-0.506 |
1.81 OR 95% CI: 0.716-4.58 |
Binary
weak
|
|
| 199.4 |
Neurofibromatosis |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 59 | 0.099 | 0.0002 | 0.082 | 0.546 0.437-0.652 |
5.49 OR 95% CI: 0.98-30.8 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma Self-reported multiple myeloma |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 5 | 0.099 | 0.0051 | 0.0824 | 0.539 0.467-0.61 |
2.28 OR 95% CI: 0.515-10.1 |
Binary
weak
|
|
| 153.2 |
Colon cancer Malignant neoplasm of colon |
MGI | P&T | UKB GWAS (FINNGEN) | 18 | 0.1 | 0.0016 | 0.0833 | 0.513 0.485-0.541 |
1.18 OR 95% CI: 0.482-2.9 |
Binary
weak
|
|
| 159.4 |
Malignant neoplasm of retroperitoneum and peritoneum ICD-10 C48 Malignant neoplasm of retroperitoneum and peritoneum |
MGI | PRS-CS | UKB GWAS (ICD10) | 906432 | 0.1 | 0 | 0.0825 | 0.544 0.49-0.598 |
1.1 OR 95% CI: 0.191-6.32 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 28 | 0.1 | 0.0034 | 0.0832 | 0.523 0.49-0.556 |
1.96 OR 95% CI: 0.831-4.63 |
Binary
weak
|
|
| 184 |
Cancer of other female genital organs malignant neoplasm of female genital organs |
MGI | lassosum | UKB GWAS (FINNGEN) | 6 | 0.1 | 0.0017 | 0.0837 | 0.464 0.44-0.491 |
1.65 OR 95% CI: 0.753-3.62 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
UKB | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 26 | 0.1 | 0.0036 | 0.0827 | 0.532 0.506-0.557 |
0.716 OR 95% CI: 0.239-2.14 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
UKB | P&T | Phelan CM et al. 2017 | 40 | 0.1 | 0.0048 | 0.0827 | 0.526 0.5-0.554 |
1.34 OR 95% CI: 0.584-3.07 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma (GWAS Catalog (2019-05-03)) |
MGI | P&T | UKB GWAS (PheCode) | 10 | 0.1 | 0.0004 | 0.0827 | 0.51 0.487-0.533 |
1.28 OR 95% CI: 0.623-2.65 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx Diagnoses - main ICD10: C32 Malignant neoplasm of larynx (UKB GWAS (ICD10)) |
MGI | lassosum | UKB GWAS (PheCode) | 175596 | 0.11 | 0.0028 | 0.0825 | 0.534 0.486-0.578 |
2.14 OR 95% CI: 0.649-7.03 |
Binary
weak
|
|
| 153.2 |
Colon cancer Malignant neoplasm of colon |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 25 | 0.11 | 0.0002 | 0.0833 | 0.508 0.481-0.536 |
1.16 OR 95% CI: 0.473-2.84 |
Binary
weak
|
|
| 153.2 |
Colon cancer ICD-10 C18 Malignant neoplasm of colon |
MGI | P&T | UKB GWAS (ICD10) | 5 | 0.11 | 0.0022 | 0.0833 | 0.508 0.482-0.535 |
1.16 OR 95% CI: 0.475-2.85 |
Binary
weak
|
|
| 157 |
Pancreatic cancer |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 30 | 0.11 | 0.006 | 0.0828 | 0.526 0.486-0.567 |
1.54 OR 95% CI: 0.486-4.87 |
Binary
weak
|
|
| 157 |
Pancreatic cancer |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 21 | 0.11 | 0.012 | 0.0828 | 0.533 0.492-0.575 |
1.1 OR 95% CI: 0.287-4.18 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system ICD-10 C45 Mesothelioma |
MGI | lassosum | UKB GWAS (ICD10) | 3360952 | 0.11 | 0.002 | 0.0827 | 0.52 0.495-0.548 |
1.13 OR 95% CI: 0.463-2.77 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 81 | 0.11 | 0 | 0.0827 | 0.508 0.481-0.533 |
1.74 OR 95% CI: 0.864-3.5 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Glioblastoma (GWAS Catalog (2019-05-03)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.11 | 0.0006 | 0.0825 | 0.527 0.487-0.567 |
1.04 OR 95% CI: 0.274-3.91 |
Binary
weak
|
|
| 193 |
Thyroid cancer Self-reported thyroid cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1042118 | 0.11 | 0.0002 | 0.0827 | 0.526 0.497-0.558 |
2.16 OR 95% CI: 1.01-4.6 |
Binary
weak
|
|
| 202.24 |
Large cell lymphoma |
MGI | P&T | UKB GWAS (PheCode) | 7 | 0.11 | 0.0328 | 0.0829 | 0.548 0.485-0.616 |
2 OR 95% CI: 0.305-13.1 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma and malignant plasma cell neoplasms |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 85 | 0.11 | 0.0002 | 0.0825 | 0.548 0.481-0.609 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 145 |
Cancer of mouth Malignant neoplasm of lip, oral cavity and pharynx |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1092985 | 0.12 | 0 | 0.0829 | 0.518 0.494-0.544 |
1.28 OR 95% CI: 0.595-2.78 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of anus and anal canal |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 877060 | 0.12 | 0.0006 | 0.0829 | 0.528 0.495-0.562 |
1.33 OR 95% CI: 0.487-3.61 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system Malignant neoplasm of respiratory system and intrathoracic organs |
MGI | lassosum | UKB GWAS (FINNGEN) | 1898 | 0.12 | 0.0012 | 0.0827 | 0.523 0.495-0.549 |
0.927 OR 95% CI: 0.349-2.47 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Malignant neoplasm of bronchus and lung |
MGI | lassosum | UKB GWAS (FINNGEN) | 380802 | 0.12 | 0.0008 | 0.0827 | 0.521 0.493-0.548 |
1.75 OR 95% CI: 0.795-3.85 |
Binary
weak
|
|
| 189.2 |
Cancer of bladder ICD-10 C67 Malignant neoplasm of bladder |
MGI | P&T | UKB GWAS (ICD10) | 10 | 0.12 | 0.0006 | 0.0922 | 0.504 0.483-0.524 |
1.1 OR 95% CI: 0.534-2.26 |
Binary
weak
|
|
| 189.2 |
Cancer of bladder Self-reported bladder cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 29094 | 0.12 | 0.002 | 0.0922 | 0.516 0.497-0.536 |
0.943 OR 95% CI: 0.439-2.02 |
Binary
weak
|
|
| 190 |
Cancer of eye Malignant neoplasm of eye and adnexa (UKB GWAS (FINNGEN)) |
MGI | lassosum | UKB GWAS (PheCode) | 2397847 | 0.12 | 0.011 | 0.0834 | 0.547 0.473-0.62 |
1.93 OR 95% CI: 0.297-12.5 |
Binary
weak
|
|
| 191.11 |
Cancer of brain ICD-10 C71 Malignant neoplasm of brain |
MGI | P&T | UKB GWAS (ICD10) | 29 | 0.12 | 0.0033 | 0.0825 | 0.528 0.486-0.571 |
2.26 OR 95% CI: 0.875-5.84 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Glioblastoma (GWAS Catalog (2019-05-03)) |
MGI | lassosum | UKB GWAS (PheCode) | 1621 | 0.12 | 0.0031 | 0.0826 | 0.538 0.501-0.576 |
1.01 OR 95% CI: 0.268-3.82 |
Binary
weak
|
|
| 193 |
Thyroid cancer ICD-10 C73 Malignant neoplasm of thyroid gland |
MGI | lassosum | UKB GWAS (ICD10) | 3017 | 0.12 | 0.0038 | 0.0828 | 0.523 0.491-0.556 |
1.14 OR 95% CI: 0.422-3.05 |
Binary
weak
|
|
| 199.4 |
Neurofibromatosis |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 5 | 0.12 | 0.0181 | 0.0822 | 0.519 0.433-0.622 |
3.4 OR 95% CI: 0.421-27.4 |
Binary
weak
|
|
| 199.4 |
Neurofibromatosis |
MGI | P&T | UKB GWAS (PheCode) | 5 | 0.12 | 0.0181 | 0.0822 | 0.519 0.433-0.622 |
3.4 OR 95% CI: 0.421-27.4 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma |
MGI | P&T | UKB GWAS (PheCode) | 207 | 0.12 | 0.0018 | 0.0826 | 0.518 0.483-0.55 |
0.814 OR 95% CI: 0.22-3.02 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 54 | 0.12 | 0.0064 | 0.0823 | 0.521 0.483-0.562 |
2.18 OR 95% CI: 0.848-5.6 |
Binary
weak
|
|
| 157 |
Pancreatic cancer |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 10 | 0.13 | 0.0107 | 0.0828 | 0.52 0.48-0.56 |
1.08 OR 95% CI: 0.284-4.12 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 34 | 0.13 | 0.0019 | 0.0832 | 0.516 0.482-0.547 |
1.04 OR 95% CI: 0.339-3.19 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 34 | 0.13 | 0.0019 | 0.0832 | 0.516 0.482-0.547 |
1.04 OR 95% CI: 0.339-3.19 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
MGI | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 131 | 0.13 | 0.0007 | 0.0828 | 0.529 0.487-0.571 |
1.81 OR 95% CI: 0.556-5.91 |
Binary
weak
|
|
| 187 |
Cancer of other male genital organs malignant neoplasm of male genital organs |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 276 | 0.13 | 0.0007 | 0.0832 | 0.539 0.485-0.591 |
1 OR 95% CI: 0.175-5.71 |
Binary
weak
|
|
| 190 |
Cancer of eye ICD-10 C69 Malignant neoplasm of eye and adnexa |
MGI | PRS-CS | UKB GWAS (ICD10) | 911547 | 0.13 | 0.0011 | 0.0834 | 0.545 0.47-0.613 |
4.58 OR 95% CI: 1.17-17.9 |
Binary
weak
|
|
| 193 |
Thyroid cancer ICD-10 C73 Malignant neoplasm of thyroid gland |
MGI | PRS-CS | UKB GWAS (ICD10) | 1027375 | 0.13 | 0.0001 | 0.0828 | 0.527 0.498-0.558 |
0.377 OR 95% CI: 0.0725-1.96 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Diagnoses - main ICD10: C81 Hodgkin's disease (UKB GWAS (ICD10)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.13 | 0.0053 | 0.0829 | 0.554 0.485-0.622 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma Follicular lymphoma |
MGI | GWAS Hits | UKB GWAS (FINNGEN) | 6 | 0.13 | 0.0002 | 0.0826 | 0.476 0.444-0.508 |
1.82 OR 95% CI: 0.719-4.59 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 25 | 0.13 | 0.0079 | 0.0824 | 0.528 0.463-0.593 |
1.59 OR 95% CI: 0.259-9.81 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue Malignant neoplasm of other and unspecified parts of tongue |
MGI | lassosum | UKB GWAS (FINNGEN) | 12655 | 0.14 | 0.0041 | 0.0828 | 0.523 0.489-0.558 |
2.09 OR 95% CI: 0.815-5.34 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system Malignant neoplasm of respiratory system and intrathoracic organs |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 136 | 0.14 | 0.0015 | 0.0827 | 0.515 0.489-0.541 |
0.504 OR 95% CI: 0.14-1.82 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system Malignant neoplasm of respiratory system and intrathoracic organs |
MGI | P&T | UKB GWAS (FINNGEN) | 136 | 0.14 | 0.0015 | 0.0827 | 0.515 0.489-0.541 |
0.504 OR 95% CI: 0.14-1.82 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system Mesothelioma |
MGI | lassosum | UKB GWAS (FINNGEN) | 3382118 | 0.14 | 0.0021 | 0.0827 | 0.519 0.493-0.547 |
1.14 OR 95% CI: 0.466-2.79 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
MGI | PRS-CS | Phelan CM et al. 2017 | 1114056 | 0.14 | 0.002 | 0.0828 | 0.537 0.494-0.582 |
1.87 OR 95% CI: 0.576-6.07 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Ovarian clear cell cancer |
UKB | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 100 | 0.14 | 0.0016 | 0.0827 | 0.518 0.491-0.546 |
1.34 OR 95% CI: 0.584-3.07 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
UKB | PRS-CS | Phelan CM et al. 2017 | 1115189 | 0.14 | 0.0006 | 0.0827 | 0.516 0.488-0.546 |
2.4 OR 95% CI: 1.25-4.62 |
Binary
weak
|
|
| 187 |
Cancer of other male genital organs malignant neoplasm of male genital organs |
MGI | Fixed threshold (5e-09) | UKB GWAS (FINNGEN) | 36 | 0.14 | 0.0003 | 0.0832 | 0.536 0.482-0.587 |
2.31 OR 95% CI: 0.684-7.82 |
Binary
weak
|
|
| 193 |
Thyroid cancer Self-reported thyroid cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 1515 | 0.14 | 0.0023 | 0.0828 | 0.518 0.488-0.549 |
1.39 OR 95% CI: 0.559-3.43 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin lymphoma |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1007370 | 0.14 | 0.0023 | 0.0828 | 0.57 0.493-0.644 |
3.02 OR 95% CI: 0.674-13.5 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Lymphomas |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 140 | 0.14 | 0.0008 | 0.0827 | 0.511 0.489-0.534 |
0.835 OR 95% CI: 0.347-2.01 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma ICD-10 C82 Follicular [nodular] non-Hodgkin's lymphoma |
MGI | Fixed threshold (5e-09) | UKB GWAS (ICD10) | 6 | 0.14 | 0.0002 | 0.0826 | 0.477 0.447-0.509 |
1.81 OR 95% CI: 0.715-4.56 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma |
MGI | Fixed threshold (5e-09) | UKB GWAS (PheCode) | 7 | 0.14 | 0.0003 | 0.0826 | 0.475 0.443-0.509 |
1.48 OR 95% CI: 0.539-4.05 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma ICD-10 C82 Follicular [nodular] non-Hodgkin's lymphoma |
MGI | GWAS Hits | UKB GWAS (ICD10) | 6 | 0.14 | 0.0002 | 0.0826 | 0.477 0.447-0.509 |
1.81 OR 95% CI: 0.715-4.56 |
Binary
weak
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 125 | 0.14 | 0.0001 | 0.0827 | 0.546 0.476-0.615 |
3.51 OR 95% CI: 0.747-16.5 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue ICD-10 C02 Malignant neoplasm of other and unspecified parts of tongue |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 7 | 0.15 | 0.0003 | 0.0828 | 0.515 0.479-0.553 |
3.25 OR 95% CI: 1.47-7.19 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue ICD-10 C02 Malignant neoplasm of other and unspecified parts of tongue |
MGI | PRS-CS | UKB GWAS (ICD10) | 951586 | 0.15 | 0.0006 | 0.0828 | 0.526 0.49-0.563 |
1.68 OR 95% CI: 0.606-4.68 |
Binary
weak
|
|
| 150 |
Cancer of esophagus ICD-10 C15 Malignant neoplasm of oesophagus |
MGI | P&T | UKB GWAS (ICD10) | 62 | 0.15 | 0.0029 | 0.0827 | 0.532 0.486-0.57 |
1.27 OR 95% CI: 0.329-4.91 |
Binary
weak
|
|
| 172.22 |
Squamous cell carcinoma Self-reported squamous cell carcinoma |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1064109 | 0.15 | 0.0002 | 0.0997 | 0.512 0.493-0.532 |
1.67 OR 95% CI: 0.961-2.89 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Self-reported cervical cancer |
MGI | Fixed threshold (5e-07) | UKB GWAS (PHESANT) | 5 | 0.15 | 0.0037 | 0.0825 | 0.519 0.483-0.555 |
1.52 OR 95% CI: 0.48-4.8 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Self-reported cervical cancer |
MGI | P&T | UKB GWAS (PHESANT) | 5 | 0.15 | 0.0037 | 0.0825 | 0.519 0.483-0.555 |
1.52 OR 95% CI: 0.48-4.8 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 25 | 0.15 | 0.0018 | 0.0828 | 0.532 0.484-0.58 |
1.37 OR 95% CI: 0.351-5.35 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 25 | 0.15 | 0.0018 | 0.0828 | 0.532 0.484-0.58 |
1.37 OR 95% CI: 0.351-5.35 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 12 | 0.15 | 0.0008 | 0.0827 | 0.493 0.467-0.517 |
1.58 OR 95% CI: 0.758-3.3 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
MGI | P&T | GWAS Catalog (2019-05-03) | 12 | 0.15 | 0.0008 | 0.0827 | 0.493 0.467-0.517 |
1.58 OR 95% CI: 0.758-3.3 |
Binary
weak
|
|
| 190 |
Cancer of eye Self-reported eye and/or adnexal cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 19193 | 0.15 | 0.0047 | 0.0835 | 0.561 0.485-0.636 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 22 | 0.15 | 0.0081 | 0.0826 | 0.536 0.473-0.598 |
4.92 OR 95% CI: 1.48-16.4 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma ICD-10 C90 Multiple myeloma and malignant plasma cell neoplasms |
MGI | PRS-CS | UKB GWAS (ICD10) | 1064537 | 0.15 | 0.0002 | 0.0826 | 0.554 0.489-0.616 |
2.51 OR 95% CI: 0.571-11 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system Mesothelioma |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 938343 | 0.16 | 0.0011 | 0.0827 | 0.518 0.49-0.546 |
1.14 OR 95% CI: 0.466-2.79 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer in ever smokers;Squamous cell lung carcinoma;Lung adenocarcinoma;Lung cancer;Lung cancer in never smokers;Familial squamous cell lung carcinoma;Familial lung adenocarcinoma;Familial lung cancer;Small cell lung carcinoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 18 | 0.16 | 0 | 0.0827 | 0.501 0.471-0.531 |
1.26 OR 95% CI: 0.512-3.1 |
Binary
weak
|
|
| 170 |
Cancer of bone and connective tissue |
MGI | lassosum | UKB GWAS (PheCode) | 245000 | 0.16 | 0.0016 | 0.083 | 0.515 0.495-0.535 |
0.827 OR 95% CI: 0.369-1.85 |
Binary
weak
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 D03 Melanoma in situ |
MGI | PRS-CS | UKB GWAS (ICD10) | 1080882 | 0.16 | 0.0017 | 0.0969 | 0.513 0.496-0.529 |
1.18 OR 95% CI: 0.697-2 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 23 | 0.16 | 0.0016 | 0.0828 | 0.531 0.481-0.578 |
1.36 OR 95% CI: 0.35-5.32 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Self-reported kidney/renal cell cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 4720259 | 0.16 | 0.001 | 0.0827 | 0.512 0.486-0.538 |
1.2 OR 95% CI: 0.528-2.75 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
UKB | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 19 | 0.16 | 0.0483 | 0.082 | 0.522 0.466-0.58 |
2.67 OR 95% CI: 0.784-9.09 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Non-follicular lymphoma |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 123 | 0.16 | 0.0004 | 0.0827 | 0.512 0.489-0.535 |
0.826 OR 95% CI: 0.343-1.99 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.16 | 0.0006 | 0.0824 | 0.532 0.466-0.601 |
3.82 OR 95% CI: 1.02-14.3 |
Binary
weak
|
|
| 204.11 |
Lymphoid leukemia, acute Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia in childhood (B cell precursor) |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 25 | 0.16 | 0.0053 | 0.0824 | 0.581 0.478-0.679 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia (GWAS Catalog (2019-05-03)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.16 | 0 | 0.0826 | 0.557 0.482-0.634 |
1.91 OR 95% CI: 0.294-12.5 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx Diagnoses - main ICD10: C32 Malignant neoplasm of larynx (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 72 | 0.17 | 0.0005 | 0.0826 | 0.53 0.484-0.577 |
1.52 OR 95% CI: 0.385-5.97 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Self-reported oesophageal cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 10 | 0.17 | 0.0032 | 0.0827 | 0.52 0.478-0.565 |
0.764 OR 95% CI: 0.14-4.16 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C19 Malignant neoplasm of rectosigmoid junction |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 102 | 0.17 | 0.0006 | 0.0829 | 0.522 0.49-0.555 |
1.33 OR 95% CI: 0.49-3.63 |
Binary
weak
|
|
| 172.2 |
Other non-epithelial cancer of skin Self-reported non-melanoma skin cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 4882215 | 0.17 | 0.0013 | 0.139 | 0.509 0.497-0.521 |
0.944 OR 95% CI: 0.61-1.46 |
Binary
weak
|
|
| 180.3 |
Cervical intraepithelial neoplasia [CIN] [Cervical dysplasia] Self-reported cin/pre-cancer cells cervix |
MGI | lassosum | UKB GWAS (PHESANT) | 5850633 | 0.17 | 0.0049 | 0.0885 | 0.525 0.496-0.555 |
0.801 OR 95% CI: 0.265-2.43 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
MGI | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 58 | 0.17 | 0.0015 | 0.0829 | 0.535 0.491-0.577 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
MGI | Fixed threshold (5e-07) | Phelan CM et al. 2017 | 8 | 0.17 | 0.0012 | 0.0829 | 0.532 0.487-0.578 |
2.43 OR 95% CI: 0.84-7.05 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 21 | 0.17 | 0.0028 | 0.0829 | 0.533 0.485-0.58 |
1.37 OR 95% CI: 0.351-5.34 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Self-reported ovarian cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 214 | 0.17 | 0.0018 | 0.0829 | 0.531 0.485-0.573 |
4.14 OR 95% CI: 1.72-9.98 |
Binary
weak
|
|
| 189.1 |
Cancer of kidney and renal pelvis |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 9 | 0.17 | 0 | 0.0827 | 0.488 0.464-0.512 |
1.84 OR 95% CI: 0.973-3.49 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 13 | 0.17 | 0.0007 | 0.0827 | 0.492 0.466-0.516 |
1.78 OR 95% CI: 0.882-3.59 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 13 | 0.17 | 0.0007 | 0.0827 | 0.492 0.466-0.516 |
1.78 OR 95% CI: 0.882-3.59 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 13 | 0.17 | 0.0007 | 0.0827 | 0.492 0.466-0.516 |
1.78 OR 95% CI: 0.882-3.59 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma ICD-10 C90 Multiple myeloma and malignant plasma cell neoplasms |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 19 | 0.17 | 0.0004 | 0.0826 | 0.534 0.469-0.598 |
1.52 OR 95% CI: 0.247-9.34 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma and malignant plasma cell neoplasms |
MGI | lassosum | UKB GWAS (FINNGEN) | 31983 | 0.17 | 0.006 | 0.0826 | 0.544 0.477-0.618 |
1.55 OR 95% CI: 0.252-9.5 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue Self-reported sarcoma/fibrosarcoma |
MGI | lassosum | UKB GWAS (PHESANT) | 1494911 | 0.18 | 0.0004 | 0.0828 | 0.514 0.489-0.539 |
1.9 OR 95% CI: 0.97-3.71 |
Binary
weak
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 D03 Melanoma in situ |
MGI | lassosum | UKB GWAS (ICD10) | 3838429 | 0.18 | 0.002 | 0.0969 | 0.512 0.496-0.528 |
1.54 OR 95% CI: 0.96-2.46 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary ICD-10 C56 Malignant neoplasm of ovary |
MGI | P&T | UKB GWAS (ICD10) | 14 | 0.18 | 0.0016 | 0.0828 | 0.519 0.475-0.563 |
1.91 OR 95% CI: 0.587-6.22 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma ICD-10 C82 Follicular [nodular] non-Hodgkin's lymphoma |
MGI | Fixed threshold (5e-07) | UKB GWAS (ICD10) | 10 | 0.18 | 0.0001 | 0.0826 | 0.479 0.447-0.511 |
1.14 OR 95% CI: 0.371-3.53 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia ICD-10 C91 Lymphoid leukaemia |
MGI | P&T | UKB GWAS (ICD10) | 6 | 0.18 | 0.001 | 0.0825 | 0.512 0.448-0.573 |
1.57 OR 95% CI: 0.256-9.68 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx ICD-10 C32 Malignant neoplasm of larynx |
MGI | PRS-CS | UKB GWAS (ICD10) | 967720 | 0.19 | 0.0006 | 0.0826 | 0.532 0.487-0.58 |
0.905 OR 95% CI: 0.162-5.05 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C21 Malignant neoplasm of anus and anal canal |
MGI | PRS-CS | UKB GWAS (ICD10) | 923679 | 0.19 | 0.0001 | 0.0829 | 0.528 0.493-0.564 |
1.65 OR 95% CI: 0.658-4.13 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system Malignant neoplasm of respiratory system and intrathoracic organs |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1110227 | 0.19 | 0.0002 | 0.0827 | 0.52 0.493-0.547 |
1.78 OR 95% CI: 0.848-3.73 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Self-reported kidney/renal cell cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1067434 | 0.19 | 0.001 | 0.0827 | 0.513 0.487-0.542 |
1.58 OR 95% CI: 0.757-3.28 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Lymphomas |
MGI | P&T | UKB GWAS (FINNGEN) | 14 | 0.19 | 0.0017 | 0.0827 | 0.496 0.474-0.52 |
0.982 OR 95% CI: 0.435-2.22 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma ICD-10 C83 Diffuse non-Hodgkin's lymphoma |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 119 | 0.19 | 0.002 | 0.0827 | 0.513 0.488-0.539 |
1.26 OR 95% CI: 0.584-2.72 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 24 | 0.19 | 0.0007 | 0.0826 | 0.492 0.459-0.524 |
1.15 OR 95% CI: 0.374-3.56 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Self-reported oesophageal cancer |
MGI | P&T | UKB GWAS (PHESANT) | 24 | 0.2 | 0.0059 | 0.0827 | 0.519 0.479-0.559 |
1.78 OR 95% CI: 0.551-5.73 |
Binary
weak
|
|
| 170.1 |
Bone cancer Cancer code, self-reported: primary bone cancer (UKB GWAS (PHESANT)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.2 | 0.0007 | 0.0829 | 0.52 0.488-0.553 |
1.58 OR 95% CI: 0.633-3.95 |
Binary
weak
|
|
| 180.3 |
Cervical intraepithelial neoplasia [CIN] [Cervical dysplasia] Self-reported cin/pre-cancer cells cervix |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1105412 | 0.2 | 0.0039 | 0.0885 | 0.525 0.498-0.553 |
0.536 OR 95% CI: 0.147-1.95 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 8 | 0.2 | 0.0004 | 0.0827 | 0.489 0.464-0.514 |
1.57 OR 95% CI: 0.752-3.27 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma ICD-10 C83 Diffuse non-Hodgkin's lymphoma |
MGI | P&T | UKB GWAS (ICD10) | 134 | 0.2 | 0.0026 | 0.0827 | 0.512 0.487-0.539 |
1.09 OR 95% CI: 0.482-2.48 |
Binary
weak
|
|
| 159.4 |
Malignant neoplasm of retroperitoneum and peritoneum ICD-10 C48 Malignant neoplasm of retroperitoneum and peritoneum |
MGI | lassosum | UKB GWAS (ICD10) | 276551 | 0.21 | 0.0028 | 0.0825 | 0.532 0.479-0.587 |
1.09 OR 95% CI: 0.19-6.3 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system |
MGI | P&T | UKB GWAS (PheCode) | 46 | 0.21 | 0.0002 | 0.0827 | 0.508 0.482-0.537 |
1.34 OR 95% CI: 0.584-3.08 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Self-reported lung cancer |
MGI | P&T | UKB GWAS (PHESANT) | 71 | 0.21 | 0.0003 | 0.0827 | 0.516 0.486-0.544 |
1 OR 95% CI: 0.374-2.68 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue Self-reported sarcoma/fibrosarcoma |
MGI | PRS-CS | UKB GWAS (PHESANT) | 971543 | 0.21 | 0.0001 | 0.0828 | 0.517 0.493-0.542 |
1.53 OR 95% CI: 0.736-3.19 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus ICD-10 C54 Malignant neoplasm of corpus uteri |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 123 | 0.21 | 0.0001 | 0.0832 | 0.514 0.485-0.547 |
0.739 OR 95% CI: 0.2-2.72 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Self-reported hodgkins lymphoma / hodgkins disease |
MGI | P&T | UKB GWAS (PHESANT) | 65 | 0.21 | 0.0196 | 0.083 | 0.533 0.461-0.608 |
2.79 OR 95% CI: 0.62-12.6 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma ICD-10 C90 Multiple myeloma and malignant plasma cell neoplasms |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 107 | 0.21 | 0.0001 | 0.0826 | 0.535 0.475-0.598 |
2.69 OR 95% CI: 0.615-11.7 |
Binary
weak
|
|
| 149 |
Cancer of larynx, pharynx, nasal cavities |
MGI | lassosum | UKB GWAS (PheCode) | 1881193 | 0.22 | 0.0009 | 0.0828 | 0.519 0.495-0.544 |
0.8 OR 95% CI: 0.303-2.11 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx Malignant neoplasm of larynx |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 15 | 0.22 | 0.0032 | 0.0826 | 0.517 0.468-0.567 |
2.16 OR 95% CI: 0.656-7.12 |
Binary
weak
|
|
| 170.1 |
Bone cancer Self-reported primary bone cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 5 | 0.22 | 0.0004 | 0.0829 | 0.504 0.471-0.538 |
1 OR 95% CI: 0.328-3.06 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Self-reported ovarian cancer |
MGI | P&T | UKB GWAS (PHESANT) | 34 | 0.22 | 0.0037 | 0.0829 | 0.518 0.473-0.562 |
1.3 OR 95% CI: 0.334-5.07 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Self-reported ovarian cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1082696 | 0.22 | 0.0004 | 0.0829 | 0.529 0.483-0.57 |
0.737 OR 95% CI: 0.133-4.07 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor (GWAS Catalog (2019-05-03)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.22 | 0 | 0.0827 | 0.515 0.489-0.536 |
1.18 OR 95% CI: 0.518-2.69 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Malignant neoplasm of eye, brain and central nervous system |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1072894 | 0.22 | 0.0008 | 0.0826 | 0.526 0.49-0.562 |
0.876 OR 95% CI: 0.235-3.27 |
Binary
weak
|
|
| 204.12 |
Lymphoid leukemia, chronic Self-reported chronic lymphocytic |
MGI | P&T | UKB GWAS (PHESANT) | 7 | 0.22 | 0.0015 | 0.0828 | 0.522 0.452-0.593 |
1.93 OR 95% CI: 0.295-12.6 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of rectosigmoid junction |
MGI | lassosum | UKB GWAS (FINNGEN) | 592740 | 0.23 | 0.001 | 0.0829 | 0.526 0.496-0.561 |
1.01 OR 95% CI: 0.331-3.1 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum Malignant neoplasm of small intestine |
MGI | P&T | UKB GWAS (FINNGEN) | 25 | 0.23 | 0.0024 | 0.0825 | 0.534 0.468-0.602 |
1.73 OR 95% CI: 0.277-10.8 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
MGI | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 27 | 0.23 | 0.002 | 0.0829 | 0.525 0.484-0.57 |
1.36 OR 95% CI: 0.349-5.28 |
Binary
weak
|
|
| 189 |
Cancer of urinary organs (incl. kidney and bladder) Malignant neoplasm of urinary organs |
MGI | P&T | UKB GWAS (FINNGEN) | 77 | 0.23 | 0.0003 | 0.0975 | 0.5 0.483-0.518 |
0.992 OR 95% CI: 0.558-1.77 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Renal cell carcinoma;Wilms tumor (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 13 | 0.23 | 0.0009 | 0.0827 | 0.489 0.463-0.513 |
1.01 OR 95% CI: 0.417-2.46 |
Binary
weak
|
|
| 194 |
Cancer of other endocrine glands Malignant neoplasm of endocrine gland |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1061061 | 0.23 | 0.0016 | 0.0827 | 0.538 0.484-0.586 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204 |
Leukemia |
MGI | P&T | UKB GWAS (PheCode) | 11 | 0.23 | 0.0016 | 0.0826 | 0.515 0.483-0.549 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 145 |
Cancer of mouth |
MGI | lassosum | UKB GWAS (PheCode) | 816404 | 0.24 | 0.0022 | 0.0829 | 0.51 0.485-0.535 |
1.11 OR 95% CI: 0.487-2.51 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue Malignant neoplasm of other and unspecified parts of tongue (UKB GWAS (FINNGEN)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 8 | 0.24 | 0.0002 | 0.0828 | 0.48 0.443-0.516 |
2.1 OR 95% CI: 0.82-5.39 |
Binary
weak
|
|
| 149 |
Cancer of larynx, pharynx, nasal cavities |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 84 | 0.24 | 0 | 0.0828 | 0.509 0.483-0.535 |
1.16 OR 95% CI: 0.511-2.64 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Malignant neoplasm of oesophagus |
MGI | lassosum | UKB GWAS (FINNGEN) | 91277 | 0.24 | 0.0065 | 0.0827 | 0.531 0.494-0.57 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 159 |
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum Malignant neoplasm of digestive organs |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 29 | 0.24 | 0.0001 | 0.0826 | 0.505 0.476-0.533 |
1.94 OR 95% CI: 0.875-4.29 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) (GWAS Catalog (2019-05-03)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119236 | 0.24 | 0.0014 | 0.0832 | 0.514 0.48-0.547 |
1.32 OR 95% CI: 0.484-3.59 |
Binary
weak
|
|
| 189.2 |
Cancer of bladder ICD-10 C67 Malignant neoplasm of bladder |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 147 | 0.24 | 0 | 0.0922 | 0.504 0.483-0.525 |
1.03 OR 95% CI: 0.499-2.11 |
Binary
weak
|
|
| 193 |
Thyroid cancer Malignant neoplasm of thyroid gland |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1054932 | 0.24 | 0.0005 | 0.0828 | 0.52 0.49-0.549 |
1.65 OR 95% CI: 0.708-3.83 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Mature T/NK-cell lymphomas |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 50 | 0.24 | 0.0004 | 0.0827 | 0.512 0.487-0.535 |
1.14 OR 95% CI: 0.53-2.44 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 17 | 0.24 | 0.0001 | 0.0827 | 0.51 0.486-0.533 |
0.982 OR 95% CI: 0.435-2.22 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma |
MGI | GWAS Hits | UKB GWAS (PheCode) | 8 | 0.24 | 0.0004 | 0.0826 | 0.474 0.442-0.506 |
1.81 OR 95% CI: 0.715-4.57 |
Binary
weak
|
|
| 204.11 |
Lymphoid leukemia, acute Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia in childhood (B cell precursor) |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 7 | 0.24 | 0.0022 | 0.0824 | 0.558 0.451-0.662 |
3.64 OR 95% CI: 0.441-30.1 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma and malignant plasma cell neoplasms |
MGI | P&T | UKB GWAS (FINNGEN) | 32 | 0.24 | 0.0019 | 0.0826 | 0.523 0.461-0.587 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 151 |
Cancer of stomach Cancer code, self-reported: stomach cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 76 | 0.25 | 0 | 0.0828 | 0.519 0.477-0.56 |
0.655 OR 95% CI: 0.121-3.53 |
Binary
weak
|
|
| 159.3 |
Malignant neoplasm of gallbladder and extrahepatic bile ducts |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 84 | 0.25 | 0.0192 | 0.0824 | 0.526 0.454-0.601 |
2.88 OR 95% CI: 0.632-13.2 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Self-reported lung cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 52 | 0.25 | 0.0001 | 0.0827 | 0.514 0.486-0.542 |
1.01 OR 95% CI: 0.376-2.7 |
Binary
weak
|
|
| 172.3 |
Carcinoma in situ of skin ICD-10 D04 Carcinoma in situ of skin |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 12 | 0.25 | 0.0006 | 0.094 | 0.499 0.474-0.524 |
1.46 OR 95% CI: 0.693-3.07 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
MGI | P&T | GWAS Catalog (2019-05-03) | 10 | 0.25 | 0.0074 | 0.0827 | 0.505 0.483-0.528 |
1.41 OR 95% CI: 0.68-2.92 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 10 | 0.25 | 0.0006 | 0.0826 | 0.478 0.446-0.51 |
1.81 OR 95% CI: 0.715-4.57 |
Binary
weak
|
|
| 149 |
Cancer of larynx, pharynx, nasal cavities |
MGI | P&T | UKB GWAS (PheCode) | 24 | 0.26 | 0.0003 | 0.0828 | 0.501 0.476-0.526 |
1.68 OR 95% CI: 0.835-3.37 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Malignant neoplasm of oesophagus |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 96 | 0.26 | 0 | 0.0827 | 0.529 0.483-0.568 |
1.28 OR 95% CI: 0.331-4.96 |
Binary
weak
|
|
| 151 |
Cancer of stomach Cancer code, self-reported: stomach cancer (UKB GWAS (PHESANT)) |
MGI | lassosum | UKB GWAS (PheCode) | 1242 | 0.26 | 0.0025 | 0.0828 | 0.525 0.483-0.561 |
2.01 OR 95% CI: 0.71-5.68 |
Binary
weak
|
|
| 157 |
Pancreatic cancer GWAS Catalog (2019-05-03) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.26 | 0.0003 | 0.0828 | 0.524 0.482-0.564 |
1.98 OR 95% CI: 0.701-5.62 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous ovarian cancer |
UKB | PRS-CS | Phelan CM et al. 2017 | 1115179 | 0.26 | 0.0017 | 0.0827 | 0.504 0.477-0.533 |
1.97 OR 95% CI: 0.971-4 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
UKB | PRS-CS | Phelan CM et al. 2017 | 1115189 | 0.26 | 0.0008 | 0.0827 | 0.509 0.483-0.536 |
2.4 OR 95% CI: 1.25-4.63 |
Binary
weak
|
|
| 189 |
Cancer of urinary organs (incl. kidney and bladder) Malignant neoplasm of urinary organs |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 122 | 0.26 | 0.0001 | 0.0975 | 0.502 0.485-0.519 |
1.23 OR 95% CI: 0.712-2.11 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Self-reported hodgkins lymphoma / hodgkins disease |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 82 | 0.26 | 0.0106 | 0.083 | 0.528 0.456-0.601 |
4.08 OR 95% CI: 1.07-15.5 |
Binary
weak
|
|
| 145 |
Cancer of mouth |
MGI | P&T | UKB GWAS (PheCode) | 21 | 0.27 | 0.0008 | 0.0829 | 0.506 0.483-0.529 |
0.774 OR 95% CI: 0.294-2.04 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue Self-reported tongue cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 1826297 | 0.27 | 0.0031 | 0.0828 | 0.514 0.479-0.55 |
0.562 OR 95% CI: 0.105-3 |
Binary
weak
|
|
| 180.3 |
Cervical intraepithelial neoplasia [CIN] [Cervical dysplasia] Self-reported cin/pre-cancer cells cervix |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 28 | 0.27 | 0.0002 | 0.0885 | 0.503 0.475-0.533 |
0.739 OR 95% CI: 0.244-2.24 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus ICD-10 C54 Malignant neoplasm of corpus uteri |
MGI | PRS-CS | UKB GWAS (ICD10) | 1101394 | 0.27 | 0.0004 | 0.0832 | 0.516 0.482-0.543 |
0.727 OR 95% CI: 0.197-2.68 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 14 | 0.27 | 0.0042 | 0.0829 | 0.526 0.481-0.571 |
0.803 OR 95% CI: 0.145-4.43 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
MGI | GWAS Hits | Phelan CM et al. 2017 | 5 | 0.27 | 0.0007 | 0.0829 | 0.522 0.474-0.567 |
2.46 OR 95% CI: 0.848-7.13 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 155 | 0.27 | 0.0001 | 0.086 | 0.552 0.48-0.618 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Self-reported kidney/renal cell cancer |
MGI | P&T | UKB GWAS (PHESANT) | 17 | 0.27 | 0.0003 | 0.0827 | 0.496 0.471-0.523 |
1.74 OR 95% CI: 0.863-3.5 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy (GWAS Catalog (2019-05-03)) |
MGI | lassosum | UKB GWAS (PheCode) | 614225 | 0.27 | 0.0048 | 0.0826 | 0.539 0.473-0.603 |
1.52 OR 95% CI: 0.247-9.42 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Self-reported oesophageal cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 406747 | 0.28 | 0.0038 | 0.0827 | 0.519 0.478-0.563 |
1.79 OR 95% CI: 0.557-5.78 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C20 Malignant neoplasm of rectum |
MGI | lassosum | UKB GWAS (ICD10) | 4790230 | 0.28 | 0.0016 | 0.083 | 0.524 0.493-0.557 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Self-reported ovarian cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 18 | 0.28 | 0.0017 | 0.0829 | 0.503 0.46-0.549 |
2.36 OR 95% CI: 0.812-6.85 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
MGI | P&T | Phelan CM et al. 2017 | 144 | 0.28 | 0.0015 | 0.0829 | 0.535 0.495-0.577 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Serous invasive ovarian cancer |
MGI | P&T | Phelan CM et al. 2017 | 104 | 0.28 | 0.0068 | 0.0829 | 0.528 0.486-0.569 |
0.783 OR 95% CI: 0.142-4.32 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Malignant neoplasm of kidney, except renal pelvis |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 132 | 0.28 | 0 | 0.0827 | 0.511 0.485-0.536 |
1.03 OR 95% CI: 0.425-2.51 |
Binary
weak
|
|
| 189.2 |
Cancer of bladder Self-reported bladder cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 131 | 0.28 | 0.002 | 0.0923 | 0.51 0.491-0.529 |
0.799 OR 95% CI: 0.354-1.8 |
Binary
weak
|
|
| 190 |
Cancer of eye ICD-10 C69 Malignant neoplasm of eye and adnexa |
MGI | lassosum | UKB GWAS (ICD10) | 1496730 | 0.28 | 0.013 | 0.0836 | 0.54 0.461-0.621 |
1.82 OR 95% CI: 0.268-12.4 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 23 | 0.28 | 0.0058 | 0.0826 | 0.511 0.476-0.546 |
0.872 OR 95% CI: 0.234-3.25 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) (GWAS Catalog (2019-05-03)) |
MGI | lassosum | UKB GWAS (PheCode) | 43 | 0.28 | 0.008 | 0.0826 | 0.506 0.47-0.538 |
1.23 OR 95% CI: 0.396-3.8 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma ICD-10 C82 Follicular [nodular] non-Hodgkin's lymphoma |
MGI | P&T | UKB GWAS (ICD10) | 5 | 0.28 | 0.0004 | 0.0826 | 0.467 0.436-0.501 |
1.8 OR 95% CI: 0.712-4.55 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 28 | 0.28 | 0.0135 | 0.0826 | 0.519 0.453-0.583 |
3.79 OR 95% CI: 1.01-14.2 |
Binary
weak
|
|
| 159 |
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum Malignant neoplasm of digestive organs |
MGI | P&T | UKB GWAS (FINNGEN) | 18 | 0.29 | 0.0009 | 0.0826 | 0.497 0.466-0.526 |
2.44 OR 95% CI: 1.18-5.03 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Self-reported cervical cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 17 | 0.29 | 0.0019 | 0.0826 | 0.511 0.471-0.549 |
1.51 OR 95% CI: 0.479-4.78 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Malignant neoplasm of cervix uteri |
MGI | P&T | UKB GWAS (FINNGEN) | 105 | 0.29 | 0.0026 | 0.0826 | 0.519 0.477-0.56 |
0.622 OR 95% CI: 0.116-3.34 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis Self-reported testicular cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1084569 | 0.29 | 0.0077 | 0.0859 | 0.539 0.462-0.614 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 190 |
Cancer of eye Malignant neoplasm of eye and adnexa |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 849853 | 0.3 | 0.0001 | 0.0836 | 0.546 0.47-0.622 |
1.99 OR 95% CI: 0.308-12.8 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 25 | 0.3 | 0.0071 | 0.0826 | 0.51 0.474-0.544 |
1.23 OR 95% CI: 0.397-3.81 |
Binary
weak
|
|
| 201 |
Hodgkin's disease ICD-10 C81 Hodgkin's disease |
MGI | PRS-CS | UKB GWAS (ICD10) | 945902 | 0.3 | 0.0008 | 0.083 | 0.528 0.451-0.603 |
4.03 OR 95% CI: 1.07-15.2 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Self-reported hodgkins lymphoma / hodgkins disease |
MGI | lassosum | UKB GWAS (PHESANT) | 304734 | 0.3 | 0.0165 | 0.083 | 0.55 0.475-0.617 |
2.94 OR 95% CI: 0.645-13.4 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Lymphomas |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 8 | 0.3 | 0.001 | 0.0827 | 0.493 0.47-0.515 |
1.14 OR 95% CI: 0.532-2.45 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue ICD-10 C01 Malignant neoplasm of base of tongue |
MGI | PRS-CS | UKB GWAS (ICD10) | 854886 | 0.31 | 0.0002 | 0.0828 | 0.523 0.488-0.558 |
0.922 OR 95% CI: 0.246-3.46 |
Binary
weak
|
|
| 157 |
Pancreatic cancer ICD-10 C25 Malignant neoplasm of pancreas |
MGI | lassosum | UKB GWAS (ICD10) | 2230 | 0.31 | 0.0042 | 0.0828 | 0.517 0.476-0.556 |
1.96 OR 95% CI: 0.691-5.55 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum Self-reported small intestine/small bowel cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 11 | 0.31 | 0.0079 | 0.0825 | 0.518 0.445-0.597 |
5.41 OR 95% CI: 1.6-18.3 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum Self-reported small intestine/small bowel cancer |
MGI | P&T | UKB GWAS (PHESANT) | 11 | 0.31 | 0.0079 | 0.0825 | 0.518 0.445-0.597 |
5.41 OR 95% CI: 1.6-18.3 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary High-grade serous ovarian cancer |
MGI | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 116 | 0.31 | 0.0008 | 0.0829 | 0.513 0.473-0.557 |
1.86 OR 95% CI: 0.571-6.04 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Ovarian clear cell cancer |
MGI | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 12 | 0.31 | 0.0005 | 0.0829 | 0.528 0.482-0.573 |
3.59 OR 95% CI: 1.42-9.08 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
MGI | P&T | Phelan CM et al. 2017 | 34 | 0.31 | 0.0095 | 0.0829 | 0.527 0.485-0.569 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia ICD-10 C91 Lymphoid leukaemia |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 21 | 0.31 | 0.0001 | 0.0825 | 0.521 0.453-0.588 |
1.51 OR 95% CI: 0.247-9.27 |
Binary
weak
|
|
| 204.12 |
Lymphoid leukemia, chronic Chronic lymphocytic leukemia (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 24 | 0.31 | 0.0002 | 0.0828 | 0.521 0.447-0.598 |
1.96 OR 95% CI: 0.299-12.8 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 15 | 0.31 | 0.006 | 0.0826 | 0.524 0.46-0.584 |
3.7 OR 95% CI: 1-13.6 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 103 | 0.32 | 0 | 0.0827 | 0.505 0.479-0.532 |
1.74 OR 95% CI: 0.83-3.65 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma ICD-10 C82 Follicular [nodular] non-Hodgkin's lymphoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 17 | 0.32 | 0.0001 | 0.0826 | 0.484 0.453-0.516 |
0.816 OR 95% CI: 0.22-3.02 |
Binary
weak
|
|
| 145 |
Cancer of mouth Malignant neoplasm of lip, oral cavity and pharynx |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 105 | 0.33 | 0.0005 | 0.0829 | 0.499 0.477-0.524 |
2.13 OR 95% CI: 1.14-3.97 |
Binary
weak
|
|
| 180.1 |
Cervical cancer ICD-10 D06 Carcinoma in situ of cervix uteri |
MGI | PRS-CS | UKB GWAS (ICD10) | 1067182 | 0.33 | 0.0008 | 0.0826 | 0.521 0.479-0.564 |
1.07 OR 95% CI: 0.282-4.08 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis ICD-10 C64 Malignant neoplasm of kidney, except renal pelvis |
MGI | PRS-CS | UKB GWAS (ICD10) | 1092593 | 0.33 | 0.0001 | 0.0827 | 0.514 0.489-0.538 |
1.58 OR 95% CI: 0.76-3.3 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Non-follicular lymphoma |
MGI | lassosum | UKB GWAS (FINNGEN) | 238 | 0.33 | 0.0009 | 0.0827 | 0.495 0.472-0.519 |
0.989 OR 95% CI: 0.438-2.23 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma ICD-10 C83 Diffuse non-Hodgkin's lymphoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 18 | 0.33 | 0.0005 | 0.0827 | 0.496 0.473-0.521 |
1.26 OR 95% CI: 0.585-2.73 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C21 Malignant neoplasm of anus and anal canal |
MGI | P&T | UKB GWAS (ICD10) | 46 | 0.34 | 0.0038 | 0.083 | 0.512 0.477-0.547 |
1.34 OR 95% CI: 0.493-3.65 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C20 Malignant neoplasm of rectum |
MGI | PRS-CS | UKB GWAS (ICD10) | 1104940 | 0.34 | 0.0001 | 0.083 | 0.521 0.488-0.553 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 10 | 0.34 | 0.0002 | 0.0826 | 0.512 0.45-0.579 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 18 | 0.34 | 0 | 0.0827 | 0.503 0.477-0.532 |
1.12 OR 95% CI: 0.46-2.75 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung ICD-10 C34 Malignant neoplasm of bronchus and lung |
MGI | Fixed threshold (5e-07) | UKB GWAS (ICD10) | 6 | 0.34 | 0.0011 | 0.0828 | 0.486 0.46-0.513 |
1.02 OR 95% CI: 0.38-2.72 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 28 | 0.34 | 0.0073 | 0.0826 | 0.51 0.474-0.545 |
0.875 OR 95% CI: 0.235-3.26 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 28 | 0.34 | 0.0073 | 0.0826 | 0.51 0.474-0.545 |
0.875 OR 95% CI: 0.235-3.26 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
MGI | P&T | GWAS Catalog (2019-05-03) | 28 | 0.34 | 0.0073 | 0.0826 | 0.51 0.474-0.545 |
0.875 OR 95% CI: 0.235-3.26 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 18 | 0.34 | 0.0057 | 0.0827 | 0.504 0.48-0.527 |
1.58 OR 95% CI: 0.787-3.16 |
Binary
weak
|
|
| 155.1 |
Malignant neoplasm of liver, primary |
MGI | P&T | UKB GWAS (PheCode) | 5 | 0.35 | 0.0022 | 0.0825 | 0.473 0.427-0.52 |
2.99 OR 95% CI: 0.99-9.04 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system ICD-10 C45 Mesothelioma |
MGI | PRS-CS | UKB GWAS (ICD10) | 934591 | 0.35 | 0.0012 | 0.0827 | 0.511 0.485-0.54 |
1.56 OR 95% CI: 0.713-3.4 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung ICD-10 C34 Malignant neoplasm of bronchus and lung |
MGI | lassosum | UKB GWAS (ICD10) | 35698 | 0.35 | 0.0021 | 0.0828 | 0.51 0.481-0.538 |
0.808 OR 95% CI: 0.268-2.44 |
Binary
weak
|
|
| 170.1 |
Bone cancer Self-reported primary bone cancer |
MGI | P&T | UKB GWAS (PHESANT) | 7 | 0.35 | 0.0022 | 0.0829 | 0.508 0.478-0.54 |
1.01 OR 95% CI: 0.33-3.08 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Self-reported cervical cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 127 | 0.35 | 0 | 0.0826 | 0.511 0.468-0.553 |
2.42 OR 95% CI: 0.933-6.3 |
Binary
weak
|
|
| 180.3 |
Cervical intraepithelial neoplasia [CIN] [Cervical dysplasia] Self-reported cin/pre-cancer cells cervix |
MGI | P&T | UKB GWAS (PHESANT) | 10 | 0.35 | 0.0008 | 0.0885 | 0.493 0.465-0.522 |
1.73 OR 95% CI: 0.784-3.84 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary High-grade serous ovarian cancer |
UKB | lassosum | Phelan CM et al. 2017 | 37433 | 0.35 | 0.0018 | 0.0827 | 0.514 0.487-0.54 |
0.923 OR 95% CI: 0.347-2.45 |
Binary
weak
|
|
| 190 |
Cancer of eye ICD-10 C69 Malignant neoplasm of eye and adnexa |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 35 | 0.35 | 0.003 | 0.0837 | 0.534 0.464-0.611 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Mature T/NK-cell lymphomas |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 10 | 0.35 | 0 | 0.0827 | 0.502 0.479-0.526 |
1.31 OR 95% CI: 0.636-2.7 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue ICD-10 C01 Malignant neoplasm of base of tongue |
MGI | lassosum | UKB GWAS (ICD10) | 1312025 | 0.36 | 0.0012 | 0.0828 | 0.52 0.484-0.554 |
0.939 OR 95% CI: 0.251-3.51 |
Binary
weak
|
|
| 151 |
Cancer of stomach Self-reported stomach cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 63785 | 0.36 | 0.0024 | 0.0829 | 0.518 0.477-0.56 |
2.47 OR 95% CI: 0.945-6.46 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of rectum |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 19 | 0.36 | 0 | 0.083 | 0.493 0.462-0.526 |
1.65 OR 95% CI: 0.66-4.15 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C21 Malignant neoplasm of anus and anal canal |
MGI | lassosum | UKB GWAS (ICD10) | 67145 | 0.36 | 0.0022 | 0.083 | 0.521 0.488-0.555 |
1.06 OR 95% CI: 0.345-3.25 |
Binary
weak
|
|
| 180.1 |
Cervical cancer ICD-10 D06 Carcinoma in situ of cervix uteri |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 93 | 0.36 | 0.0002 | 0.0826 | 0.515 0.477-0.551 |
1.51 OR 95% CI: 0.478-4.77 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Self-reported ovarian cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 100 | 0.36 | 0.0019 | 0.0829 | 0.514 0.466-0.558 |
2.36 OR 95% CI: 0.813-6.87 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary High-grade serous ovarian cancer |
MGI | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 14 | 0.36 | 0.0008 | 0.0829 | 0.514 0.472-0.558 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
MGI | PRS-CS | Phelan CM et al. 2017 | 1114056 | 0.36 | 0.0004 | 0.0829 | 0.528 0.482-0.572 |
1.36 OR 95% CI: 0.348-5.29 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
MGI | lassosum | Phelan CM et al. 2017 | 59 | 0.36 | 0.0056 | 0.0829 | 0.552 0.511-0.593 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis ICD-10 C62 Malignant neoplasm of testis |
MGI | Fixed threshold (5e-07) | UKB GWAS (ICD10) | 5 | 0.36 | 0.0017 | 0.086 | 0.529 0.461-0.601 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Self-reported kidney/renal cell cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 13 | 0.36 | 0.0002 | 0.0827 | 0.491 0.466-0.518 |
2.32 OR 95% CI: 1.24-4.33 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma (GWAS Catalog (2019-05-03)) |
MGI | lassosum | UKB GWAS (PheCode) | 39308 | 0.36 | 0.0009 | 0.0827 | 0.509 0.484-0.535 |
2.41 OR 95% CI: 1.37-4.24 |
Binary
weak
|
|
| 209 |
Neuroendocrine tumors Neuroblastoma;Neuroblastoma (high-risk);Sporadic neuroblastoma;Neuroblastoma (11q deletion) |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 10 | 0.36 | 0.0004 | 0.0826 | 0.517 0.459-0.572 |
1.18 OR 95% CI: 0.204-6.85 |
Binary
weak
|
|
| 209 |
Neuroendocrine tumors Neuroblastoma;Neuroblastoma (high-risk);Sporadic neuroblastoma;Neuroblastoma (11q deletion) |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 10 | 0.36 | 0.0004 | 0.0826 | 0.517 0.459-0.572 |
1.18 OR 95% CI: 0.204-6.85 |
Binary
weak
|
|
| 209 |
Neuroendocrine tumors Neuroblastoma;Neuroblastoma (high-risk);Sporadic neuroblastoma;Neuroblastoma (11q deletion) |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 10 | 0.36 | 0.0004 | 0.0826 | 0.517 0.459-0.572 |
1.18 OR 95% CI: 0.204-6.85 |
Binary
weak
|
|
| 209 |
Neuroendocrine tumors Neuroblastoma;Neuroblastoma (high-risk);Sporadic neuroblastoma;Neuroblastoma (11q deletion) |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 10 | 0.36 | 0.0004 | 0.0826 | 0.517 0.459-0.572 |
1.18 OR 95% CI: 0.204-6.85 |
Binary
weak
|
|
| 153.2 |
Colon cancer Self-reported colon cancer/sigmoid cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 5818307 | 0.37 | 0.0009 | 0.0833 | 0.513 0.485-0.538 |
0.948 OR 95% CI: 0.356-2.53 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer and mesothelioma |
MGI | lassosum | UKB GWAS (FINNGEN) | 73073 | 0.37 | 0.0009 | 0.0828 | 0.516 0.488-0.546 |
0.564 OR 95% CI: 0.155-2.05 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer and mesothelioma |
MGI | lassosum | UKB GWAS (FINNGEN) | 73073 | 0.37 | 0.0009 | 0.0828 | 0.516 0.488-0.546 |
0.564 OR 95% CI: 0.155-2.05 |
Binary
weak
|
|
| 190 |
Cancer of eye Malignant neoplasm of eye and adnexa |
MGI | lassosum | UKB GWAS (FINNGEN) | 195920 | 0.37 | 0.0146 | 0.0837 | 0.534 0.456-0.608 |
1.91 OR 95% CI: 0.296-12.4 |
Binary
weak
|
|
| 201 |
Hodgkin's disease ICD-10 C81 Hodgkin's disease |
MGI | lassosum | UKB GWAS (ICD10) | 31680 | 0.37 | 0.0107 | 0.0831 | 0.521 0.455-0.59 |
1.82 OR 95% CI: 0.289-11.5 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 113 | 0.37 | 0.0051 | 0.0825 | 0.523 0.452-0.591 |
5.09 OR 95% CI: 1.53-16.9 |
Binary
weak
|
|
| 204.11 |
Lymphoid leukemia, acute Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia in childhood (B cell precursor) |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 5 | 0.37 | 0.0053 | 0.0826 | 0.534 0.426-0.65 |
2.64 OR 95% CI: 0.348-20 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue Malignant neoplasm of other and unspecified parts of tongue (UKB GWAS (FINNGEN)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.38 | 0 | 0.0828 | 0.523 0.486-0.559 |
0.928 OR 95% CI: 0.247-3.48 |
Binary
weak
|
|
| 159.3 |
Malignant neoplasm of gallbladder and extrahepatic bile ducts |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.38 | 0.0027 | 0.0825 | 0.529 0.454-0.599 |
5.32 OR 95% CI: 1.56-18.2 |
Binary
weak
|
|
| 170.1 |
Bone cancer Self-reported primary bone cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 48 | 0.38 | 0.0002 | 0.0829 | 0.512 0.479-0.546 |
1.59 OR 95% CI: 0.635-3.97 |
Binary
weak
|
|
| 172.2 |
Other non-epithelial cancer of skin Self-reported non-melanoma skin cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 18 | 0.38 | 0.0001 | 0.139 | 0.494 0.483-0.506 |
1.6 OR 95% CI: 1.12-2.28 |
Binary
weak
|
|
| 172.21 |
Basal cell carcinoma Self-reported rodent ulcer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 96 | 0.38 | 0.0003 | 0.109 | 0.5 0.484-0.516 |
1.03 OR 95% CI: 0.582-1.8 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary High-grade serous ovarian cancer |
MGI | P&T | Phelan CM et al. 2017 | 9 | 0.38 | 0.0014 | 0.0829 | 0.52 0.48-0.56 |
0.774 OR 95% CI: 0.14-4.27 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis ICD-10 C62 Malignant neoplasm of testis |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 76 | 0.38 | 0.0003 | 0.086 | 0.532 0.459-0.598 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis ICD-10 C62 Malignant neoplasm of testis |
MGI | P&T | UKB GWAS (ICD10) | 10 | 0.38 | 0.0024 | 0.086 | 0.528 0.459-0.597 |
1.68 OR 95% CI: 0.25-11.2 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Malignant neoplasm of eye, brain and central nervous system |
MGI | P&T | UKB GWAS (FINNGEN) | 36 | 0.38 | 0.0005 | 0.0826 | 0.508 0.47-0.543 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin lymphoma |
MGI | P&T | UKB GWAS (FINNGEN) | 117 | 0.38 | 0.0177 | 0.083 | 0.526 0.455-0.593 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Glioblastoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 94 | 0.39 | 0.0016 | 0.0826 | 0.513 0.474-0.55 |
1.01 OR 95% CI: 0.269-3.82 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Malignant neoplasm of brain |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1050964 | 0.39 | 0.0004 | 0.0826 | 0.508 0.471-0.549 |
1.43 OR 95% CI: 0.454-4.49 |
Binary
weak
|
|
| 194 |
Cancer of other endocrine glands Malignant neoplasm of endocrine gland |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 82 | 0.39 | 0.0003 | 0.0827 | 0.507 0.447-0.567 |
4.01 OR 95% CI: 1.27-12.6 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma Follicular lymphoma |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 103 | 0.39 | 0.0001 | 0.0826 | 0.502 0.47-0.535 |
2.16 OR 95% CI: 0.908-5.13 |
Binary
weak
|
|
| 204.22 |
Myeloid leukemia, chronic |
MGI | P&T | UKB GWAS (PheCode) | 62 | 0.39 | 0.0247 | 0.0825 | 0.538 0.433-0.645 |
4.58 OR 95% CI: 0.489-42.8 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Self-reported lung cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 5700 | 0.4 | 0.0028 | 0.0828 | 0.513 0.484-0.541 |
0.801 OR 95% CI: 0.266-2.41 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 10 | 0.4 | 0.0008 | 0.0832 | 0.51 0.478-0.542 |
0.736 OR 95% CI: 0.2-2.71 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Invasive epithelial ovarian cancer |
MGI | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 219 | 0.4 | 0 | 0.0829 | 0.527 0.488-0.57 |
0.814 OR 95% CI: 0.148-4.49 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Diagnoses - main ICD10: C56 Malignant neoplasm of ovary (UKB GWAS (ICD10)) |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1095247 | 0.4 | 0.0027 | 0.0829 | 0.525 0.478-0.568 |
1.26 OR 95% CI: 0.323-4.94 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis ICD-10 C62 Malignant neoplasm of testis |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 13 | 0.4 | 0.0008 | 0.086 | 0.534 0.468-0.604 |
1.53 OR 95% CI: 0.217-10.8 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1061611 | 0.4 | 0.009 | 0.0861 | 0.531 0.468-0.594 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.11 |
Lymphoid leukemia, acute Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia in childhood (B cell precursor) |
MGI | P&T | GWAS Catalog (2019-05-03) | 21 | 0.4 | 0.0092 | 0.0826 | 0.559 0.461-0.657 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.2 |
Myeloid leukemia ICD-10 C92 Myeloid leukaemia |
MGI | P&T | UKB GWAS (ICD10) | 8 | 0.4 | 0.011 | 0.0826 | 0.514 0.458-0.576 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 157 |
Pancreatic cancer Malignant neoplasm of pancreas |
MGI | lassosum | UKB GWAS (FINNGEN) | 174 | 0.41 | 0.0046 | 0.0828 | 0.506 0.464-0.55 |
1.11 OR 95% CI: 0.292-4.21 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Endometrioid ovarian cancer |
MGI | PRS-CS | Phelan CM et al. 2017 | 1114056 | 0.41 | 0 | 0.0829 | 0.523 0.479-0.573 |
2.49 OR 95% CI: 0.858-7.24 |
Binary
weak
|
|
| 157 |
Pancreatic cancer ICD-10 C25 Malignant neoplasm of pancreas |
MGI | P&T | UKB GWAS (ICD10) | 6 | 0.42 | 0.0006 | 0.0828 | 0.486 0.445-0.529 |
2.01 OR 95% CI: 0.711-5.67 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Self-reported uterine/endometrial cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 115 | 0.42 | 0.0014 | 0.0832 | 0.511 0.478-0.544 |
0.722 OR 95% CI: 0.196-2.66 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Self-reported uterine/endometrial cancer |
MGI | P&T | UKB GWAS (PHESANT) | 115 | 0.42 | 0.0014 | 0.0832 | 0.511 0.478-0.544 |
0.722 OR 95% CI: 0.196-2.66 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary High-grade serous ovarian cancer |
MGI | lassosum | Phelan CM et al. 2017 | 20012 | 0.42 | 0.0049 | 0.0829 | 0.516 0.475-0.56 |
0.824 OR 95% CI: 0.149-4.55 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis ICD-10 C62 Malignant neoplasm of testis |
MGI | lassosum | UKB GWAS (ICD10) | 2944812 | 0.42 | 0.0041 | 0.0861 | 0.527 0.461-0.599 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 194 |
Cancer of other endocrine glands Malignant neoplasm of endocrine gland |
MGI | P&T | UKB GWAS (FINNGEN) | 123 | 0.42 | 0.0044 | 0.0828 | 0.519 0.46-0.579 |
1.3 OR 95% CI: 0.223-7.59 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma and malignant plasma cell neoplasms |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1060905 | 0.42 | 0.0006 | 0.0827 | 0.531 0.47-0.596 |
1.5 OR 95% CI: 0.243-9.19 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue Self-reported tongue cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 41 | 0.43 | 0 | 0.0828 | 0.511 0.477-0.547 |
0.929 OR 95% CI: 0.248-3.49 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of anus and anal canal |
MGI | lassosum | UKB GWAS (FINNGEN) | 79687 | 0.43 | 0.0018 | 0.083 | 0.527 0.493-0.558 |
1.34 OR 95% CI: 0.493-3.65 |
Binary
weak
|
|
| 172.3 |
Carcinoma in situ of skin ICD-10 D04 Carcinoma in situ of skin |
MGI | P&T | UKB GWAS (ICD10) | 65 | 0.43 | 0.0021 | 0.094 | 0.503 0.479-0.528 |
0.9 OR 95% CI: 0.368-2.2 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
UKB | lassosum | Phelan CM et al. 2017 | 1467601 | 0.43 | 0.0028 | 0.0827 | 0.507 0.48-0.534 |
1.13 OR 95% CI: 0.464-2.77 |
Binary
weak
|
|
| 200.1 |
Polycythemia vera |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 19 | 0.43 | 0.0001 | 0.0826 | 0.513 0.453-0.577 |
1.58 OR 95% CI: 0.256-9.73 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 7 | 0.43 | 0.0004 | 0.0827 | 0.46 0.441-0.48 |
1.78 OR 95% CI: 0.943-3.36 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 7 | 0.43 | 0.0004 | 0.0827 | 0.46 0.441-0.48 |
1.78 OR 95% CI: 0.943-3.36 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 5 | 0.43 | 0.0003 | 0.0827 | 0.456 0.438-0.476 |
1.94 OR 95% CI: 1.05-3.58 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma |
MGI | P&T | GWAS Catalog (2019-05-03) | 7 | 0.43 | 0.0004 | 0.0827 | 0.46 0.441-0.48 |
1.78 OR 95% CI: 0.943-3.36 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Lymphomas |
MGI | lassosum | UKB GWAS (FINNGEN) | 215 | 0.43 | 0.0005 | 0.0827 | 0.478 0.458-0.501 |
0.993 OR 95% CI: 0.44-2.24 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy (GWAS Catalog (2019-05-03)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.43 | 0 | 0.0827 | 0.532 0.467-0.599 |
1.52 OR 95% CI: 0.25-9.32 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx ICD-10 C32 Malignant neoplasm of larynx |
MGI | P&T | UKB GWAS (ICD10) | 106 | 0.44 | 0.0018 | 0.0826 | 0.518 0.472-0.567 |
2.16 OR 95% CI: 0.642-7.25 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx Malignant neoplasm of larynx |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 978910 | 0.44 | 0.001 | 0.0826 | 0.526 0.479-0.571 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C21 Malignant neoplasm of anus and anal canal |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 64 | 0.44 | 0.0026 | 0.083 | 0.509 0.475-0.544 |
1.05 OR 95% CI: 0.343-3.22 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 5 | 0.44 | 0 | 0.0827 | 0.505 0.477-0.532 |
1.37 OR 95% CI: 0.595-3.14 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Cancer code, self-reported: cervical cancer (UKB GWAS (PHESANT)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119236 | 0.44 | 0.0004 | 0.0826 | 0.51 0.471-0.548 |
3.78 OR 95% CI: 1.68-8.53 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
MGI | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 26 | 0.44 | 0.0004 | 0.0829 | 0.525 0.481-0.57 |
1.34 OR 95% CI: 0.343-5.22 |
Binary
weak
|
|
| 189.2 |
Cancer of bladder Self-reported bladder cancer |
MGI | P&T | UKB GWAS (PHESANT) | 155 | 0.44 | 0.0021 | 0.0923 | 0.507 0.488-0.527 |
0.549 OR 95% CI: 0.21-1.44 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
UKB | GWAS Hits | GWAS Catalog (2019-05-03) | 16 | 0.44 | 0.0453 | 0.0821 | 0.507 0.449-0.56 |
1.88 OR 95% CI: 0.464-7.64 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma Other and unspecified types of non-Hodgkin lymphoma |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1054742 | 0.44 | 0 | 0.0827 | 0.505 0.481-0.529 |
1.95 OR 95% CI: 1.02-3.7 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Diagnoses - main ICD10: C21 Malignant neoplasm of anus and anal canal (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 17 | 0.45 | 0.001 | 0.083 | 0.502 0.466-0.533 |
1.63 OR 95% CI: 0.651-4.09 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of rectum |
MGI | lassosum | UKB GWAS (FINNGEN) | 1249593 | 0.45 | 0.0007 | 0.083 | 0.508 0.473-0.541 |
1.34 OR 95% CI: 0.493-3.66 |
Binary
weak
|
|
| 159 |
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum Malignant neoplasm of digestive organs |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 130 | 0.45 | 0.0003 | 0.0826 | 0.508 0.477-0.538 |
2.43 OR 95% CI: 1.18-5 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Ovarian clear cell cancer |
UKB | P&T | Phelan CM et al. 2017 | 84 | 0.45 | 0.0028 | 0.0827 | 0.51 0.482-0.538 |
1.76 OR 95% CI: 0.839-3.7 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Non-follicular lymphoma |
MGI | P&T | UKB GWAS (FINNGEN) | 12 | 0.45 | 0.0017 | 0.0827 | 0.496 0.472-0.52 |
1.59 OR 95% CI: 0.824-3.09 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia |
MGI | P&T | UKB GWAS (PheCode) | 10 | 0.45 | 0.0178 | 0.0826 | 0.498 0.442-0.561 |
1.57 OR 95% CI: 0.256-9.66 |
Binary
weak
|
|
| 204.2 |
Myeloid leukemia ICD-10 C92 Myeloid leukaemia |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 9 | 0.45 | 0.0074 | 0.0826 | 0.51 0.454-0.572 |
3.04 OR 95% CI: 0.866-10.7 |
Binary
weak
|
|
| 153 |
Colorectal cancer Self-reported large bowel cancer/colorectal cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 99 | 0.46 | 0.0005 | 0.0831 | 0.505 0.482-0.527 |
1.38 OR 95% CI: 0.668-2.86 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Cancer code, self-reported: cervical cancer (UKB GWAS (PHESANT)) |
MGI | P&T | UKB GWAS (PheCode) | 5 | 0.46 | 0.0015 | 0.0826 | 0.492 0.454-0.531 |
1.04 OR 95% CI: 0.273-3.95 |
Binary
weak
|
|
| 187 |
Cancer of other male genital organs malignant neoplasm of male genital organs |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1111493 | 0.46 | 0.0014 | 0.0833 | 0.519 0.47-0.57 |
1.67 OR 95% CI: 0.416-6.72 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 114 | 0.46 | 0.003 | 0.0826 | 0.506 0.472-0.54 |
2.31 OR 95% CI: 0.967-5.53 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Self-reported brain cancer / primary malignant brain tumour |
MGI | P&T | UKB GWAS (PHESANT) | 82 | 0.46 | 0.0005 | 0.0826 | 0.512 0.473-0.55 |
0.603 OR 95% CI: 0.113-3.22 |
Binary
weak
|
|
| 194 |
Cancer of other endocrine glands Malignant neoplasm of endocrine gland |
MGI | lassosum | UKB GWAS (FINNGEN) | 11722 | 0.46 | 0.0056 | 0.0828 | 0.514 0.458-0.566 |
2.18 OR 95% CI: 0.522-9.12 |
Binary
weak
|
|
| 200 |
Myeloproliferative disease |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 5 | 0.46 | 0.0004 | 0.0826 | 0.493 0.464-0.521 |
1.46 OR 95% CI: 0.632-3.36 |
Binary
weak
|
|
| 157 |
Pancreatic cancer Malignant neoplasm of pancreas |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1062840 | 0.47 | 0.0001 | 0.0829 | 0.506 0.464-0.548 |
2.49 OR 95% CI: 0.954-6.52 |
Binary
weak
|
|
| 190 |
Cancer of eye Malignant neoplasm of eye and adnexa (UKB GWAS (FINNGEN)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.47 | 0.0002 | 0.0837 | 0.53 0.459-0.603 |
1.88 OR 95% CI: 0.29-12.1 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 11 | 0.47 | 0.0051 | 0.0827 | 0.498 0.476-0.522 |
0.912 OR 95% CI: 0.377-2.21 |
Binary
weak
|
|
| 153.2 |
Colon cancer ICD-10 C18 Malignant neoplasm of colon |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 24 | 0.49 | 0.0005 | 0.0833 | 0.5 0.473-0.527 |
0.966 OR 95% CI: 0.362-2.58 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Self-reported lung cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 10 | 0.49 | 0 | 0.0828 | 0.492 0.463-0.519 |
1.71 OR 95% CI: 0.777-3.76 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Self-reported uterine/endometrial cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1097611 | 0.49 | 0 | 0.0832 | 0.508 0.475-0.539 |
1.03 OR 95% CI: 0.335-3.14 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary ICD-10 C56 Malignant neoplasm of ovary |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 101 | 0.49 | 0 | 0.0829 | 0.505 0.459-0.551 |
1.35 OR 95% CI: 0.347-5.26 |
Binary
weak
|
|
| 191.11 |
Cancer of brain ICD-10 C71 Malignant neoplasm of brain |
MGI | PRS-CS | UKB GWAS (ICD10) | 1055124 | 0.49 | 0.0002 | 0.0826 | 0.514 0.476-0.556 |
0.607 OR 95% CI: 0.113-3.25 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Malignant neoplasm of brain |
MGI | lassosum | UKB GWAS (FINNGEN) | 3656328 | 0.49 | 0.0005 | 0.0826 | 0.51 0.473-0.545 |
1.84 OR 95% CI: 0.658-5.17 |
Binary
weak
|
|
| 204.22 |
Myeloid leukemia, chronic |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 72 | 0.49 | 0.0062 | 0.0825 | 0.53 0.423-0.642 |
4.48 OR 95% CI: 0.473-42.5 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue |
MGI | lassosum | UKB GWAS (PheCode) | 534767 | 0.5 | 0.0017 | 0.0828 | 0.511 0.486-0.535 |
0.807 OR 95% CI: 0.306-2.13 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus ICD-10 C54 Malignant neoplasm of corpus uteri |
MGI | lassosum | UKB GWAS (ICD10) | 2360050 | 0.5 | 0.0033 | 0.0832 | 0.511 0.478-0.543 |
0.73 OR 95% CI: 0.198-2.69 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.5 | 0 | 0.0826 | 0.508 0.473-0.542 |
0.485 OR 95% CI: 0.092-2.56 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue Malignant neoplasm of other and unspecified parts of tongue |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 10 | 0.51 | 0.0006 | 0.0828 | 0.505 0.469-0.542 |
1.71 OR 95% CI: 0.618-4.76 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 105 | 0.51 | 0.0003 | 0.0828 | 0.51 0.472-0.555 |
1.27 OR 95% CI: 0.328-4.89 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum Self-reported small intestine/small bowel cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 59 | 0.51 | 0.0005 | 0.0826 | 0.501 0.435-0.568 |
4.18 OR 95% CI: 1.11-15.8 |
Binary
weak
|
|
| 172.2 |
Other non-epithelial cancer of skin Self-reported non-melanoma skin cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 112 | 0.51 | 0.0001 | 0.139 | 0.501 0.49-0.513 |
0.868 OR 95% CI: 0.565-1.33 |
Binary
weak
|
|
| 172.3 |
Carcinoma in situ of skin ICD-10 D04 Carcinoma in situ of skin |
MGI | lassosum | UKB GWAS (ICD10) | 118 | 0.51 | 0.0039 | 0.094 | 0.504 0.48-0.528 |
1.1 OR 95% CI: 0.481-2.54 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
UKB | P&T | Phelan CM et al. 2017 | 45 | 0.51 | 0.0053 | 0.0827 | 0.51 0.481-0.538 |
0.924 OR 95% CI: 0.348-2.46 |
Binary
weak
|
|
| 189.2 |
Cancer of bladder Malignant neoplasm of bladder |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 125 | 0.51 | 0 | 0.0923 | 0.502 0.481-0.523 |
1.01 OR 95% CI: 0.489-2.07 |
Binary
weak
|
|
| 189.2 |
Cancer of bladder Malignant neoplasm of bladder |
MGI | P&T | UKB GWAS (FINNGEN) | 5 | 0.51 | 0.0007 | 0.0923 | 0.468 0.449-0.487 |
0.767 OR 95% CI: 0.34-1.73 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Non-follicular lymphoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 18 | 0.51 | 0.001 | 0.0827 | 0.495 0.472-0.519 |
0.675 OR 95% CI: 0.257-1.77 |
Binary
weak
|
|
| 204.11 |
Lymphoid leukemia, acute Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia in childhood (B cell precursor) |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 10 | 0.51 | 0.0024 | 0.0827 | 0.543 0.451-0.632 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 45 | 0.51 | 0.0241 | 0.0827 | 0.516 0.443-0.583 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
MGI | P&T | GWAS Catalog (2019-05-03) | 45 | 0.51 | 0.0241 | 0.0827 | 0.516 0.443-0.583 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 153.2 |
Colon cancer Self-reported colon cancer/sigmoid cancer |
MGI | P&T | UKB GWAS (PHESANT) | 11 | 0.52 | 0.0011 | 0.0833 | 0.492 0.467-0.521 |
0.73 OR 95% CI: 0.243-2.19 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C21 Malignant neoplasm of anus and anal canal |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 16 | 0.52 | 0.0027 | 0.083 | 0.499 0.467-0.535 |
0.444 OR 95% CI: 0.0847-2.33 |
Binary
weak
|
|
| 170.1 |
Bone cancer Self-reported primary bone cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 839358 | 0.52 | 0.0013 | 0.0829 | 0.51 0.478-0.543 |
1.31 OR 95% CI: 0.482-3.57 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary ICD-10 C56 Malignant neoplasm of ovary |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 10 | 0.52 | 0.0007 | 0.0829 | 0.496 0.449-0.541 |
1.41 OR 95% CI: 0.36-5.49 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 41 | 0.52 | 0.003 | 0.0861 | 0.525 0.461-0.588 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma Other and unspecified types of non-Hodgkin lymphoma |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 80 | 0.52 | 0.0001 | 0.0827 | 0.505 0.48-0.53 |
0.747 OR 95% CI: 0.284-1.97 |
Binary
weak
|
|
| 150 |
Cancer of esophagus ICD-10 C15 Malignant neoplasm of oesophagus |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 25 | 0.53 | 0.0012 | 0.0828 | 0.51 0.462-0.551 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Diagnoses - main ICD10: C56 Malignant neoplasm of ovary (UKB GWAS (ICD10)) |
MGI | P&T | UKB GWAS (FINNGEN) | 193 | 0.53 | 0.0009 | 0.0829 | 0.513 0.469-0.556 |
0.826 OR 95% CI: 0.15-4.56 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) (GWAS Catalog (2019-05-03)) |
MGI | lassosum | UKB GWAS (PheCode) | 333485 | 0.54 | 0.0049 | 0.0832 | 0.513 0.48-0.543 |
0.729 OR 95% CI: 0.198-2.69 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
MGI | GWAS Hits | GWAS Catalog (2019-05-03) | 12 | 0.54 | 0.0047 | 0.0827 | 0.496 0.474-0.52 |
1.08 OR 95% CI: 0.474-2.44 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 54 | 0.54 | 0.0108 | 0.0827 | 0.509 0.436-0.58 |
1.23 OR 95% CI: 0.194-7.84 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma Self-reported multiple myeloma |
MGI | PRS-CS | UKB GWAS (PHESANT) | 872863 | 0.54 | 0.0021 | 0.0827 | 0.513 0.448-0.579 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 155 |
Cancer of liver and intrahepatic bile duct ICD-10 C22 Malignant neoplasm of liver and intrahepatic bile ducts |
MGI | P&T | UKB GWAS (ICD10) | 9 | 0.55 | 0.0017 | 0.0826 | 0.498 0.459-0.536 |
1.62 OR 95% CI: 0.51-5.18 |
Binary
weak
|
|
| 172.2 |
Other non-epithelial cancer of skin Self-reported non-melanoma skin cancer |
MGI | P&T | UKB GWAS (PHESANT) | 177 | 0.55 | 0.0008 | 0.139 | 0.5 0.489-0.512 |
1.12 OR 95% CI: 0.756-1.65 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Primary_lymphoid and hematopoietic malignant neoplasms |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 19 | 0.55 | 0 | 0.0827 | 0.487 0.464-0.509 |
0.838 OR 95% CI: 0.348-2.02 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Lymphomas |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1109478 | 0.55 | 0.0003 | 0.0827 | 0.505 0.482-0.527 |
1.16 OR 95% CI: 0.539-2.49 |
Binary
weak
|
|
| 149.1 |
Cancer of oropharynx |
MGI | lassosum | UKB GWAS (PheCode) | 442201 | 0.56 | 0.0026 | 0.083 | 0.515 0.464-0.561 |
2.41 OR 95% CI: 0.715-8.1 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Doctor diagnosed lung cancer (not mesothelioma) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 32 | 0.56 | 0.0007 | 0.0828 | 0.504 0.475-0.532 |
0.337 OR 95% CI: 0.065-1.74 |
Binary
weak
|
|
| 170 |
Cancer of bone and connective tissue |
MGI | P&T | UKB GWAS (PheCode) | 27 | 0.56 | 0.0004 | 0.083 | 0.493 0.471-0.514 |
0.826 OR 95% CI: 0.368-1.85 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 11 | 0.56 | 0.0003 | 0.0828 | 0.474 0.45-0.5 |
1.16 OR 95% CI: 0.51-2.65 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma (GWAS Catalog (2019-05-03)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.56 | 0.0001 | 0.0827 | 0.51 0.487-0.531 |
1.31 OR 95% CI: 0.635-2.7 |
Binary
weak
|
|
| 155.1 |
Malignant neoplasm of liver, primary |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 9 | 0.57 | 0.0011 | 0.0825 | 0.484 0.435-0.534 |
2.21 OR 95% CI: 0.664-7.38 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue ICD-10 C49 Malignant neoplasm of other connective and soft tissue |
MGI | lassosum | UKB GWAS (ICD10) | 394653 | 0.57 | 0.0006 | 0.0828 | 0.506 0.482-0.532 |
1.17 OR 95% CI: 0.514-2.66 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary ICD-10 C56 Malignant neoplasm of ovary |
MGI | PRS-CS | UKB GWAS (ICD10) | 1091510 | 0.57 | 0.0001 | 0.0829 | 0.518 0.474-0.56 |
3.09 OR 95% CI: 1.15-8.29 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue |
MGI | P&T | UKB GWAS (PheCode) | 6 | 0.58 | 0.001 | 0.0828 | 0.456 0.435-0.477 |
1.35 OR 95% CI: 0.623-2.92 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous ovarian cancer |
MGI | P&T | Phelan CM et al. 2017 | 176 | 0.58 | 0.0021 | 0.0829 | 0.521 0.475-0.565 |
0.792 OR 95% CI: 0.143-4.38 |
Binary
weak
|
|
| 189.1 |
Cancer of kidney and renal pelvis |
MGI | P&T | UKB GWAS (PheCode) | 162 | 0.58 | 0.0004 | 0.0827 | 0.501 0.478-0.523 |
1.04 OR 95% CI: 0.461-2.36 |
Binary
weak
|
|
| 191.1 |
Cancer of brain and nervous system Glioma;Non-glioblastoma glioma;Glioma (high-grade) |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 20 | 0.58 | 0.0047 | 0.0826 | 0.501 0.465-0.535 |
0.873 OR 95% CI: 0.234-3.25 |
Binary
weak
|
|
| 204.11 |
Lymphoid leukemia, acute Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia in childhood (B cell precursor) |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 17 | 0.58 | 0.0059 | 0.0827 | 0.54 0.448-0.633 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Self-reported rectal cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 183063 | 0.59 | 0.001 | 0.083 | 0.507 0.47-0.541 |
0.742 OR 95% CI: 0.201-2.73 |
Binary
weak
|
|
| 155.1 |
Malignant neoplasm of liver, primary |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.6 | 0.0022 | 0.0825 | 0.506 0.459-0.555 |
2.25 OR 95% CI: 0.672-7.54 |
Binary
weak
|
|
| 159.3 |
Malignant neoplasm of gallbladder and extrahepatic bile ducts |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 8 | 0.6 | 0.0169 | 0.0826 | 0.483 0.417-0.549 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 159.3 |
Malignant neoplasm of gallbladder and extrahepatic bile ducts |
MGI | lassosum | UKB GWAS (PheCode) | 177340 | 0.6 | 0.0285 | 0.0826 | 0.523 0.45-0.595 |
2.96 OR 95% CI: 0.66-13.3 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system Malignant neoplasm of respiratory system and intrathoracic organs |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 9 | 0.6 | 0.0006 | 0.0827 | 0.48 0.454-0.505 |
1.11 OR 95% CI: 0.453-2.71 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;Ovarian clear cell cancer |
MGI | P&T | GWAS Catalog (2019-05-03) | 10 | 0.6 | 0.0061 | 0.0829 | 0.505 0.459-0.549 |
0.799 OR 95% CI: 0.145-4.41 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Self-reported brain cancer / primary malignant brain tumour |
MGI | lassosum | UKB GWAS (PHESANT) | 24094 | 0.6 | 0.0023 | 0.0826 | 0.509 0.474-0.55 |
3.13 OR 95% CI: 1.35-7.28 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Primary_lymphoid and hematopoietic malignant neoplasms |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 8 | 0.6 | 0.0001 | 0.0827 | 0.477 0.456-0.497 |
0.686 OR 95% CI: 0.261-1.8 |
Binary
weak
|
|
| 209 |
Neuroendocrine tumors Neuroblastoma;Neuroblastoma (high-risk);Sporadic neuroblastoma;Neuroblastoma (11q deletion) |
MGI | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 7 | 0.6 | 0.0006 | 0.0826 | 0.507 0.452-0.56 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 209 |
Neuroendocrine tumors Neuroblastoma;Neuroblastoma (high-risk);Sporadic neuroblastoma;Neuroblastoma (11q deletion) |
MGI | P&T | GWAS Catalog (2019-05-03) | 7 | 0.6 | 0.0006 | 0.0826 | 0.507 0.452-0.56 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Self-reported rectal cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1018916 | 0.61 | 0.0002 | 0.083 | 0.507 0.475-0.54 |
1.35 OR 95% CI: 0.494-3.67 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia Lymphoid leukaemia |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 20 | 0.61 | 0.0037 | 0.0826 | 0.511 0.45-0.58 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 151 |
Cancer of stomach Self-reported stomach cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 889207 | 0.62 | 0.0005 | 0.0829 | 0.507 0.463-0.546 |
1.55 OR 95% CI: 0.489-4.91 |
Binary
weak
|
|
| 159 |
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum Malignant neoplasm of digestive organs |
MGI | lassosum | UKB GWAS (FINNGEN) | 4 | 0.62 | 0.0015 | 0.0826 | 0.505 0.474-0.535 |
3.75 OR 95% CI: 2.02-6.95 |
Binary
weak
|
|
| 159.3 |
Malignant neoplasm of gallbladder and extrahepatic bile ducts |
MGI | P&T | UKB GWAS (PheCode) | 114 | 0.62 | 0.0362 | 0.0826 | 0.502 0.43-0.573 |
1.89 OR 95% CI: 0.3-11.9 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung ICD-10 C34 Malignant neoplasm of bronchus and lung |
MGI | P&T | UKB GWAS (ICD10) | 10 | 0.62 | 0.0027 | 0.0828 | 0.491 0.464-0.519 |
1.02 OR 95% CI: 0.38-2.72 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum ICD-10 C17 Malignant neoplasm of small intestine |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 41 | 0.63 | 0 | 0.0826 | 0.507 0.446-0.568 |
1.73 OR 95% CI: 0.276-10.8 |
Binary
weak
|
|
| 170 |
Cancer of bone and connective tissue |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 93 | 0.63 | 0 | 0.083 | 0.501 0.481-0.522 |
0.701 OR 95% CI: 0.293-1.68 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 16 | 0.63 | 0.005 | 0.0827 | 0.494 0.471-0.519 |
1.58 OR 95% CI: 0.79-3.17 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma Diffuse large B cell lymphoma;Follicular lymphoma |
MGI | Fixed threshold (5e-07) | GWAS Catalog (2019-05-03) | 16 | 0.63 | 0.005 | 0.0827 | 0.494 0.471-0.519 |
1.58 OR 95% CI: 0.79-3.17 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma ICD-10 C83 Diffuse non-Hodgkin's lymphoma |
MGI | lassosum | UKB GWAS (ICD10) | 363554 | 0.63 | 0.0044 | 0.0827 | 0.502 0.476-0.528 |
1.26 OR 95% CI: 0.584-2.72 |
Binary
weak
|
|
| 145.5 |
Cancer of the mouth floor |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.64 | 0.0035 | 0.0826 | 0.515 0.441-0.586 |
2.65 OR 95% CI: 0.612-11.4 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Diagnoses - main ICD10: C21 Malignant neoplasm of anus and anal canal (UKB GWAS (ICD10)) |
MGI | P&T | UKB GWAS (PheCode) | 13 | 0.64 | 0.0017 | 0.083 | 0.498 0.466-0.531 |
2.28 OR 95% CI: 1.01-5.12 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Malignant neoplasm of corpus uteri |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1104808 | 0.64 | 0.0001 | 0.0832 | 0.506 0.472-0.537 |
0.733 OR 95% CI: 0.199-2.7 |
Binary
weak
|
|
| 184 |
Cancer of other female genital organs malignant neoplasm of female genital organs |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 105 | 0.64 | 0.0004 | 0.0837 | 0.507 0.479-0.537 |
0.76 OR 95% CI: 0.253-2.29 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma ICD-10 C83 Diffuse non-Hodgkin's lymphoma |
MGI | PRS-CS | UKB GWAS (ICD10) | 1087052 | 0.64 | 0.0026 | 0.0827 | 0.508 0.484-0.533 |
0.75 OR 95% CI: 0.285-1.98 |
Binary
weak
|
|
| 202.24 |
Large cell lymphoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 11 | 0.64 | 0.0184 | 0.0832 | 0.505 0.442-0.572 |
1.98 OR 95% CI: 0.307-12.8 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue Malignant neoplasm of other and unspecified parts of tongue (UKB GWAS (FINNGEN)) |
MGI | lassosum | UKB GWAS (PheCode) | 4854389 | 0.65 | 0.0007 | 0.0828 | 0.513 0.474-0.55 |
0.939 OR 95% CI: 0.251-3.52 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx ICD-10 C32 Malignant neoplasm of larynx |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 56 | 0.65 | 0.0002 | 0.0826 | 0.51 0.461-0.557 |
3.39 OR 95% CI: 1.24-9.26 |
Binary
weak
|
|
| 149.9 |
Cancer of nasal cavities Cancer of of nasal cavities |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 49 | 0.65 | 0 | 0.0828 | 0.5 0.434-0.56 |
1.55 OR 95% CI: 0.253-9.54 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum ICD-10 C17 Malignant neoplasm of small intestine |
MGI | PRS-CS | UKB GWAS (ICD10) | 903170 | 0.65 | 0.0023 | 0.0826 | 0.509 0.44-0.581 |
1.79 OR 95% CI: 0.285-11.3 |
Binary
weak
|
|
| 172.1 |
Melanomas of skin, dx or hx ICD-10 D03 Melanoma in situ |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 95 | 0.65 | 0.0002 | 0.0969 | 0.498 0.482-0.516 |
0.87 OR 95% CI: 0.47-1.61 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin's lymphoma;Nodular sclerosis Hodgkin lymphoma |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 10 | 0.65 | 0.0328 | 0.0821 | 0.504 0.453-0.56 |
1.88 OR 95% CI: 0.463-7.64 |
Binary
weak
|
|
| 170.1 |
Bone cancer Cancer code, self-reported: primary bone cancer (UKB GWAS (PHESANT)) |
MGI | lassosum | UKB GWAS (PheCode) | 141650 | 0.66 | 0.0014 | 0.0829 | 0.515 0.483-0.548 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 180 |
Cervical cancer and dysplasia |
MGI | lassosum | UKB GWAS (PheCode) | 80 | 0.66 | 0.0021 | 0.0909 | 0.476 0.453-0.498 |
1.1 OR 95% CI: 0.483-2.52 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-07) | UKB GWAS (PheCode) | 22 | 0.66 | 0.0019 | 0.0862 | 0.505 0.441-0.566 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.2 |
Myeloid leukemia Myeloid leukaemia |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 74 | 0.66 | 0.0003 | 0.0826 | 0.497 0.443-0.553 |
3.05 OR 95% CI: 0.856-10.8 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer and mesothelioma |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 7 | 0.67 | 0.0002 | 0.0828 | 0.493 0.466-0.52 |
0.561 OR 95% CI: 0.155-2.04 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Lung cancer and mesothelioma |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 7 | 0.67 | 0.0002 | 0.0828 | 0.493 0.466-0.52 |
0.561 OR 95% CI: 0.155-2.04 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
MGI | GWAS Hits | Phelan CM et al. 2017 | 10 | 0.67 | 0.0064 | 0.0829 | 0.517 0.467-0.562 |
0.802 OR 95% CI: 0.145-4.42 |
Binary
weak
|
|
| 200 |
Myeloproliferative disease |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 19 | 0.67 | 0.0016 | 0.0826 | 0.491 0.465-0.517 |
1.47 OR 95% CI: 0.637-3.39 |
Binary
weak
|
|
| 200 |
Myeloproliferative disease |
MGI | P&T | UKB GWAS (PheCode) | 25 | 0.67 | 0.0019 | 0.0826 | 0.493 0.466-0.519 |
1.24 OR 95% CI: 0.504-3.05 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Marginal zone lymphoma;Waldenström macroglobulinemia / lymphoplasmacytic lymphoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 111 | 0.67 | 0 | 0.0827 | 0.502 0.479-0.526 |
0.987 OR 95% CI: 0.437-2.23 |
Binary
weak
|
|
| 204 |
Leukemia |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 14 | 0.67 | 0.0007 | 0.0826 | 0.503 0.47-0.538 |
0.531 OR 95% CI: 0.1-2.81 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Malignant neoplasm of cervix uteri |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 70 | 0.68 | 0.0013 | 0.0826 | 0.501 0.461-0.542 |
1.05 OR 95% CI: 0.276-3.98 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Malignant neoplasm of corpus uteri |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 134 | 0.68 | 0.0002 | 0.0832 | 0.498 0.465-0.529 |
1.32 OR 95% CI: 0.484-3.59 |
Binary
weak
|
|
| 189.2 |
Cancer of bladder ICD-10 C67 Malignant neoplasm of bladder |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 28 | 0.68 | 0.0004 | 0.0923 | 0.497 0.476-0.517 |
0.43 OR 95% CI: 0.146-1.27 |
Binary
weak
|
|
| 149 |
Cancer of larynx, pharynx, nasal cavities |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 11 | 0.69 | 0 | 0.0828 | 0.48 0.456-0.506 |
0.977 OR 95% CI: 0.403-2.37 |
Binary
weak
|
|
| 149.1 |
Cancer of oropharynx |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 77 | 0.69 | 0.005 | 0.083 | 0.502 0.452-0.552 |
1.02 OR 95% CI: 0.181-5.75 |
Binary
weak
|
|
| 149.1 |
Cancer of oropharynx |
MGI | P&T | UKB GWAS (PheCode) | 77 | 0.69 | 0.005 | 0.083 | 0.502 0.452-0.552 |
1.02 OR 95% CI: 0.181-5.75 |
Binary
weak
|
|
| 155 |
Cancer of liver and intrahepatic bile duct |
MGI | lassosum | UKB GWAS (PheCode) | 1007258 | 0.69 | 0.0006 | 0.0826 | 0.506 0.467-0.547 |
2.62 OR 95% CI: 0.997-6.87 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Cancer code, self-reported: cervical cancer (UKB GWAS (PHESANT)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 12 | 0.69 | 0.0002 | 0.0826 | 0.491 0.454-0.53 |
1.04 OR 95% CI: 0.273-3.93 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus ICD-10 C54 Malignant neoplasm of corpus uteri |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 20 | 0.69 | 0.002 | 0.0832 | 0.493 0.461-0.524 |
1.64 OR 95% CI: 0.654-4.11 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus ICD-10 C54 Malignant neoplasm of corpus uteri |
MGI | P&T | UKB GWAS (ICD10) | 20 | 0.69 | 0.002 | 0.0832 | 0.493 0.461-0.524 |
1.64 OR 95% CI: 0.654-4.11 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Self-reported brain cancer / primary malignant brain tumour |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 47 | 0.69 | 0 | 0.0826 | 0.509 0.469-0.549 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma Self-reported multiple myeloma |
MGI | lassosum | UKB GWAS (PHESANT) | 37583 | 0.69 | 0.001 | 0.0827 | 0.518 0.455-0.578 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Doctor diagnosed lung cancer (not mesothelioma) |
MGI | lassosum | UKB GWAS (PHESANT) | 97897 | 0.7 | 0.0006 | 0.0828 | 0.503 0.474-0.529 |
0.806 OR 95% CI: 0.268-2.43 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue Self-reported sarcoma/fibrosarcoma |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 50 | 0.7 | 0.0004 | 0.0828 | 0.496 0.471-0.522 |
1.91 OR 95% CI: 0.976-3.73 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
MGI | PRS-CS | Phelan CM et al. 2017 | 1114056 | 0.7 | 0.0001 | 0.0829 | 0.507 0.462-0.553 |
1.3 OR 95% CI: 0.333-5.07 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma Other and unspecified types of non-Hodgkin lymphoma |
MGI | lassosum | UKB GWAS (FINNGEN) | 1314 | 0.7 | 0.0004 | 0.0827 | 0.451 0.431-0.474 |
1.44 OR 95% CI: 0.693-2.97 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma ICD-10 C90 Multiple myeloma and malignant plasma cell neoplasms |
MGI | lassosum | UKB GWAS (ICD10) | 68757 | 0.7 | 0.0025 | 0.0827 | 0.501 0.432-0.581 |
3.83 OR 95% CI: 1.04-14.1 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma |
MGI | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 7 | 0.71 | 0.0003 | 0.0828 | 0.517 0.476-0.562 |
0.769 OR 95% CI: 0.14-4.21 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma |
MGI | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 7 | 0.71 | 0.0003 | 0.0828 | 0.517 0.476-0.562 |
0.769 OR 95% CI: 0.14-4.21 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma |
MGI | P&T | GWAS Catalog (2019-05-03) | 7 | 0.71 | 0.0003 | 0.0828 | 0.517 0.476-0.562 |
0.769 OR 95% CI: 0.14-4.21 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Malignant neoplasm of corpus uteri |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 17 | 0.71 | 0.0001 | 0.0832 | 0.48 0.449-0.511 |
0.444 OR 95% CI: 0.0845-2.33 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous ovarian cancer |
MGI | PRS-CS | Phelan CM et al. 2017 | 1114046 | 0.71 | 0.0003 | 0.0829 | 0.51 0.467-0.558 |
2.38 OR 95% CI: 0.819-6.89 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Malignant neoplasm of kidney, except renal pelvis |
MGI | P&T | UKB GWAS (FINNGEN) | 11 | 0.71 | 0.0005 | 0.0827 | 0.486 0.463-0.511 |
0.46 OR 95% CI: 0.128-1.65 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Hodgkin lymphoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 10 | 0.71 | 0.0001 | 0.0831 | 0.508 0.443-0.573 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma ICD-10 C85 Other and unspecified types of non-Hodgkin's lymphoma |
MGI | lassosum | UKB GWAS (ICD10) | 48 | 0.71 | 0.0042 | 0.0827 | 0.488 0.465-0.512 |
0.753 OR 95% CI: 0.286-1.98 |
Binary
weak
|
|
| 149.9 |
Cancer of nasal cavities Cancer of of nasal cavities |
MGI | P&T | UKB GWAS (PheCode) | 6 | 0.72 | 0.0024 | 0.0829 | 0.486 0.424-0.552 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of rectum |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 155 | 0.72 | 0.0002 | 0.083 | 0.504 0.475-0.537 |
0.434 OR 95% CI: 0.0827-2.28 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system Malignant neoplasm of respiratory system and intrathoracic organs |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 27 | 0.72 | 0 | 0.0827 | 0.492 0.465-0.518 |
0.511 OR 95% CI: 0.141-1.85 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue Melignant neoplasm of mesothelium and soft tissue |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 83 | 0.72 | 0.0005 | 0.0828 | 0.499 0.473-0.524 |
0.803 OR 95% CI: 0.304-2.12 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
MGI | P&T | Phelan CM et al. 2017 | 254 | 0.72 | 0.0054 | 0.0829 | 0.509 0.463-0.554 |
1.84 OR 95% CI: 0.564-5.98 |
Binary
weak
|
|
| 189.1 |
Cancer of kidney and renal pelvis |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.72 | 0.0002 | 0.0827 | 0.503 0.479-0.526 |
0.692 OR 95% CI: 0.264-1.82 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx Diagnoses - main ICD10: C32 Malignant neoplasm of larynx (UKB GWAS (ICD10)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.73 | 0.0002 | 0.0826 | 0.508 0.464-0.556 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 172.3 |
Carcinoma in situ of skin ICD-10 D04 Carcinoma in situ of skin |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 92 | 0.73 | 0.0011 | 0.094 | 0.498 0.475-0.522 |
0.768 OR 95% CI: 0.289-2.05 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Malignant neoplasm of cervix uteri |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 9 | 0.73 | 0.0014 | 0.0826 | 0.491 0.45-0.529 |
1.07 OR 95% CI: 0.282-4.06 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma |
MGI | lassosum | UKB GWAS (PheCode) | 6090866 | 0.73 | 0.0009 | 0.0826 | 0.502 0.468-0.536 |
0.819 OR 95% CI: 0.221-3.04 |
Binary
weak
|
|
| 153.2 |
Colon cancer Malignant neoplasm of colon |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 136 | 0.74 | 0.0007 | 0.0833 | 0.507 0.481-0.536 |
0.313 OR 95% CI: 0.0606-1.61 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of anus and anal canal |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 70 | 0.74 | 0.0007 | 0.083 | 0.496 0.465-0.53 |
1.34 OR 95% CI: 0.491-3.64 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Malignant neoplasm of cervix uteri |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1049464 | 0.74 | 0.0019 | 0.0826 | 0.501 0.46-0.543 |
1.48 OR 95% CI: 0.469-4.69 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Endometrioid ovarian cancer |
UKB | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 98 | 0.74 | 0 | 0.0827 | 0.508 0.483-0.533 |
0.716 OR 95% CI: 0.239-2.15 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 7 | 0.75 | 0.0002 | 0.0828 | 0.462 0.425-0.502 |
1.79 OR 95% CI: 0.556-5.78 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue Malignant neoplasm of other connective and soft tissue |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 74 | 0.75 | 0.0002 | 0.0828 | 0.499 0.473-0.523 |
1.16 OR 95% CI: 0.511-2.65 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
MGI | Fixed threshold (5e-09) | Phelan CM et al. 2017 | 5 | 0.75 | 0.0077 | 0.0829 | 0.504 0.46-0.551 |
1.9 OR 95% CI: 0.582-6.23 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
MGI | P&T | Phelan CM et al. 2017 | 5 | 0.75 | 0.0077 | 0.0829 | 0.504 0.46-0.551 |
1.9 OR 95% CI: 0.582-6.23 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous ovarian cancer |
UKB | P&T | Phelan CM et al. 2017 | 29 | 0.75 | 0.0007 | 0.0827 | 0.503 0.475-0.531 |
0.924 OR 95% CI: 0.348-2.46 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Malignant neoplasm of kidney, except renal pelvis |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 21 | 0.75 | 0.0001 | 0.0827 | 0.494 0.471-0.519 |
1.4 OR 95% CI: 0.645-3.03 |
Binary
weak
|
|
| 190 |
Cancer of eye Self-reported eye and/or adnexal cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 34 | 0.75 | 0.0073 | 0.0837 | 0.492 0.414-0.565 |
3.29 OR 95% CI: 0.71-15.3 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx ICD-10 C32 Malignant neoplasm of larynx |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 15 | 0.77 | 0.0001 | 0.0826 | 0.501 0.451-0.55 |
2.12 OR 95% CI: 0.642-7 |
Binary
weak
|
|
| 155.1 |
Malignant neoplasm of liver, primary |
MGI | lassosum | UKB GWAS (PheCode) | 6162796 | 0.77 | 0.002 | 0.0826 | 0.498 0.452-0.548 |
2.24 OR 95% CI: 0.672-7.44 |
Binary
weak
|
|
| 190 |
Cancer of eye Malignant neoplasm of eye and adnexa |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 49 | 0.77 | 0.007 | 0.0837 | 0.501 0.425-0.577 |
1.93 OR 95% CI: 0.299-12.4 |
Binary
weak
|
|
| 190 |
Cancer of eye Malignant neoplasm of eye and adnexa |
MGI | P&T | UKB GWAS (FINNGEN) | 49 | 0.77 | 0.007 | 0.0837 | 0.501 0.425-0.577 |
1.93 OR 95% CI: 0.299-12.4 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx Self-reported larynx/throat cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 11 | 0.78 | 0.0013 | 0.0826 | 0.493 0.447-0.54 |
2.12 OR 95% CI: 0.645-6.97 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
MGI | GWAS Hits | Phelan CM et al. 2017 | 6 | 0.79 | 0.0037 | 0.0829 | 0.506 0.461-0.551 |
1.87 OR 95% CI: 0.571-6.13 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
UKB | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 146 | 0.79 | 0.0016 | 0.0827 | 0.51 0.483-0.538 |
0.717 OR 95% CI: 0.239-2.15 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Self-reported brain cancer / primary malignant brain tumour |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 7 | 0.79 | 0.0001 | 0.0826 | 0.503 0.461-0.542 |
0.978 OR 95% CI: 0.258-3.7 |
Binary
weak
|
|
| 202.2 |
Non-Hodgkin lymphoma ICD-10 C85 Other and unspecified types of non-Hodgkin's lymphoma |
MGI | P&T | UKB GWAS (ICD10) | 38 | 0.79 | 0.0062 | 0.0827 | 0.492 0.469-0.516 |
1.26 OR 95% CI: 0.585-2.72 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma (GWAS Catalog (2019-05-03)) |
MGI | P&T | UKB GWAS (PheCode) | 45 | 0.8 | 0.0022 | 0.0828 | 0.504 0.465-0.548 |
1.27 OR 95% CI: 0.329-4.92 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C20 Malignant neoplasm of rectum |
MGI | P&T | UKB GWAS (ICD10) | 16 | 0.8 | 0.0008 | 0.083 | 0.488 0.457-0.521 |
1.04 OR 95% CI: 0.34-3.19 |
Binary
weak
|
|
| 187.2 |
Malignant neoplasm of testis Diagnoses - main ICD10: C62 Malignant neoplasm of testis (UKB GWAS (ICD10)) |
MGI | P&T | UKB GWAS (PheCode) | 48 | 0.8 | 0.0043 | 0.0862 | 0.512 0.447-0.574 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma |
UKB | Fixed threshold (5e-05) | GWAS Catalog (2019-05-03) | 7 | 0.81 | 0.0009 | 0.0826 | 0.503 0.472-0.532 |
3.33 OR 95% CI: 1.78-6.25 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma |
UKB | Fixed threshold (5e-06) | GWAS Catalog (2019-05-03) | 7 | 0.81 | 0.0009 | 0.0826 | 0.503 0.472-0.532 |
3.33 OR 95% CI: 1.78-6.25 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma |
UKB | P&T | GWAS Catalog (2019-05-03) | 7 | 0.81 | 0.0009 | 0.0826 | 0.503 0.472-0.532 |
3.33 OR 95% CI: 1.78-6.25 |
Binary
weak
|
|
| 184 |
Cancer of other female genital organs malignant neoplasm of female genital organs |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1111495 | 0.81 | 0 | 0.0837 | 0.507 0.479-0.533 |
0.545 OR 95% CI: 0.15-1.97 |
Binary
weak
|
|
| 194 |
Cancer of other endocrine glands Malignant neoplasm of endocrine gland |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 19 | 0.81 | 0.0005 | 0.0828 | 0.497 0.445-0.553 |
1.31 OR 95% CI: 0.222-7.69 |
Binary
weak
|
|
| 194 |
Cancer of other endocrine glands Malignant neoplasm of endocrine gland |
MGI | Fixed threshold (5e-07) | UKB GWAS (FINNGEN) | 5 | 0.81 | 0.001 | 0.0828 | 0.487 0.434-0.538 |
1.29 OR 95% CI: 0.219-7.63 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia |
MGI | lassosum | UKB GWAS (PheCode) | 14079 | 0.81 | 0.0119 | 0.0826 | 0.502 0.432-0.566 |
2.68 OR 95% CI: 0.615-11.7 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 10 | 0.81 | 0.0046 | 0.0827 | 0.499 0.439-0.56 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.4 |
Multiple myeloma Multiple myeloma (hyperdiploidy);Multiple myeloma (IgH translocation);Multiple myeloma;Multiple myeloma and monoclonal gammopathy (GWAS Catalog (2019-05-03)) |
MGI | P&T | UKB GWAS (PheCode) | 10 | 0.81 | 0.0046 | 0.0827 | 0.499 0.439-0.56 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Doctor diagnosed lung cancer (not mesothelioma) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 5 | 0.82 | 0.003 | 0.0828 | 0.497 0.47-0.524 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 165.1 |
Cancer of bronchus; lung Doctor diagnosed lung cancer (not mesothelioma) |
MGI | P&T | UKB GWAS (PHESANT) | 5 | 0.82 | 0.003 | 0.0828 | 0.497 0.47-0.524 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 182 |
Malignant neoplasm of uterus Endometrial cancer;Endometrial cancer (endometrioid histology);Endometrial endometrioid carcinoma;Endometrial cancer (Non-endometrioid histology) (GWAS Catalog (2019-05-03)) |
MGI | P&T | UKB GWAS (PheCode) | 28 | 0.82 | 0.0043 | 0.0832 | 0.49 0.458-0.522 |
0.729 OR 95% CI: 0.198-2.69 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
MGI | Fixed threshold (5e-07) | Phelan CM et al. 2017 | 13 | 0.82 | 0.0047 | 0.0829 | 0.511 0.462-0.556 |
0.804 OR 95% CI: 0.146-4.43 |
Binary
weak
|
|
| 189.1 |
Cancer of kidney and renal pelvis |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 83 | 0.82 | 0.0003 | 0.0827 | 0.495 0.473-0.517 |
0.868 OR 95% CI: 0.36-2.09 |
Binary
weak
|
|
| 191.11 |
Cancer of brain Malignant neoplasm of brain |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 16 | 0.82 | 0.0001 | 0.0826 | 0.498 0.461-0.536 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma Follicular lymphoma |
MGI | P&T | UKB GWAS (FINNGEN) | 169 | 0.82 | 0.0007 | 0.0826 | 0.491 0.458-0.525 |
2.15 OR 95% CI: 0.906-5.11 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia ICD-10 C91 Lymphoid leukaemia |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 91 | 0.82 | 0 | 0.0826 | 0.495 0.434-0.552 |
2.64 OR 95% CI: 0.604-11.5 |
Binary
weak
|
|
| 157 |
Pancreatic cancer ICD-10 C25 Malignant neoplasm of pancreas |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 17 | 0.83 | 0 | 0.0829 | 0.492 0.448-0.533 |
1.04 OR 95% CI: 0.273-3.99 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis Malignant neoplasm of kidney, except renal pelvis |
MGI | lassosum | UKB GWAS (FINNGEN) | 37 | 0.83 | 0.0012 | 0.0827 | 0.503 0.482-0.53 |
1.17 OR 95% CI: 0.515-2.68 |
Binary
weak
|
|
| 201 |
Hodgkin's disease Diagnoses - main ICD10: C81 Hodgkin's disease (UKB GWAS (ICD10)) |
MGI | P&T | UKB GWAS (PheCode) | 17 | 0.83 | 0.0076 | 0.0831 | 0.477 0.402-0.546 |
1.71 OR 95% CI: 0.27-10.8 |
Binary
weak
|
|
| 145 |
Cancer of mouth Malignant neoplasm of tonsil |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 56 | 0.84 | 0.0001 | 0.083 | 0.499 0.475-0.525 |
0.759 OR 95% CI: 0.288-2 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of rectum |
MGI | P&T | UKB GWAS (FINNGEN) | 110 | 0.84 | 0.0008 | 0.083 | 0.5 0.47-0.533 |
1.03 OR 95% CI: 0.337-3.16 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Low-grade serous and serous borderline ovarian cancer |
MGI | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 28 | 0.84 | 0.0076 | 0.0829 | 0.51 0.466-0.555 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Esophageal adenocarcinoma (GWAS Catalog (2019-05-03)) |
MGI | lassosum | UKB GWAS (PheCode) | 64075 | 0.85 | 0.0025 | 0.0828 | 0.502 0.457-0.546 |
2.31 OR 95% CI: 0.803-6.66 |
Binary
weak
|
|
| 153.2 |
Colon cancer Self-reported colon cancer/sigmoid cancer |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 18 | 0.85 | 0.0003 | 0.0833 | 0.486 0.46-0.512 |
0.514 OR 95% CI: 0.142-1.86 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue Self-reported tongue cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 868459 | 0.86 | 0.0004 | 0.0828 | 0.502 0.468-0.54 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 149.1 |
Cancer of oropharynx |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.86 | 0.0004 | 0.083 | 0.508 0.457-0.558 |
1.71 OR 95% CI: 0.427-6.85 |
Binary
weak
|
|
| 149.4 |
Cancer of larynx Self-reported larynx/throat cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 72 | 0.87 | 0.0011 | 0.0826 | 0.506 0.464-0.552 |
1.51 OR 95% CI: 0.383-5.95 |
Binary
weak
|
|
| 153.2 |
Colon cancer Self-reported colon cancer/sigmoid cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 138 | 0.87 | 0.0001 | 0.0833 | 0.496 0.47-0.525 |
0.729 OR 95% CI: 0.243-2.19 |
Binary
weak
|
|
| 155 |
Cancer of liver and intrahepatic bile duct |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.87 | 0.0002 | 0.0826 | 0.504 0.458-0.548 |
1.6 OR 95% CI: 0.499-5.1 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.87 | 0 | 0.0826 | 0.493 0.428-0.561 |
2.96 OR 95% CI: 0.656-13.4 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue Self-reported sarcoma/fibrosarcoma |
MGI | P&T | UKB GWAS (PHESANT) | 61 | 0.87 | 0.0005 | 0.0828 | 0.495 0.47-0.522 |
1.72 OR 95% CI: 0.853-3.45 |
Binary
weak
|
|
| 180.1 |
Cervical cancer ICD-10 C53 Malignant neoplasm of cervix uteri |
MGI | PRS-CS | UKB GWAS (ICD10) | 978092 | 0.87 | 0.0017 | 0.0826 | 0.502 0.465-0.539 |
1.06 OR 95% CI: 0.278-4.01 |
Binary
weak
|
|
| 190 |
Cancer of eye Malignant neoplasm of eye and adnexa (UKB GWAS (FINNGEN)) |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 71 | 0.88 | 0.001 | 0.0837 | 0.486 0.403-0.56 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.1 |
Lymphoid leukemia ICD-10 C91 Lymphoid leukaemia |
MGI | lassosum | UKB GWAS (ICD10) | 11436 | 0.88 | 0.0046 | 0.0826 | 0.504 0.445-0.565 |
1.58 OR 95% CI: 0.259-9.59 |
Binary
weak
|
|
| 204.12 |
Lymphoid leukemia, chronic Self-reported chronic lymphocytic |
MGI | lassosum | UKB GWAS (PHESANT) | 3533 | 0.88 | 0.0074 | 0.0829 | 0.498 0.423-0.565 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 150 |
Cancer of esophagus Self-reported oesophageal cancer |
MGI | Fixed threshold (5e-05) | UKB GWAS (PHESANT) | 60 | 0.89 | 0.0011 | 0.0828 | 0.502 0.46-0.543 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 151 |
Cancer of stomach Self-reported stomach cancer |
MGI | P&T | UKB GWAS (PHESANT) | 6 | 0.89 | 0.0011 | 0.0829 | 0.504 0.459-0.544 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Mucinous ovarian carcinoma |
UKB | Fixed threshold (5e-06) | Phelan CM et al. 2017 | 27 | 0.89 | 0.0034 | 0.0827 | 0.503 0.477-0.528 |
1.76 OR 95% CI: 0.839-3.7 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis ICD-10 C64 Malignant neoplasm of kidney, except renal pelvis |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 24 | 0.89 | 0.0003 | 0.0827 | 0.486 0.462-0.515 |
1.56 OR 95% CI: 0.75-3.25 |
Binary
weak
|
|
| 189.11 |
Malignant neoplasm of kidney, except pelvis ICD-10 C64 Malignant neoplasm of kidney, except renal pelvis |
MGI | P&T | UKB GWAS (ICD10) | 24 | 0.89 | 0.0003 | 0.0827 | 0.486 0.462-0.515 |
1.56 OR 95% CI: 0.75-3.25 |
Binary
weak
|
|
| 200.1 |
Polycythemia vera |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 95 | 0.89 | 0.0012 | 0.0826 | 0.501 0.436-0.567 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 200.1 |
Polycythemia vera |
MGI | P&T | UKB GWAS (PheCode) | 95 | 0.89 | 0.0012 | 0.0826 | 0.501 0.436-0.567 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 202.21 |
Nodular lymphoma ICD-10 C82 Follicular [nodular] non-Hodgkin's lymphoma |
MGI | PRS-CS | UKB GWAS (ICD10) | 1047514 | 0.89 | 0 | 0.0826 | 0.502 0.467-0.536 |
0.814 OR 95% CI: 0.219-3.02 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus Malignant neoplasm of rectosigmoid junction |
MGI | P&T | UKB GWAS (FINNGEN) | 21 | 0.9 | 0.0008 | 0.083 | 0.493 0.462-0.526 |
0.731 OR 95% CI: 0.199-2.69 |
Binary
weak
|
|
| 155 |
Cancer of liver and intrahepatic bile duct ICD-10 C22 Malignant neoplasm of liver and intrahepatic bile ducts |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 11 | 0.9 | 0.0008 | 0.0826 | 0.493 0.451-0.535 |
0.696 OR 95% CI: 0.128-3.77 |
Binary
weak
|
|
| 157 |
Pancreatic cancer GWAS Catalog (2019-05-03) |
MGI | P&T | UKB GWAS (PheCode) | 18 | 0.9 | 0.0013 | 0.0829 | 0.49 0.449-0.531 |
1.09 OR 95% CI: 0.288-4.16 |
Binary
weak
|
|
| 172.22 |
Squamous cell carcinoma Self-reported squamous cell carcinoma |
MGI | Fixed threshold (5e-06) | UKB GWAS (PHESANT) | 19 | 0.9 | 0.0001 | 0.0998 | 0.49 0.471-0.508 |
1.22 OR 95% CI: 0.66-2.25 |
Binary
weak
|
|
| 204 |
Leukemia Self-reported leukaemia |
MGI | PRS-CS | UKB GWAS (PHESANT) | 943472 | 0.9 | 0.0015 | 0.0826 | 0.501 0.467-0.537 |
0.876 OR 95% CI: 0.235-3.26 |
Binary
weak
|
|
| 145 |
Cancer of mouth |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 11 | 0.91 | 0.0001 | 0.083 | 0.482 0.459-0.507 |
0.943 OR 95% CI: 0.389-2.28 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum |
MGI | P&T | UKB GWAS (PheCode) | 73 | 0.91 | 0.0049 | 0.0826 | 0.504 0.432-0.577 |
1.73 OR 95% CI: 0.273-11 |
Binary
weak
|
|
| 159.4 |
Malignant neoplasm of retroperitoneum and peritoneum Diagnoses - main ICD10: C48 Malignant neoplasm of retroperitoneum and peritoneum (UKB GWAS (ICD10)) |
MGI | PRS-CS | UKB GWAS (PheCode) | 1119238 | 0.91 | 0.0001 | 0.0826 | 0.513 0.454-0.568 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 202 |
Cancer of other lymphoid, histiocytic tissue Mature T/NK-cell lymphomas |
MGI | P&T | UKB GWAS (FINNGEN) | 80 | 0.91 | 0.001 | 0.0827 | 0.498 0.474-0.52 |
1.13 OR 95% CI: 0.527-2.43 |
Binary
weak
|
|
| 204.11 |
Lymphoid leukemia, acute Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia in childhood (B cell precursor) |
UKB | Fixed threshold (5e-09) | GWAS Catalog (2019-05-03) | 5 | 0.91 | 0.0014 | 0.0828 | 0.476 0.355-0.605 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 145.2 |
Cancer of tongue Malignant neoplasm of other and unspecified parts of tongue |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 49 | 0.92 | 0.0007 | 0.0828 | 0.501 0.465-0.54 |
0.556 OR 95% CI: 0.105-2.96 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 90 | 0.92 | 0.004 | 0.0826 | 0.503 0.435-0.574 |
1.71 OR 95% CI: 0.27-10.8 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum Malignant neoplasm of small intestine |
MGI | lassosum | UKB GWAS (FINNGEN) | 2552539 | 0.92 | 0.0069 | 0.0826 | 0.504 0.442-0.569 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 170.1 |
Bone cancer Self-reported primary bone cancer |
MGI | lassosum | UKB GWAS (PHESANT) | 2805117 | 0.92 | 0.0029 | 0.0829 | 0.498 0.466-0.53 |
1.3 OR 95% CI: 0.477-3.52 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary High-grade serous ovarian cancer |
UKB | PRS-CS | Phelan CM et al. 2017 | 1115189 | 0.92 | 0.0003 | 0.0827 | 0.503 0.475-0.532 |
1.13 OR 95% CI: 0.464-2.77 |
Binary
weak
|
|
| 204 |
Leukemia Self-reported leukaemia |
MGI | lassosum | UKB GWAS (PHESANT) | 349179 | 0.92 | 0.0014 | 0.0826 | 0.505 0.469-0.541 |
1.25 OR 95% CI: 0.401-3.86 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C20 Malignant neoplasm of rectum |
MGI | Fixed threshold (5e-06) | UKB GWAS (ICD10) | 19 | 0.93 | 0.0005 | 0.083 | 0.49 0.459-0.522 |
1.05 OR 95% CI: 0.343-3.22 |
Binary
weak
|
|
| 190 |
Cancer of eye Malignant neoplasm of eye and adnexa |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 7 | 0.93 | 0.0021 | 0.0837 | 0.496 0.417-0.571 |
1.86 OR 95% CI: 0.286-12.1 |
Binary
weak
|
|
| 204.2 |
Myeloid leukemia Myeloid leukaemia |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 8 | 0.93 | 0.0077 | 0.0826 | 0.5 0.445-0.549 |
1.28 OR 95% CI: 0.217-7.59 |
Binary
weak
|
|
| 145 |
Cancer of mouth Malignant neoplasm of tonsil |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 950488 | 0.94 | 0.0006 | 0.083 | 0.501 0.476-0.526 |
0.935 OR 95% CI: 0.386-2.26 |
Binary
weak
|
|
| 153.3 |
Malignant neoplasm of rectum, rectosigmoid junction, and anus ICD-10 C21 Malignant neoplasm of anus and anal canal |
MGI | Fixed threshold (5e-07) | UKB GWAS (ICD10) | 8 | 0.94 | 0.0018 | 0.083 | 0.484 0.452-0.518 |
1.04 OR 95% CI: 0.341-3.2 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
MGI | Fixed threshold (5e-07) | Phelan CM et al. 2017 | 7 | 0.94 | 0.0009 | 0.0829 | 0.5 0.456-0.548 |
1.33 OR 95% CI: 0.343-5.18 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary ICD-10 C56 Malignant neoplasm of ovary |
MGI | lassosum | UKB GWAS (ICD10) | 49464 | 0.94 | 0.0009 | 0.0829 | 0.499 0.457-0.54 |
0.82 OR 95% CI: 0.148-4.54 |
Binary
weak
|
|
| 149.1 |
Cancer of oropharynx ICD-10 C09 Malignant neoplasm of tonsil |
MGI | lassosum | UKB GWAS (ICD10) | 41255 | 0.95 | 0.0016 | 0.083 | 0.497 0.447-0.546 |
2.48 OR 95% CI: 0.735-8.36 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue Malignant neoplasm of other connective and soft tissue |
MGI | P&T | UKB GWAS (FINNGEN) | 12 | 0.95 | 0.0014 | 0.0828 | 0.49 0.464-0.516 |
2.09 OR 95% CI: 1.1-3.99 |
Binary
weak
|
|
| 145.3 |
Cancer of major salivary glands |
MGI | Fixed threshold (5e-05) | UKB GWAS (PheCode) | 81 | 0.96 | 0.0006 | 0.0826 | 0.494 0.448-0.544 |
0.861 OR 95% CI: 0.155-4.77 |
Binary
weak
|
|
| 159.4 |
Malignant neoplasm of retroperitoneum and peritoneum Diagnoses - main ICD10: C48 Malignant neoplasm of retroperitoneum and peritoneum (UKB GWAS (ICD10)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 9 | 0.96 | 0.0006 | 0.0826 | 0.466 0.415-0.515 |
1.06 OR 95% CI: 0.185-6.12 |
Binary
weak
|
|
| 184.11 |
Malignant neoplasm of ovary Epithelial ovarian cancer |
UKB | Fixed threshold (5e-05) | Phelan CM et al. 2017 | 111 | 0.96 | 0.003 | 0.0827 | 0.5 0.472-0.529 |
1.13 OR 95% CI: 0.463-2.76 |
Binary
weak
|
|
| 204.21 |
Myeloid leukemia, acute |
MGI | P&T | UKB GWAS (PheCode) | 23 | 0.96 | 0.0148 | 0.0826 | 0.487 0.415-0.554 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.21 |
Myeloid leukemia, acute |
MGI | lassosum | UKB GWAS (PheCode) | 40976 | 0.96 | 0.0147 | 0.0826 | 0.502 0.431-0.565 |
1.89 OR 95% CI: 0.292-12.3 |
Binary
weak
|
|
| 159.2 |
Malignant neoplasm of small intestine, including duodenum Malignant neoplasm of small intestine |
MGI | Fixed threshold (5e-05) | UKB GWAS (FINNGEN) | 51 | 0.97 | 0.0001 | 0.0827 | 0.508 0.44-0.577 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue Malignant neoplasm of other connective and soft tissue |
MGI | Fixed threshold (5e-06) | UKB GWAS (FINNGEN) | 11 | 0.97 | 0.0008 | 0.0828 | 0.49 0.464-0.516 |
1.35 OR 95% CI: 0.625-2.93 |
Binary
weak
|
|
| 170.2 |
Cancer of connective tissue ICD-10 C49 Malignant neoplasm of other connective and soft tissue |
MGI | PRS-CS | UKB GWAS (ICD10) | 1002162 | 0.97 | 0 | 0.0828 | 0.504 0.48-0.53 |
0.448 OR 95% CI: 0.125-1.61 |
Binary
weak
|
|
| 180.1 |
Cervical cancer Self-reported cervical cancer |
MGI | PRS-CS | UKB GWAS (PHESANT) | 1107375 | 0.97 | 0.0001 | 0.0826 | 0.502 0.466-0.541 |
1.46 OR 95% CI: 0.46-4.6 |
Binary
weak
|
|
| 165 |
Cancer within the respiratory system Mesothelioma |
MGI | P&T | UKB GWAS (FINNGEN) | 18 | 0.98 | 0.0005 | 0.0827 | 0.497 0.47-0.526 |
1.34 OR 95% CI: 0.582-3.07 |
Binary
weak
|
|
| 153.2 |
Colon cancer ICD-10 C18 Malignant neoplasm of colon |
MGI | Fixed threshold (5e-05) | UKB GWAS (ICD10) | 144 | 0.99 | 0 | 0.0833 | 0.497 0.47-0.525 |
1.61 OR 95% CI: 0.736-3.53 |
Binary
weak
|
|
| 180.3 |
Cervical intraepithelial neoplasia [CIN] [Cervical dysplasia] Cancer code, self-reported: cin/pre-cancer cells cervix (UKB GWAS (PHESANT)) |
MGI | lassosum | UKB GWAS (PheCode) | 38 | 0.99 | 0.0038 | 0.0886 | 0.519 0.49-0.549 |
0.334 OR 95% CI: 0.0641-1.74 |
Binary
weak
|
|
| 204.11 |
Lymphoid leukemia, acute Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia in childhood (B cell precursor) (GWAS Catalog (2019-05-03)) |
MGI | Fixed threshold (5e-06) | UKB GWAS (PheCode) | 7 | 0.99 | 0.0072 | 0.0827 | 0.482 0.382-0.578 |
0 OR 95% CI: 0-0 |
Binary
weak
|
|
| 204.2 |
Myeloid leukemia Myeloid leukaemia |
MGI | PRS-CS | UKB GWAS (FINNGEN) | 1034666 | 1 | 0.0003 | 0.0826 | 0.505 0.448-0.557 |
0 OR 95% CI: 0-0 |
Binary
weak
|